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Abstract 
Objectives: To determine the effectiveness of lateral approach to subacromial 
injection compared to posterior approach for the treatment of subacromial 
impingement syndrome (SAIS); and to establish the experiences of SAIS 
patients receiving these injections associated with better clinical outcomes. 
 
Design: This study used a mixed methods approach that combines a pragmatic 
randomised control trial to investigate which injection approach is better and a 
semi-structured qualitative interview to investigate the experiences of SAIS 
patients receiving these injections. 
 
Settings: Out-patients community musculoskeletal service 
 
Sample: 80 patients with SAIS for the randomised control study and 20 
participants for the semi-structured qualitative interview. 
 
Interventions: The Intervention group received a single subacromial injection 
with a 21-gauge Green needle with a 40 mg/ml of Kenalog and a 4 ml 1% of 
Lidocaine through a lateral approach. The Control group received an identical 
treatment except that the location was by a posterior approach.  
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Outcome measures: Difference in improvements in the overall patient reported 
outcome measures (PROMs) and shoulder pain and disability index score 
(SPADI) at 8 and 12 weeks follow-up between the two groups. 
  
Results: A moderate but statistically and clinically significant difference in 
improvement in day-time pain (mean change score) occurred in favour of the 
lateral group (mean = 3.7) compared with the posterior group (mean = 2.3) 
between week 0 to 8 (1.4 points [95% CI 0.3 to 2.6, p = 0.018]).  However, there 
were no statistically significant differences between the groups in night-time pain, 
shoulder function and SPADI scores. There was a statistically and clinically 
significant difference (p = 0.001) within the groups for all clinical outcomes 
between week 0 to 8 and between week 0 and 12. This was confirmed by 
participants from the semi-structured interviews which were conducted 12 weeks 
after the injection. 
 
Conclusion: There were no real significant differences in the treatments; 
however, both forms of treatment were associated with significant improvement 
in shoulder pain, function and disability. This was confirmed by participants from 
the semi-structured interviews, who felt that they improved not only because of 
the effect of the cortisone injection, but also because of other factors such as 
education about their treatment, exercise information, the experience and skills 
of the injecting clinicians, access to treatment as well as good customer service. 
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Glossary and Abbreviations 
Word Meaning 
ACJ Acromioclavicular Joint 
BMI Body Mass Index 
CSP Chartered Society of Physiotherapy 
ESP Extended Scope Practitioner 
GHJ Glenohumeral Joint 
GP General Practitioner 
ITT Intention to treat analysis  
L Lateral 
MCID Minimum Clinically Important Difference 
MRI Magnetic Resonance Imaging 
MSK Musculoskeletal  
NHS National Health Service  
NPS Numeric Pain Score 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
P Posterior 
PGDs Patient Group Directions 
PIS Participant Information Sheet 
PROMs Patient Reported Outcome Measures 
RCT Randomised Clinical Trial 
RCIS Rotator Cuff Impingement Syndrome  
ROM Range of Movement 
SAIS Subacromial Impingement Syndrome 
SIS Shoulder Impingement Syndrome 
SOM Society of Orthopaedic Medicine  
SPADI Shoulder Pain and Disability Index 
VAS Visual Analogue Scale 
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CHAPTER 1 INTRODUCTION 
 
1.1 Introduction and Background 
Shoulder pain is one of the most common musculoskeletal conditions affecting 
the general population and a common reason for consulting their general 
practitioner (GP) (Linsell et al 2006). In the UK, the incidence of shoulder pain is 
very common and one in three people will suffer from shoulder pain at some 
point (Van der Heijden 1999, Linsell et al 2006). For the first time, a UK report in 
2011 - 2012 says that the prevalence of work related upper limb disorders 
including shoulder pain exceeded those of low back pain (Health & Safety 
Executive 2012). Of all the disorders of shoulder pain, subacromial impingement 
syndrome (SAIS) is the most common.  
 
As a preamble, before taking you through the journey of this research it is 
imperative to give a little background of myself. I am an Extended Scope 
Practitioner (ESP) Physiotherapist working in a community musculoskeletal 
service. My job entails among others the provision of cortisone injection not 
necessarily as a stand-alone treatment but as an adjunct to rehabilitation for 
patients with shoulder pathologies such as SAIS. The use of cortisone injection 
for the management of SAIS is supported by the recent systematic review by 
Diercks et al (2014) and an extensive review undertaken by Hanchard et al 
(2004). Traditionally ESPs are trained to inject the shoulder either through a 
lateral or posterior approach. Whilst shoulder cortisone injection can be provided 
either through a posterior (back) or a lateral (side) approach to patients with 
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SAIS, in my practice, I have observed that the posterior is predominantly used 
even though anatomically the structures of the subacromial region are closer to 
the lateral than the posterior border of the shoulder. Whilst a cortisone injection 
is effective in relieving symptoms of pain and inflammation in people with SAIS, 
we do not know if people are more or less likely to benefit if they are injected 
from the side or the back of the shoulder. This knowledge gap was my main 
motivation for undertaking this study. 
 
This thesis set out to find out whether people with SAIS who are injected from 
the side (lateral) of their shoulder would have better pain relief and improved 
shoulder function compared to those who are injected from the back (posterior) 
of the shoulder. All participants in the study were referred by their GP with 
shoulder pain and during their first appointment, were identified by an injecting 
clinician through a face-to-face assessment to determine if they have a diagnosis 
of SAIS and would benefit from a cortisone injection. 
 
The remaining part of this chapter focuses on the background information on the 
development of this research. It considers the incidence and definition of both 
shoulder pain and SAIS, the cost implication of SAIS and subacromial injection 
for treatment of SAIS. It also considers the uncertainty of evidence regarding 
needle placement in subacromial injections and the experiences of patients 
receiving these injections as a gap in current knowledge and therefore the 
purpose of this study. 
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1.2 Shoulder Pain - Why it is a Problem 
Shoulder pain is a common and often persistent musculoskeletal problem (Van 
der Heijden 1999, Roquelaure et al 2006, Diercks et al 2014). Shoulder pain is 
associated with significant morbidity and it increases linearly with age peaking at 
50 years (Van der Heijden 1999, Linsell et al 2006). In the UK, shoulder 
disorders rank fourth only to disorders of the back, knee and chest in frequency 
of occurrence, affecting all ages (Jordan et al 2010). Shoulder pain is often 
associated with difficulties with performing functional activities such as getting 
dressed (Linsell et al 2006), throwing a baseball (Seroyer et al 2009), impaired 
ability to sleep (Kromer et al 2009), hence affecting mood and concentration 
(Green et al 2003). 
 
The cumulative annual prevalence and incidence of shoulder disorders such as 
SAIS in the UK’s general medical practice has been reported to be 2.36% and 
1.47 % respectively (Linsell et al 2006). According to Greving et al (2012) it 
accounts for approximately 12 % of GP contacts in primary care. In Australia, it 
has been reported that shoulder disorders account for 1.2% of all GP 
encounters, ranking third only to back and neck disorders as reasons for 
musculoskeletal consultations (Bridges-Webb 1992). A Dutch study by Luime et 
al (2004) has reported one-year prevalence rates for shoulder disorders as 
ranging from 5% to 47%. Figures obtained from the US National Ambulatory 
Medical Care Survey (NAMCS) 1993 to 2000 show that 1% of all office visits to 
GPs are for shoulder pain, and that 25% of these visits are to primary care 
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doctors (Wofford 2005). These lower figures reflect that not all shoulder pain 
sufferers consult their GP, while Hanchard et al (2013) reports this to be in the 
region of 50-80%, Bongers (2001) approximates this to be in the order of 40-
50%.   
 
In addition to the high incidence, shoulder dysfunction is often persistent and 
recurrent with 64% of suffers reporting ongoing symptoms after 3 years (Linsell 
et al 2006). Some studies have demonstrated persisting pain and disability from 
12 months (Van der Windt et al 1995) to 18 months (Chard 1991) in up to 50% of 
cases. 50% of patients referred to primary care with new episodes of shoulder 
pain would experience complete resolution at 6 months rising to only 60% after a 
year (Van der Windt et al 1996). Linsell et al (2006) found that during a 3 year 
follow up period of patients consulting for shoulder disorders in UK primary care, 
22.4% of patients were referred to secondary care, 30.8% were prescribed non-
steroidal anti-inflammatory drugs (NSAIDs), and 10.6% were given a cortisone 
injection by their GP.  
 
1.3 What is Shoulder Pain? 
Shoulder pain is a symptom rather than a distinct pathology. Shoulder disorders 
such as SAIS, frozen shoulder, shoulder instability and acromioclavicular 
dysfunction are the most common causes of shoulder pain (National Health 
Service 2012). SAIS is a frequent cause of shoulder pain (Picavet & Schouten 
2003, Hanchard et al 2013); and it accounts for 44% to 65% of all complaints of 
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shoulder pain during a GP visit (Vecchio et al 1993, Van der Windt et al 1995). 
This is consistent with a UK study that found SAIS was the most common reason 
for people consulting for shoulder problems in the UK primary care setting 
(Linsell et al 2006). This result was based on a large, nationwide sample. 
 
Two systematic reviews (Van der Windt et al 2000, Van Rijn 2010) found 
occupational risk factors for shoulder pain such as lifting heavy loads, working in 
awkward postures, engaging in repetitive movements and being exposed to 
vibration. Psychosocial factors that were identified include mental stress, work 
pressure, lack of control at work and job satisfaction (Van der Windt et al 2000, 
van Rijn 2010). The clinical manifestation of SAIS varies widely because it is a 
collection of soft tissue pathologies rather than a distinct pathology (Lewis 2008), 
and it mainly causes shoulder pain, limiting range of movement, affecting patient 
function and quality of life. Some patients experience severe acute or chronic 
pain and loss of function (Bokor et al 1993). Pain often located at the anterior-
lateral aspect shoulder and radiates to the side of the arm especially when the 
arm is elevated (Lewis et al 2001). Pain is also aggravated with placing the arm 
behind the back, arm elevation or overhead activities associated with daily living 
(Lewis et al 2005). Night pain may be present in SAIS, and is particularly 
associated with rotator cuff tears (Zuckerman et al 1991), but it is also a common 
feature of adhesive capsulitis (Hanchard et al 2004). 
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1.4 Definition of Subacromial Impingement Syndrome 
During the elevation of the shoulder, the humeral tuberosities pass close under 
the coracoacromial arch, leaving little clearance for the intervening soft tissues 
(Hanchard et al 2004, Hanchard et al 2013). These consist of superficial to deep 
structures such as the subacromial bursa, the rotator cuff tendons, and the long 
head of biceps. If there is not enough space, these soft tissues can become 
pinched. This is called SAIS or otherwise rotator cuff impingement syndrome 
(Lewis 2008), shoulder impingement syndrome, painful arc syndrome (Hanchard 
et al 2004), and subacromial pain syndrome (Lewis 2011). Therefore, SAIS is a 
collection of soft tissue pathologies rather than a specific pathology (Lewis 
2008). In practice, a diagnosis of SAIS is still based on findings of a clinical 
examination for the majority of patients (Dinnes et al 2003).  
 
1.5 Cost Implications of Subacromial Impingement Syndrome 
The impact of shoulder pain on the economy is high because the cost involved in 
its management is huge (Lewis 2011). Using figures from a comprehensive 
evaluation of shoulder disorders (Garg et al 2010) Arthritis Research UK, has 
estimated the cost of shoulder pain in the general population to be in the region 
of £100 million. In 2005 a multicentre randomised clinical trial (RCT) conducted 
in the UK found that the total mean costs, per patient, for cortisone injection and 
physiotherapy treatment of unilateral shoulder pain were £71.28 and £114.60 
respectively (James et al 2005). Ketola et al (2009) reported that in London, the 
average cost of surgery/post-surgical rehabilitation for patients with shoulder 
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impingement syndrome is estimated at £3500 (Ketola et al 2009). In New York, 
USA, it was reported to be $4860. Although these figures indicate that the cost of 
cortisone injection, physiotherapy and surgery for SAIS varies widely, 
physiotherapy and surgery have each been reported to cost more when 
compared to cortisone injections (James et al 2005 & Ketola et al 2009). From 
these figures, the combined cost of physiotherapy and cortisone injection for 
SAIS is less compared to surgery (James et al 2005, Ketola et al 2009). The 
reports and figures from these studies show therefore that SAIS is a significant 
health burden on the health-care budget, for patients, healthcare practitioners, 
and policy makers (Bennell et al 2007 & Garg et al 2010). 
 
1.6 Subacromial Injection for Treatment of Subacromial Impingement 
Syndrome 
 
Subacromial injection is the recommended treatment for patients with SAIS, 
particularly where physiotherapy has failed or pain is limiting exercise (Hanchard 
et al 2004, Lewis 2011 & Diercks et al 2014). The result of a literature search 
demonstrates that cortisone injection is commonly used in SAIS. A recent 
systematic review and meta-analysis of RCTs shows that cortisone injections 
provide moderate pain relief for patients with rotator cuff disorders up to two 
months after the injection (Mohamadi et al 2016), but the benefit was not 
sustained after this time. Previous systematic reviews that investigated the 
effectiveness of cortisone injection in treatment of shoulder pain (Johansson et al 
2002, Buchbinder et al 2003, Arroll & Goodyear-Smith 2005) have reported 
varying methodological quality and heterogeneity of populations and commented 
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that sample sizes were generally small. However, their conclusions were 
nevertheless similar: subacromial cortisone injection is effective in the 
management of SAIS and more effective when compared with placebo, 
acupuncture, ice, heat and exercise. Both the Johansson et al (2002) and Arroll 
& Goodyear-Smith (2005) reviews agree that cortisone injection is superior to 
NSAIDs in reducing pain and improving shoulder function, with the latter study 
reporting improvement lasting up to 9 months. The findings of those reviews are 
consistent with the recommendations of the National Institute for Clinical 
Excellence (NICE 2015), a systematic review (Hanchard et al 2004) that was 
commissioned by the Chartered Society of Physiotherapy (CSP) and a recent 
Dutch review (Diercks et al 2014) which recommends that cortisone injection 
should be provided to patients with SAIS.  
 
1.7 Evidence for Approaches to Subacromial Injections and Patient 
Experience 
 
Anterior, posterior and lateral approaches of subacromial injections are 
described in the literature (Sardelli & Burks 2008, Marder et al 2012, Saunders 
2010, Saunders & Longworth 2012) with the latter two most commonly used 
(Saunders 2010). However, there is no concrete evidence supporting the use of 
posterior route of needle placement in SAIS over the lateral approach. Yet 
anecdotal evidence suggests that clinicians, including musculoskeletal Extended 
Scope Practitioners (ESPs), have mainly used the former approach. Previous 
RCTs (Henkus et al 2006, Kang et al 2008, Goel et al 2012, Marder et al 2012) 
and one comparative study (Sardelli & Burks) have investigated needle 
9 
   
 
 
  
 
placements in SAIS using an MRI, radiographic contrast dye, radiopaque 
contrast and arthroscopy respectively as the reference standard. However, in 
normal musculoskeletal practice (primary care setting) where most people with 
shoulder pain are diagnosed and managed (Hanchard et al 2013), ESPs 
commonly inject the shoulder without the use of imaging as a reference for 
evaluation. Furthermore, the findings of these efficacy studies suggest that there 
is conflicting evidence supporting the use of a posterior route of needle 
placement over a lateral approach in the treatment of patients with SAIS. None 
of these studies directly evaluates the influence of psychosocial factors such as 
patient experiences regarding lateral or posterior needle placement in SAIS. 
Despite these limitations, these studies provide some useful information for 
future research.   
 
There is paucity of evidence in the subjective experience of SAIS patients 
receiving subacromial injections. A UK qualitative study was found that described 
the experience of patients’ living with a symptomatic rotator cuff tear (RCT) their 
symptoms, the impact upon their daily lives and the coping strategies utilised by 
these patients (Minns et al 2014). A previous qualitative study has explored 
patients’ experiences with frozen shoulder and their treatment with Bowen 
technique (Carter 2002), and a semi-structured qualitative study investigated the 
patients’ perceptions and priorities regarding frozen shoulder (Jones et al 2013). 
Although these studies have provided useful information on the qualitative 
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experience of patients with shoulder pathology, they lack information on the 
experiences of patients with SAIS receiving cortisone injection. 
 
To my knowledge, just one study (Nyman et al 2012) was found that investigated 
the experiences of patients with supraspinatus tendinitis who had received both 
physiotherapy and cortisone injection or had undergone open or arthroscopic 
shoulder surgery. Although 26 participants were interviewed only three of them 
received cortisone injection after receiving physiotherapy. The findings of these 
studies and others are presented throughout this study. 
 
1.8 The Knowledge Gaps in Current Research 
Four key gaps in the current research evidence were identified from the 
discussion and the issues raised in the preceding sections of this chapter. The 
first is the lack of consensus regarding the superiority of a posterior versus a 
lateral to subacromial injection in treatment of patients with SAIS among authors 
of previous shoulder studies. Secondly, these studies used an imaging tool as 
the reference standard for evaluating needle placement accuracy making it 
difficult to replicate them in normal community musculoskeletal service where 
most people with shoulder pain are diagnosed and treated (Hanchard et al 
2013). Thirdly, none of these studies considered the qualitative experience of 
patients’ receiving these injections. Finally, a lack of mixed research that 
combined a pragmatic RCT and qualitative semi-structured interview was 
identified as a significant gap in knowledge. 
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1.9 Purpose of the Study 
The purpose of this pragmatic study was to compare the effectiveness of a 
lateral and a posterior approach to subacromial injection for patients with SAIS. It 
was also to establish the experiences of patients with SAIS receiving these 
subacromial injections. The expectation is that this study will add to the body of 
knowledge required to help clinicians make effective treatment choices on 
needle placement for patients with SAIS and to understand the experiences of 
those patients receiving the treatment. A greater knowledge of both aspects is 
more likely to provide better improvement that is vital for patients, funding 
providers and researchers. There is currently very little qualitative research into 
the experiences of patients with SAIS receiving subacromial injections. This 
study will therefore provide health professionals, researchers and policy makers 
with a better understanding of the experiences of SAIS patients receiving 
subacromial injections and thus how best to manage them.  
 
To address the gap in the current knowledge regarding both aspects of 
subacromial injections and the experiences of patients receiving these injections, 
two main research questions were formulated. The first question is whether a 
lateral approach to subacromial injection is better in the treatment of SAIS 
compared to a posterior or standard approach. The second question is what are 
the experiences of patients with SAIS receiving these injections. 
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1.10 Chapter Summary 
Chapter 1 has introduced the research topic and presented why shoulder pain is a 
problem, described it and defined SAIS. It highlighted the use of cortisone injection 
for treatment of SAIS patients, the lack of concrete evidence on needle placement 
to subacromial, lack of literature on the qualitative experiences of patients 
receiving subacromial injections, the knowledge gap and the purpose of the study. 
The reminder of the study is organised into five chapters. 
 
1.11 Introduction to Chapters Two to Six 
Chapter 2 presents a review of the literature on the shoulder joint and rotator cuff 
muscles, SAIS with particular reference to its clinical presentation, classification, 
aetiology, diagnostic difficulties and clinical assessment. It also includes discussion 
on the current trend in National Health Service (NHS) musculoskeletal practice, 
the role of ESP in musculoskeletal practice, current treatment for SAIS, issue of 
needle placement in subacromial injections, the evidence on needle placement in 
subacromial injections and patient experience. The research question, null and 
alternative hypothesis and the aims of the research are also discussed in this 
chapter. In Chapter 3 the research design and the methodology that were used for 
this study are discussed. The sample populations, sample size calculation, 
interventions, treatment procedure, baseline comparability, instruments used to 
collect both the quantitative and the qualitative data and the measures followed 
are also discussed. Chapter 4 presents the data analysis and results of both the 
quantitative and qualitative analysis. In Chapter 5 the discussion on the findings of 
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both the quantitative and the qualitative data are presented. Chapter 6 contains 
the limitations of the study, reflection on my practice, implications of the study, 
recommendations for further research and conclusion. 
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 Introduction 
This chapter deals with the literature search for both the quantitative and 
qualitative study. The discussion of the quantitative literature review will include 
general review of literature on the shoulder, SAIS, and current trends in the NHS 
musculoskeletal practice, the role of ESPs in musculoskeletal practice, current 
treatment for SAIS, issue of needle placement in subacromial injections, the 
evidence on needle placement in subacromial injections. The qualitative aspect 
will focus on research within the of context musculoskeletal physiotherapy such 
as the experiences of patients with SAIS receiving subacromial injections. The 
research question, null and alternative hypothesis and the aims of the research 
are also discussed. 
 
2.2 Data Source and Search Strategy 
Following on from the research questions, the search strategy for the literature 
review was in two parts: 
1. Quantitative literature search 
2. Qualitative literature search 
 
2.2.1 Quantitative Literature Search 
The search strategy was aimed at optimally retrieving relevant papers that were 
appropriate to the research question, as well as minimising retrieval of irrelevant 
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papers (Higgins & Green 2006). To achieve this objective, a number of widely 
accepted databases were searched. These include:  
I. A search for papers was conducted through the search engine of the 
University of Essex Ebscohost, using CINAHL (Cumulative Index to 
Nursing & Allied Health Literature) Complete, MEDLINE (Medical 
Literature Analysis and Retrieval System) and E-Journey database with 
full text from 1980 to April 2014 and updated in December 2016 via the 
Chartered Society of Physiotherapy (CSP) Ebscohost 
II. The updated search through the Chartered Society of Physiotherapy 
(CSP) Ebscohost, contained AMED (Allied and Complimentary Medicine), 
MEDLINE, CINAHL Plus with Full Text, SportDiscus and EBSCO Ebooks 
III. Reference Lists: These were searched from the relevant primary and 
review studies 
IV. Grey Literature: The following were searched via – 
a. SIGIE (System for Information on Grey Literature in Europe) 
V. Conference Proceedings: These were searched via: 
a. ZETOC  
b. ISI (Institute for Scientific Information) web of science 
VI. Cochrane Library 
VII. PEDro (Physiotherapy Evidence Database) 
VIII. The Internet: The following were searched 
a. Department of Health (http://www.dh.gov.uk) 
b. Google Scholar (http://www.scholar.google.co.uk) 
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c. Google (http://www.google.co.uk) 
IX. Relevant Clinical Guidelines 
a. NICE (National Institute for Clinical Excellence) 
b. The CSP (Chartered Society of Physiotherapy) 
c. SIGN (Scottish Intercollegiate Guidelines Network) 
 
In addition to the above, relevant physiotherapy textbooks were consulted for 
information on the anatomy, assessment and management of shoulder pain and 
subacromial impingement syndrome. 
 
The search was limited to human subjects published in the English language. 
Non-English language studies for example, Chinese and German were not 
included because of the challenges of translation into English language such as 
cost and time. According to the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins & Green 2006), an electronic search strategy should in 
general have three sets of terms. These include terms to search for - 
1. The population of interest – subacromial impingement syndrome 
2. The intervention(s) investigated – cortisone injection 
3. The types of study design to be included – non-RCTs, RCT 
 
The search strategy began with the use of multiple terms that describe SAIS 
such as shoulder pain and shoulder impingement syndrome.  These terms were 
linked together using the Boolean operator “OR” to ensure that articles retrieved 
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contained at least one of the search terms. The same process was repeated for 
a second and a third set of terms related to the intervention (cortisone injection) 
and the study design (qualitative studies, systematic reviews, RCTs, non-RCTs) 
respectively. These three sets of terms were then combined together with the 
Boolean operator “AND”. This allows for the retrieval of studies that are relevant 
to the study design and address both the population of interest and the 
intervention to be investigated. The following 'MESH' headings and keywords 
were used; ‘shoulder pain’, ‘shoulder impingement syndrome’, ‘subacromial 
impingement syndrome’, ‘shoulder$’, ‘subacromial$’, ‘supraspinatus$’, ‘rotator 
cuff$’, ‘bursitis’, ‘impinge$’, ‘tendonitis’, ‘tendinitis’, ‘pain’, ‘pathology$’ in 
combination with ‘cortisone injection’ or ‘hydrocortisone injection’ or 
triamcinolone acetonide injection or Kenalog injection, and not limited to ‘clinical 
trials’. 
 
The following lines: S10, S15 and S21 of the updated search through the 
Chartered Society of Physiotherapy (CSP) Ebscohost were used respectively to 
identify records related to the population (SAIS) and intervention (cortisone 
injection) and studies of the appropriate design. See Table 1 for detailed 
description. 
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Table 1: Quantitative Search - Combined Results of the CSP Electronic 
Database Searches of AMED, CINAHL, CINAHL Plus with Full Text, CSP 
Online Library Catalogue, eBook Collection (EBSCOhost), MEDLINE, 
SPORTDiscus 
 
# Search Terms Combined 
Results from 
above 
Database 
Searches 
S1 Shoulder pain 18,952 
S2 Subacromial impingement syndrome  2,848 
S3 Shoulder impingement syndrome  3,789 
S4 Rotator cuff  20,575 
S5 Rotator cuff tendinopathy 435 
S6 Supraspinatus tendonitis  91 
S7 ((shoulder$ or subacromial$ supraspinatus$ or rotator 
cuff$) adj6 (bursitis or impinge$ or tendonitis or tendinitis 
or pain$ or pathology$)).mp.  
1,732 
S8 ((Sub-acromial or Subacromial) adj4 (bursitis$ or 
impinge or impingement or compression or 
decompression)).mp.  
495 
S9 Bursitis  7,095 
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8  135,289 
S11 INJECTIONS 470,468 
S12 ((steroid$ or corticosteroid$ or sub-acromial or 
subacromial) adj5 (inject$).mp  
391 
S13 ((steroid$ or corticosteroid$ or sub-acromial or 
subacromial) adj5 (inject$ or Kenalog or Triamcinolone$ 
or Depo-Medrone or Methlyprednisolone$ or 
Lidocaine)).mp  
15 
S14 ((steroid$ or corticosteroid$ or sub-acromial or 
subacromial) adj5 (inject$ or approach$ or route$ or 
posterior$ or lateral$ or anterior$).mp  
714 
S15 S10 OR S11 OR S12 OR S13 488,894 
S16 (Reviews$ or Clinical trial$ or Controlled trial$).pt.  3,390,654 
S17 (random$ or randomize$).mp.  531,091 
S18 (placebo$ or no treatment$).mp.  353,472 
S19 ((single or double) adj (blind$ or mask$)).mp.  635 
S20 S15 OR S16 OR S17 OR S18 3,814,037 
S21 S10 AND S15 AND S20 4,265 
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2.2.1.1 Results of the Quantitative Search 
A total of 4265 citations were retrieved from the CSP Ebscohost electronic 
databases and additional 25 papers were also found from the reference lists and 
grey literature. There were 3041 citations after removal of 1249 duplicates. After 
careful evaluation of the titles and/or abstracts, a total of 3002 articles that were 
not related to the study were excluded from the 3041 citations and 39 full text 
articles were left. Of the 39 potentially eligible studies, 17 were excluded with 
reasons and 22 articles that were possibly relevant to this study were identified 
(see Figure 1 for details). Titles and abstracts of these remaining articles were 
then hand searched for studies that directly evaluated the effects of different 
needle approaches to subacromial injection or effects of cortisone injection in the 
treatment of SAIS. Several of these literatures broadly discussed the terms SAIS 
and cortisone injection. However, seven systematic reviews (van der Heijden GJ 
et al 1996, Johansson et al 2002, Buchbinder et al 2003, Arroll & Goodyear-
Smith 2005, Koester et al 2007, Gaujoux-Viala et al 2009, Mohamadi et al 2016), 
were identified that directly evaluated the effects of cortisone injection in the 
treatment of SAIS. Seven RCTs (Adebajo 1990, Blair 1996, Winter et al 1997, 
Plafki et al 2000, Akgun et al 2004, Penning et al 2012, Min et al 2013) were 
identified that evaluated the effects of cortisone injection in the treatment of 
SAIS. Three non RCTs (Eustace 1997, Yamakado 2002, Esenyel 2003), directly 
evaluated the effect of one approach of cortisone injection in the treatment of 
SAIS. Four RCTs (Henkus et al 2006, Kang et al 2008, Goel et al 2012 and 
Marder et al 2012) and one non RCT (Sardelli & Burks 2008) directly evaluated 
20 
   
 
 
  
 
the effects of different approaches of cortisone injection in SAIS treatment. See 
Tables 2 and 3 for details of included studies. 
 
Figure 1: Flow Chart for the Quantitative Search Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4265 Citations identified through database 
searching: 
a. CINAHL Plus with Full Text (3,171) 
b. eBook Collection(EBSCOhost) (39) 
c. CINAHL (241) 
d. MEDLINE (709) 
e. SPORTDiscus (105) 
25 additional 
citations identified 
through other 
source 
1249 duplicates removed from the 
combined searches (n = 4290) 
3041 potential relevant citations 
screened 
3002 citations 
excluded at title 
or abstract with 
reasons 
39 Full text studies retrieved for 
detailed assessment for eligibility 
22 studies included as part of 
the quantitative synthesis 
17 full text articles 
excluded with 
reasons: 
Not intervention of 
interest = 15 
Commentary = 2 
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Table 2: A Summary of the Characteristics of Some the included Studies (Non RCTs & RCTs) 
Study Design Sample 
Size  
Intervention Outcome Measures Follow-up Summary of Findings Limitations 
Adebajo 
(1990) 
RCT n = 60 Group 1: (20 patients): 
50 mg diclofenac 3 
times a day for 28 days 
+ subacromial injection 
of 3ml of 0.5% 
lignocaine  
Group 2: (20 patients): 
diclofenac placebo 
tablets + subacromial 
injection of 2ml 0.5% 
lignocaine & 1ml of 
80mg/ml triamcinolone 
hexacetomide.  
Group 3: (20 patients): 
diclofenac placebo 
tablets + subacromial 
injection of 3ml 0.5% 
lignocaine.  
All patients instructed in 
pendulum and wall 
climbing exercises to 
perform at home. 
1. Overall pain 
severity assessed by 
10cm VAS (0 = no 
pain, 10 = severe 
pain)  
2. Limitation of 
function on 4-point 
scale (0 = no 1 = 
mild, 2 = moderate 
and 3 = severe 
limitation of function 
respectively)  
3. Active and passive 
ROM measured to 
the nearest 5 
degrees with a 
pendulum 
goniometer. 
 
Outcome 
assessed at 
baseline and 4 
weeks  
Both groups 1 and 2 
forms of treatment were 
superior to placebo in 
improving shoulder pain, 
active abduction and 
function. Triamcinolone 
injection showed the 
greatest effect in these 
respects, and was 
significantly superior to 
diclofenac when patients 
showing improvements in 
all 3 variables together 
(responders) were 
considered. 
The 
weakness of 
this study 
includes the 
short follow-
up period. 
Akgun et al 
(2004) 
RCT n = 48  Group 1: 10 cc of 1% 
lignocaine + 40 mg of 
steroid for the 1st and 
2nd injections, group 2: 
10 cc of 1% lignocaine + 
40 mg of steroid for the 
1st injection and only 10 
cc of 1% lignocaine for 
the 2nd injection, group 
3: only 10 cc of 1% 
lignocaine for the 1st 
and 2nd injections. All 
the patients had NSAID 
plus pendulum 
exercises. 
Shoulder pain during 
rest, activity, and 
causing disturbance 
of sleep was 
evaluated using a 
VAS. Shoulder 
function was 
investigated by total 
Constant score. 
Baseline, 1 
and 3 months’ 
post treatment 
All the groups showed 
significant improvements 
in shoulder pain and 
function at the first and 
second evaluation. Group 
1 patients had more 
favourably improved 
values in pain causing 
sleep disturbance and 
functional limitation than 
the other 2 groups only in 
the 1st month after 
therapy onset.  
Although the 
results of this 
study 
supported the 
use of 
cortisone 
injections for 
SAIS, the 
same sample 
size was 
small. 
22 
   
 
 
  
 
Study Design Sample 
Size  
Intervention Outcome Measures Follow-up Summary of Findings Limitations 
Blair 1996 RCT n = 40 Group 1 (21 patients): 
6ml of 1% lidocaine 
without epinephrine.  
Group 2 (19 patients): 
2ml containing 40 mg of 
triamcinolone acetonide 
per ml with 4 ml of 1% 
lidocaine without 
epinephrine.  
All patients underwent a 
standardised program of 
physiotherapy. 
Assessed at baseline 
and every 4 weeks 
until completion of 
study (not defined) - 
(mean duration of 
follow up was 33 
weeks (range: 12-55) 
and 28 weeks 
(range: 12-52) in 
corticosteroid and 
placebo groups 
respectively).  
1. Performance of 5 
ADL.  
2. Overall subjective 
assessment of pain 
on 4-point scale 
injection.  
3. Detailed physical 
examination and 
measurement of 
ROM using a 
goniometer 
Assessed at 
baseline and 
every 4 weeks 
(mean 
duration of 
follow up was 
33 weeks and 
28 weeks in 
corticosteroid 
and placebo 
groups 
respectively).  
At follow-up evaluation, at 
a mean of 33 weeks in 
corticosteroid group and 
28 weeks in placebo 
group, the corticosteroid 
group was significantly 
better with respect to pain 
and range of motion but 
there was no significant 
difference between the 
two groups with respect to 
improvement in 
performance of activities 
of daily living. 
Although the 
results of this 
study 
supported the 
use of 
cortisone 
injections for 
SAIS, the 
same sample 
size was 
small. The 
variation in 
the follow-up 
periods 
between the 
groups could 
make the 
pooling of the 
results for 
systematic 
review and 
meta-
analysis 
difficult. 
Esenyel 
2003 
 
Non 
RCT 
48 
patients 
(29 
women, 
19 men; 
mean 
age 
46.5 
years; 
range 
23 to 58 
years) 
Contrast material was 
added to a mixture of 
steroid and local 
anesthetic solution. 
Shoulder  
function and pain 
were evaluated by 
VAS, range of 
movement of the 
joint, and Constant 
scores. 
Before 
treatment, 30 
minutes 
& two weeks 
post injections 
The injections were 
placed accurately in 42 
patients (87%), while in 
six patients (12.5%), 
delivery to the target site 
failed. Although both 
groups showed significant 
improvements 30 minutes 
after the injections  
(p<0.05). Only the 
injections that were 
accurately placed showed 
significant improvement  
This was a 
non RCT and 
although 
accurately 
placed 
injections 
improved 
shoulder 
outcomes, 
the follow-up 
periods were 
very short, 
therefore the  
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Study 
 
Design Sample 
Size  
Intervention Outcome Measures Follow-up Summary of Findings Limitations 
      after 2 weeks evidence is 
limited 
Eustace 
1997 
Non 
RCT 
n = 37 Local injections of a 
mixture of triamcinolone 
and radiographic 
contrast material using a 
standardised technique 
VAS, joint ROM, a 
five-point global 
rating scale of 
maximum and 
current benefit 
Before and 
two weeks 
after the 
injection 
14 of the 38 procedures 
(37%) were judged to be 
accurately placed: four of 
the 14 attempted 
subacromial injections 
(29%) and 10 of the 24 
attempted glenohumeral 
injections (42%). There 
were significant 
differences in relation to 
outcome between the 
accurately placed and the 
inaccurately placed 
groups 
 
This was a 
non RCT and 
the follow-up 
periods were 
short and 
sample size 
was short, 
therefore the 
evidence is 
limited 
Goel et al 
2012 
RCT n = 50, 
Aged ≥ 
18 (23 
women 
& 27 
men), 
mean 
age 
64.5 
years 
(42-87 
years), 
Anteriol
ateral 
group (n 
= 22), 
posterio
r group 
(n = 28) 
A combination of 3mls 
0.5% bupivacaine and 3 
mls of radiographic dye 
VAS & Constant-
Murley Score to 
assess pain & 
function respectively 
Pre-injection & 
30 minutes 
after the 
injection 
22 injections (78.5%) 
were accurately placed in 
SAIS with the posterior 
approach and in 14 
patients (63.6%) with 
anterolateral approach. 
This difference was 
statistically significant (P< 
0.05). Only patients who 
received injection 
accurately in SAS with 
either method had a 
reduction in pain of an 
average of 4 points on 
VAS, and improvement in 
the Constant score of 
average 14 points. 
 
 
 
Although this 
RCT showed 
that the 
posterior 
route of 
shoulder 
injection is 
more 
accurate 
compared to 
the 
anterolateral, 
it has failed 
to 
demonstrate 
clinical 
effectiveness 
due to the 
short follow-
up periods 
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Study 
 
Design Sample 
Size  
Intervention Outcome Measures Follow-up Summary of Findings Limitations 
Henkus et 
al 2006 
RCT n = 35 
(22 
women, 
11 men; 
average 
age, 46 
years; 
range, 
25 to 64 
years)  
A mixture of 
bupivacaine, 
methylprednisolone, and 
gadolinium-DTPA 
directly followed by MRI 
to determine the actual 
site of Injection 
The Constant Score, 
Simple Shoulder 
Test, and VAS for 
pain 
Within 24 
hours and 6 
weeks after 
infiltration 
13 injections (76%) were 
in the subacromial bursa 
with a posterior approach 
and 10 (69%) with an 
anteromedial approach. A 
positive correlation 
between the injection 
confidence of the 
orthopaedic surgeon and 
the MRI was found in 
66%. Only injection of the 
subacromial bursa alone 
resulted in a significant 
decrease of the pain (P = 
.004) and an increase in 
the functional scores. 
Injection in the bursa and 
rotator cuff muscle 
showed a significant 
increase in pain (P = 
.032) but no change in 
clinical scores. The body 
mass index (BMI) had no 
influence on the scores 
 
The 
weakness of 
this study 
includes the 
short follow-
up period and 
small sample 
size. 
Kang et al 
2008 
RCT n = 58 
(28 men 
and 30 
women) 
A subacromial  
injection of 
corticosteroids, local 
anesthetic, and contrast 
dye from 1 of 3 
locations: anterolateral, 
lateral, or posterior 
 
 
 
 
 
 Accuracy was 
confirmed by 3 
radiographic views of 
the shoulder, while 
clinical ratings were 
assessed by the 
UCLA shoulder score 
and a 10-point VAS 
pain 
During the 
initial, post-
injection, and 
3-month visits. 
Overall accuracy was 
70%, with no difference 
among the 3 portals. 
Accuracy was not related 
to BMI. Also, 
accurate injections did not 
significantly improve the 
UCLA score, pain scale, 
or patient satisfaction at 3 
months. In contrast, 
accurate injections 
produced a positive  
The use of 
composite 
interventions 
of NSAIDs, 
physical 
therapy and 
cortisone 
injection/local 
anaesthetic 
on each 
patient 
makes it was  
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Study 
 
Design Sample 
Size  
Intervention Outcome Measures Follow-up Summary of Findings Limitations 
      Neer's impingement test 
more often (35/39 vs 9/16; 
P = .009). Overall, there 
was an improvement in 
the UCLA score (26.2-
32.2; P < .001) and a 
decrease in the pain scale 
(7.2-3.43; P < .001) at 3-
month follow-up. In 
conclusion, the accuracy 
of injection was 70% 
 
difficult to 
single out the 
contributions 
of the 
additional 
effects of 
cortisone 
injection 
alone. 
 
Marder et 
al 2012 
RCT n = 75 Radiopaque contrast 
medium, corticosteroid, 
and local anesthetic. 
Accuracy of injection 
into the bursa - intra 
& extrabursa. Pain 
VAS 
Between thirty 
minutes and 
one hour after 
injection, after 
exercising the 
arm, the 
patient was 
asked again to 
record the 
level of pain 
The rate of accuracy 
varied 56% -posterior 
route, 84% -anterior route, 
and 92% -lateral route (p 
= 0.006; chi-square test). 
The accuracy through 
posterior route was 
significantly lower 
compared to the anterior 
or the lateral route (p < 
0.05 for both 
comparisons; Poisson 
regression). The accuracy 
of injection was 
significantly lower in 
females than in males (p 
< 0.006; chi-square test). 
Among males, no 
differences between the 
routes were noted (with 
accuracy rates of 89% for 
the posterior route, 92% 
for the anterior route, and 
93% for the lateral route). 
Among females, accuracy  
The use of a 
single 
experienced 
orthopaedic 
consultant to 
complete the 
arthroscopic 
evaluation of 
the needle 
distance 
might have 
introduced 
assessment 
bias - limiting 
intra-rater 
reliability 
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      rate was lower for the 
posterior route than for 
either the anterior or the 
lateral route (38%- 
posterior route, 77% - 
anterior route, and 91% -
lateral route) (p < 0.05). 
 
Min et al 
(2013) 
RCT n = 32 40 mg triamcinolone; 
and the NSAID syringe 
contained 60 mg 
ketorolac. 
Arc of motion, VAS 
for evaluating pain, 
and the UCLA (The 
University of 
California at Los 
Angeles) shoulder 
rating scale 
At 1 month 
follow-up 
At 1 month follow-up, both 
groups showed increased 
ROM and reduced pain. 
The steroid group 
decreased in active 
abduction while the 
NSAID group increased 
(steroid: 134°, NSAID: 
151°, P = .03). The mean 
improvement in the UCLA 
shoulder scale at 4 weeks 
was 7.15 for the NSAID 
group and 2.13 for the 
steroid group (P = .03). 
Subgroup analysis of the 
UCLA scale demonstrated 
an increase in both 
forward flexion strength (P 
= .04) and patient 
satisfaction (P = .03) in 
the NSAID group. 
 
The 
weakness of 
this study 
includes the 
short follow-
up period and 
small sample 
size. 
Penning et 
al 2012 
RCT n = 159 
patients 
(84 
women 
and 75 
men, 
mean 
age of  
Subacromial injections 
using lidocaine with one 
of hyaluronic acid (51 
patients), corticosteroid 
(53 patients) or placebo 
(55 patients). 
 
 
Primary outcome 
was pain on a VAS, 
and secondary 
outcomes included 
the CMS score, 
shoulder pain score, 
functional mobility 
score, shoulder  
Assessed at 3, 
6, 12 and 26 
weeks 
Corticosteroid injections 
were more effective in 
reducing pain than 
hyaluronic acid injections 
and placebo in the first 3 
to 12 weeks. At 26 weeks, 
the cortisone group 
showed better reduction  
Although the 
authors 
report that 
the other 
outcome 
measures 
showed 
similar results  
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  53 (20 
to 87) 
 disability 
questionnaire and 
pain-specific 
disability score. 
 in pain than the hyaluronic 
acid group, but it was not 
more effective than the 
placebo group. 
with the pain 
scale, the 
presentation 
of the results 
lacked 
sufficient 
clarity. 
Plafki et al 
2000 
RCT n = 50 Group 1(10 patients): 
10ml injection of pure 
0.5% bupivacaine  
Group 2(20 patients): 
10mg injection of 
triamcinolone acetonide 
(corticosteroid) with 
10ml 0.5% bupivacaine  
Group 3(20 patients): 
4mg injection 
dexamethasone-21-
palmitat (lipoid 
corticosteroid, 
equivalent to 2.5mg 
dexamethasone) with 10 
ml of 0.5% bupivacaine. 
All injections were into 
subacromial bursae with 
positioning verified by 
ultrasound. All patients 
received standardised 
physiotherapy program 
(cryotherapy and 
strengthening exercises) 
1) impingement 
signs  
2) pain scale  
3) Patte score - 
judges subjective 
estimation of pain, 
function, force and 
overall handicap 
(excellent when 
score > 85%)  
4) Ultrasound 
examination 
Assessed at 
baseline, 1, 6 
and 26 weeks  
Treatment in group 1 had 
to be stopped because of 
inefficacy. In groups 2 and 
3 favorable results were 
achieved in 19 out of 40 
patients 
The fact that 
group 1 (the 
placebo arm) 
only had 10 
participants 
while the 
other 
intervention 
groups had 
20 
participants 
each warrant 
cautious 
interpretation 
of the study. 
Sardelli & 
Burks 2008 
Non 
RCT 
n = 30 
(18 men 
and 12 
women) 
Arthroscopic evaluation 
of needle length 
distance to the 
subacromial bursa using 
a spinal needle 
Needle length from 
lateral, anterior and 
posterior routes to 
the subacromial 
space 
 
No follow-up The mean distance with 
anterior route was 2.9 +/- 
0.6 cm. The mean 
distance with lateral route 
was 2.9 +/- 0.7 cm. The  
This was an 
accuracy 
study 
therefore it 
does not  
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      mean distance with 
posterior needle 
placement was 5.2 +/- 1.1 
cm. The mean BMI for the 
group of patients was 
27.5. The minimum was 
18.7, and the maximum 
was 42.8. 
demonstrate 
efficacy of 
subacromial 
cortisone 
injection in 
SAIS patients 
Winter et al 
1997 
RCT n = 114 First week: All received 
50 mg diclofenac 
sodium three times 
daily.  
Then on the basis of 
reassessment they were 
divided into diagnostic 
groups. Within the 
synovial group, patients 
were allocated to group 
A (47 patients): 
corticosteroid injection 
(1-3 injections as 
needed at baseline, 1 
week and after 2 weeks, 
of 1 ml of 40 mg/ml 
triamcinolone acetonide 
with 9 ml of 10 mg/ml 
lignocaine) into 2 out of 
3 synovial structures 
(glenohumeral joint, 
capsule, subacromial 
space and ACJ; Group 
B (32 patients): 
manipulation and 
mobilisation of cervical 
spine, upper thoracic 
spine, upper ribs, ACJ 
joint, GHJ once weekly  
1) Pain assessed by 
the shoulder pain 
score (6 item 
questionnaire and 
101-point numerical 
pain scale) (7 points 
= no pain to 28 
=severe pain)  
2) active and passive 
ROM of GHJ, 
cervical spine, upper 
thoracic spine, 
palpating the muscle 
tendons on the head 
of humerus, the ACJ, 
and the upper ribs  
3) felt "cured" 
(defined as 
disappearance of 
shoulder complaints 
or a decrease to 
such an extent that 
they were no longer 
difficult, did not need 
treatment, or no 
longer interfered with 
normal working) or if 
treatment failed 
 
Assessment at 
baseline and 
2, 6, 11 
weeks. 
In the shoulder girdle 
group duration of 
complaints was 
significantly shorter after 
manipulation compared 
with physiotherapy (P < 
0.001). Also the number 
of patients reporting 
treatment failure was less 
with manipulation. In the 
synovial group duration of 
complaints was shortest 
after corticosteroid 
injection compared with 
manipulation and 
physiotherapy (P < 
0.001). Drop out due to 
treatment failure was low 
in the injection group 
(17%) and high in the 
manipulation group (59%) 
and physiotherapy group 
(51%). 
Loss to follow 
up was 
greater than 
50% in the 
manipulation 
and 
physiotherap
y groups 
compared to 
the injection 
group which 
was 17%, 
this could 
limit the 
conclusions 
of the study 
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   with a maximum of 6 
treatments) Group C (35 
patients): physiotherapy 
twice a week. Could use 
exercise therapy, 
massage, physical 
applications but no 
mobilization and 
manipulation techniques 
were allowed. 
 
 
   
Yamakado 
2002 
Non 
RCT 
n = 53 
patients 
(34 
women 
and 19 
men; 
mean 
age, 
74.5 
years; 
range, 
49 to 
91) 
A mixture of 0.5 mL (2.5 
mg) betamethasone 
acetate and 3 mL of 
radiographic contrast 
material (iotrolan) and 7 
mL of 1% lidocaine 
using a lateral approach 
Radiographs of the 
shoulder joint were 
taken immediately 
after the injection to 
determine the 
structure reached by 
the injection. Pain 
expressed as Neer & 
Hawkins 
impingement signs 
were obtained before 
and 15 minutes after 
the injection, and 
subjectively 
assessed using a 4-
point self-
administered pain 
score. Pain reduction 
due to subacromial & 
intradeltoid injection 
was compared. 
Before and 15 
minutes after 
the injection, 
Thirty-nine of the 56 
injections (70%) were 
judged to have reached 
the subacromial bursa. 
Twelve (21%) were seen 
to have entered the 
deltoid muscle; 2 (4%) 
were in the glenohumeral 
joint; and 3 (5%) were 
subcutaneous. A 
comparison of 
subacromial bursal with 
intradeltoid injection 
showed no significant 
differences in pain 
reduction expressed as 
impingement signs (1.5 vs 
1.7 in the Neer 
impingement sign and 1.6 
vs 1.6 in the Hawkins 
impingement sign, 
respectively). 
 
The 
weakness of 
this study 
include the 
short follow-
up period 
which is not 
applicable in 
normal 
clinical 
practice 
where 
injection 
follow-up 
periods are 
much longer 
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Table 3: Summary of Findings of Some Key Systematic Reviews included In the Study 
Author Review’s Aim Findings Conclusion 
Arroll & 
Goodyear-
Smith (2005) 
To determine the 
effectiveness of intra-
articular and 
subacromial injections of 
corticosteroid for 
treatment rotator cuff 
tendonitis and frozen 
shoulder. 
Seven studies were reviewed for corticosteroids versus 
placebo and three for corticosteroids versus NSAIDs. The 
relative risk for improvement for subacromial corticosteroid 
injection for rotator cuff tendonitis was 3.08 (95% confidence 
interval [CI] = 1.94 to 4.87). The number needed to treat based 
on the pooled relative risk was 3.3 (95% CI = 1.8 to 7.7) 
patients to obtain one improvement. The relative risk for high 
dose (50 mg of prednisone or more) was 5.9 (95% CI = 2.8 to 
12.6). The relative risk for improvement with steroids compared 
with NSAIDs was 1.43 (95% CI = 0.95 to 2.16). The number 
needed to treat for corticosteroids versus NSAIDs was 2.5 
(95% CI = 1 to 9) for one significant study. The relative risks for 
intra-articular steroid injection for rotator cuff tendonitis were 
not statistically significant. 
 
Subacromial injections of 
corticosteroids are effective for 
improvement for rotator cuff 
tendonitis up to a 9-month period. 
They are also probably more 
effective than NSAID medication. 
Higher doses may be better than 
lower doses for subacromial 
corticosteroid injection for rotator cuff 
tendonitis 
Buchbinder et 
al (2003) 
To determine the 
efficacy and safety of 
corticosteroid injections 
in the treatment of adults 
with shoulder pain 
Twenty-six trials met inclusion criteria. The number, site and 
dosage of injections varied widely between studies. The 
number of participants per trial ranged from 20 to 114 (median 
52 participants). Methodological quality was variable. For 
rotator cuff disease, subacromial steroid injection was 
demonstrated to have a small benefit over placebo in some 
trials however no benefit of subacromial steroid injection over 
NSAID was demonstrated based upon the pooled results of 
three trials. For adhesive capsulitis, two trials suggested a 
possible early benefit of intra-articular steroid injection over 
placebo but there was insufficient data for pooling of any of the 
trials. One trial suggested short-term benefit of intra-articular 
corticosteroid injection over physiotherapy in the short-term 
(success at seven weeks RR=1.66 (1.21, 2.28) 
 
Although several studies were 
reviewed, the overall evidence is 
limited because of the small sample 
sizes, variable methodological 
quality and heterogeneity of the 
studies. However, subacromial 
corticosteroid injection for rotator cuff 
disease and intra-articular injection 
for adhesive capsulitis may be 
beneficial although their effect may 
be small and not well-maintained.  
Gaujoux-Viala 
et al (2009) 
To assess the efficacy 
and safety of steroid 
injections for patients 
with tendonitis of the 
shoulder or elbow. 
In all, 20 RCTs were analysed (744 patients treated by 
injections and 987 patients treated by controls; 618 shoulders 
and 1113 elbows). The pooled analysis indicated only short-
term effectiveness of steroids compared to the controls for pain 
and function [example, pain at week 1–3 ES = 1.18 95% CI 
0.27 to 2.09), pain at week 4–8 ES = 1.30 (95% CI 0.55 to  
Steroid injections are well tolerated 
and more effective for tendonitis in 
the short-term than pooled other 
treatments, though similar to 
NSAIDs. No long-term benefit was 
shown. 
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  pain at week 12–24 ES = −0.38 (95% CI −0.85 to 0.08) and 
2.04), pain at week 48 ES = 0.07 (95% CI −0.60 to 0.75)]. 
Sensitivity analyses indicated similar results whatever the 
localisation, type of steroid and type of comparator except for 
NSAIDs: steroid injections were not significantly better than 
NSAIDs in the short-term. Compared with other treatments, 
steroid injections appeared more effective in acute or subacute 
tendonitis. The main side effects were transient pain after 
injection and skin modification. 
 
Johansson et 
al (2002) 
To determine which 
treatments for 
patients with 
subacromial pain are 
trusted by (GPs) and 
physiotherapists, and to 
compare trusted 
treatments 
with evidence from a 
systematic critical review 
of the scientific 
literature 
 
 
Forty studies were included. The methodological quality varied 
and only one treatment had definitive evidence for efficacy for 
non-specific patients, namely injection of corticosteroids.  
Clinicians’ trust in corticosteroids 
injected into the subacromial bursa is 
supported by definitive evidence for 
short-term efficacy. Acupuncture is a 
trusted treatment for subacromial 
pain and supported by tentative 
evidence for efficacy. The tentative 
evidence for ultrasound therapy as 
being ineffective in patients with 
subacromial pain, together with 
evidence from earlier reviews, leads 
us to question both the trust in this 
therapy and its use in practice. This 
study has demonstrated very little 
congruence between the trust that 
primary care clinicians demonstrate 
for specific therapies and the 
available scientific evidence for their 
efficacy 
Koester et al 
(2007) 
To investigate whether 
subacromial 
corticosteroid injections 
are effective in the 
treatment of rotator cuff 
disease 
Nine RCTs (number of participants unclear) were included in 
the review. The included RCTs met between four and eight of 
the eight validity assessment criteria. 
Four out of 6 RCTs reported a statistically significant 
improvement in pain on a visual analogue scale for patients 
receiving cortisone subacromial injection, relative to controls. 
One reported night-time pain relief at 1 month, but no 
differences at 3 months. Three out of 7 RCTs reporting ROM 
found a statistically significant improvement, ranging from 14 to 
45 degrees. Two RCTs found no difference between 
There is little reproducible evidence 
to support the efficacy of 
subacromial corticosteroid injection 
in managing rotator cuff disease. 
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  subacromial cortisone injection and control groups on 
measures of function. Of the 2 RCTs that did find a significant 
difference, one reported that this was not significant at the 3- 
month follow-up. Among the 9 RCTs included, a single case of 
mild skin hypopigmentation at the site of injection was reported 
for CSI, with no complications reported in the control groups 
 
Mohamadi et 
al (2016) 
 
 
 
 
 
 
 
 
 
 
Do corticosteroid 
injections reduce pain in 
patients with rotator cuff 
tendinosis 3 months 
after injection, and if so, 
what is the number 
needed to treat (NNT)? 
(2) Are multiple 
injections better than 
one single injection with 
respect to pain reduction 
at 3 months 
 
Fourteen RCTs were included in the systematic review, 
although 3 of these studies had a Jadad score 
(a measure of methodological quality) of less than 3, so only 
11 RCTs (n=726) were included in the 
meta-analysis. Corticosteroid injection did not reduce pain 
intensity in adult patients with rotator cuff tendinosis more 
than a placebo injection at the 3-month assessment. The 
largest effect on pain relief was between 4 and 8 weeks with a 
SMD of 0.52 (range, 0.27–0.78) (p \0.001). At least five 
patients must be treated for one patient’s pain to be transiently 
reduced to no more than mild. Repeated injections were not 
found to be more effective than a single injection at any time 
 
Cortisone injection into the shoulder 
provides some short term pain relief 
for patients with rotator cuff 
tendinosis and cannot modify the 
natural course of the disease 
 
 
 
 
 
 
Van der 
Heijden GJ et 
al (1996) 
The study was designed 
to assess the efficacy of 
steroid injections for 
shoulder disorders. 
Only three out of the 16 studies scored more than 50 points, 
indicating a generally poor quality of methods. Most studies 
reported small sample sizes. The flaws most often found were 
incomparability of co-interventions and poor blinding of 
therapist. The methods assessment was frequently hampered 
by incomplete information about randomization, prognostic 
comparability, compliance, outcome measures included, 
blinding of patients and blinding of outcome measurement. 
The evidence in favour of the 
efficacy of steroid injections for 
shoulder disorders is scarce. The 
methods of most studies appear to 
be of poor quality. The few studies 
that appear to be credible do not 
provide conclusive evidence about 
which patients at what time in the 
course of shoulder disorders benefit 
most from steroid injections 
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2.2.2 Qualitative Literature Search 
The strategy for the qualitative study mirrored that of the quantitative search (see 
section 2.2.1) and covered similar a period. In the qualitative search strategy 
specific subject headings and additional text words describing the population of 
interest (such as shoulder pain, subacromial impingement syndrome) were used 
to identify relevant studies. These were combined using the Boolean operator 
'AND' with subheadings of: patient experience, education, patient perception, 
patient attitude, exercise information, information, information leaflet, qualitative 
interview and qualitative study.  
 
2.2.2.1 Searching Other Resources 
The other resources that were searched for the qualitative study included those 
mentioned in pages 15 and 16 (items II - IX). References of the review articles 
were screened to identify potentially relevant qualitative studies.  
 
2.2.2.2 Results of the Qualitative Search 
A total of 1367 articles were retrieved from the CSP Ebscohost electronic 
databases for the qualitative search (see Table 4). There were 969 citations after 
removal of 398 duplicates. After careful evaluation of the titles and/or abstracts, 
966 articles that were not related to the study were excluded from the 969 
citations and 3 articles that were possibly relevant to this study were identified 
(see Figure 2 for details). Of this number, only one article was found to be 
directly relevant to this thesis.  
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Table 4: Qualitative Searches - Combined Results of the CSP Electronic 
Database Searches of AMED, CINAHL, CINAHL Plus with Full Text, CSP 
Online Library Catalogue, eBook Collection (EBSCOhost), MEDLINE, 
SPORTDiscus 
# Search Terms Combined Results from 
above Database 
Searches 
S1 shoulder pain 18,968 
S2 Subacromial impingement syndrome 2,848 
S3 Shoulder impingement syndrome 3,791 
S4 Rotator cuff 20,583 
S5 Rotator cuff tendinopathy 435 
S6 Supraspinatus tendonitis 91 
S7 (shoulder$ or subacromial$ supraspinatus$ or rotator cuff$) 
adj6 (bursitis or impinge$ or tendonitis or tendinitis or pain$ 
or pathology$) 
1,733 
S8 (Sub-acromial or Subacromial) adj4 (bursitis$ or impinge or 
impingement or compression or decompression) 
495 
S9 Bursitis 7,097 
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR 
S9 
135,337 
S11 INJECTIONS 470,563 
S12 (steroid$ or corticosteroid$ or sub-acromial or subacromial) 
adj6 (inject$ or Kenalog or Triamcinolone$ or Depo-
Medrone or Methlyprednisolone$ or Lidocaine)  
390 
S13 (steroid$ or corticosteroid$ or sub-acromial or subacromial) 
adj6 (inject$ or Kenalog or Triamcinolone$ or Depo-
Medrone or Methlyprednisolone$ or Lidocaine)  
78633 
S14 (steroid$ or corticosteroid$ or sub-acromial or subacromial) 
adj6 (inject$ or approach$ or route$ or posterior$ or lateral$ 
or anterior$) 
529,828 
S15 S11 OR S12 OR S13 OR S14  488,894 
S16 Clinical trial$ or Controlled trial$ or Qualitative study$ or 
Interview$).pt.  
1,905,338 
S17 (random$ or randomize$).mp  13 
S18 (patient experience [mh] OR perception OR understanding 
OR education patient OR education [mh])  
1,771,520 
S19 (patient centred care [mh] OR information booklet [tw] OR 
book* [tw] OR pamphlet* [tw] OR leaflet* [tw] OR poster* 
[tw] OR education* [tw] OR information* [tw])  
11 
S20 S16 OR S17  1,905,338 
S21 S18 OR S19  1,771,526 
S22 S10 AND S15 AND S20 AND S21  1,367 
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Figure 2: Flow Chart for the Qualitative Search Result 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1367 Citations identified through database 
searching: 
a. CINAHL Plus with Full Text (1302) 
b. eBook Collection(EBSCOhost) (35) 
c. CINAHL (15) 
d. MEDLINE (12) 
e. SPORTDiscus (3) 
398 duplicates removed from the 
combined searches (n = 969) 
969 potential relevant citations 
screened 
966 citations 
excluded at title 
or abstract with 
reasons 
3 Full text studies retrieved for 
detailed assessment for eligibility 
2 full text articles 
excluded with 
reasons: 
Not population of 
interest = 2 
 
1 study included as part of the 
qualitative review 
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2.3 Discussion of the Literature Review 
The findings of both the quantitative and qualitative literature review will be 
discussed in this section. 
 
2.4 Discussion of the Quantitative Literature Review Findings 
This section and the associated subsections describe the quantitative literature 
review on the anatomy shoulder joint and rotator cuff muscles, SAIS with 
particular reference to its clinical presentation, classification, aetiology, 
diagnostic difficulties and clinical assessment. It discusses the outcomes used in 
the study and their justification. It also includes discussion on the current trend in 
National Health Service (NHS) musculoskeletal practice, the role of ESP in 
musculoskeletal practice, current treatment for SAIS, issue of needle placement 
in subacromial injections and the evidence on needle placement in subacromial 
injections. 
 
2.4.1 Anatomy of SAIS 
2.4.2 The Shoulder 
The human shoulder joint is a complex structure consisting of the glenohumeral 
joint, acromioclavicular joint, sternoclavicular joint and scapulothoracic joint. As 
the major joint in the shoulder complex, the glenohumeral joint which is primarily 
a ball and socket type of synovial joint permits the greatest range of any joint in 
the body (Terry & Chopp 2000, Zheng et al 2016). The glenohumeral joint cavity 
is cushioned by articular cartilage covering the face of the glenoid fossa and the 
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head of the humerus, which is about four times the size of the glenoid fossa 
(Terry & Chopp 2000). This makes the joint very mobile allowing movement in all 
directions including flexion, extension, abduction, adduction, circumduction 
(rotation through 360 degrees), internal rotation, external rotation, and horizontal 
flexion (Haering et al 2014, Kesson & Atkins 2005). However, the laxity of the 
glenohumeral articular surface challenges the stability of the shoulder (Masters & 
Burley 2007, Zheng et al 2016). Yamamoto & Itoi (2014) in a review of 
biomechanics of the shoulder and rotator cuff repair report that the capsulolabral 
ligament complex together with the rotator cuff muscles provides the dynamic 
support (Yamamoto & Itoi 2014).  However, Zheng et al (2016) in a review of the 
clinical implications and modelling techniques of the shoulder complex have 
argued that the understanding about the individual contributions of these 
supporting structures to joint stability and mobility and their relations with each 
other are still limited. This view was supported by Yamamoto & Itoi (2014) in a 
review of shoulder biomechanics. The humerus has two tuberosities – the 
greater and the lesser. The greater tuberosity has three facets into which the 
tendons of the supraspinatus, infraspinatus, and teres minor insert (Terry & 
Chopp 2000). The lesser tuberosity is where the tendon of subscapularis inserts. 
These muscles form the rotator cuff.  
 
2.4.3 Rotator Cuff Muscles 
The ‘‘rotator cuff’’ comprises four muscles; the subscapularis, the supraspinatus, 
the infraspinatus and the teres minor, and their tendons which surround and 
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stabilize the shoulder joint during movement (see Figures 3 & 4) (Ogilvie-Harris 
& Demaziere 1993, Galatz et al 2001). They maintain the head of the humerus in 
the glenoid fossa (Kesson & Atkins 2005), and are involved with the deltoid 
muscle during shoulder elevation (Nordin & Frankel 1989). Previous authors hold 
a common view that the four rotator cuff tendons are separate entities 
(Basmajian & DeLuca 1985, Romanes 1986, Williams 1995) and because of this, 
muscle and tendon-specific tests have been developed (Cyriax & Cyriax 1993). 
However, with passage of time it is now clear that all four tendons fuse to form 
the rotator cuff (Hanchard et al 2011), except for subscapularis which is separate 
and joined to the rest of the cuff through the rotator interval (Funk 2005). The 
clear implication of this anatomical structure is that it is not possible clinically to 
distinguish individual tendon pathology selectively (Lewis & Tennent 2007). 
However, our understanding of the anatomy, mechanics and the biology of the 
rotator cuff is important to our treatment plans (Funk 2005). 
 
Figure 3: Rotator Cuff Muscles                Figure 4: Long Head of Biceps 
 
 
(Reproduced with permission from Endoszkop.com 2015 & WebMD 2014) 
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At the neck of the humerus, the insertion of the rotator cuff is interrupted only by 
the bicipital groove, through which the long head of the biceps brachii tendon 
passes laterally and distally from its origin on the superior lip of the glenoid. This 
tendon, together with those of the rotator cuff has been identified as a source of 
shoulder pain through degeneration and overuse (Kesson & Atkins 2005). 
 
Several bursae (large lubricating sac) have been identified with the shoulder joint 
including the subdeltoid (subacromial), subscapular and subcoracoid bursae. 
However, the bursa most commonly involved with shoulder pathology such as 
SAIS is the subacromial bursa, which lies between the acromion, the deltoid, and 
the joint capsule (Hanchard et al 2013). It also lies under the acromion and the 
coracoacromial ligament and between the supraspinutus tendon (O’Sullivan & 
Siegelman 2012). The pinching of the subacromial bursa, the rotator cuff 
tendons, and the long head of biceps between the acromion superiorly and the 
greater tuberosity of the humerus below are called SAIS (Neer & Welsh 1997, 
Masters & Burley 2007). Irritation of the bursa and cuff (due to degeneration, and 
reversible by conservative treatment) and rotator cuff full thickness have been 
implicated as a continuum of impingement severity (Neer & Welsh 1997). 
 
2.4.4 Subacromial Impingement Syndrome 
Subacromial impingement syndrome is frequently used as an umbrella term to 
describe a variety of conditions such as rotator cuff impingement syndrome 
(RCIS), subacromial bursitis, rotator cuff tendonitis, shoulder impingement 
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syndrome (SIS), supraspinatus tendonitis and painful arc syndrome (Lewis et al 
2001). Lewis (2008), in a literature review on assessment of rotator cuff 
tendinopathy/SAIS, identified rotator cuff tendonitis, supraspinatus tendonitis and 
subacromial bursitis as diagnostic labels associated with rotator cuff disease. 
Furthermore, the CSP, in its clinical guidelines for impingement syndrome, 
referred to SAIS as RCIS or SIS or painful arc syndrome (Hanchard et al 2004). 
It has been reported that these conditions may act independently or in 
combination, and can manifest as anterior or anterior-lateral-superior shoulder 
pain (Lewis et al 2001). For the purpose of this research, SAIS will be used to 
refer to any of the above-mentioned conditions. 
 
2.5 Diagnosis of SAIS 
2.5.1 Clinical Symptoms of Subacromial Impingement Syndrome 
The clinical manifestation of SAIS varies from patients experiencing only mild 
discomfort and transient weakness, to severe acute or chronic pain and loss of 
function (Bokor et al 1993). Pain is often located at the anterior lateral aspect of 
the shoulder and radiates to the side of the arm (Lewis et al 2001). Classically, 
there is a painful arc during elevation or lowering of the arm, or both, as the 
humeral tuberosities pass under the coracoacromial arch (Hanchard et al 2004, 
Neer 1983). Pain is also aggravated with placing the arm behind the back 
(American Academy of Orthopaedic Surgeons 2008), arm elevation or overhead 
activities associated with daily living (Lukasiewicz et al 1999, Ludewig & Cook 
2002, Lewis et al 2005). Night pain may be present in RCIS, and is particularly 
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associated with rotator cuff tears (Zuckerman et al 1991), but it is also a common 
feature of adhesive capsulitis (Hanchard et al 2004). However, if linked with age, 
night pain can be suggestive of RCIS (Hanchard et al 2004). This is consistent 
with the Litaker et al (2000) study that demonstrated arthrographically 
determined cuff tears which were significantly (P < 0.05) correlated with three 
factors: age (> 65), night pain and weak external rotation. 
 
Hanchard et al (2013) in a review of physical tests for shoulder impingements 
and local lesions of bursa, tendon or labrum that may accompany impingement 
reports that clinicians tend to use two or three positive clinical findings to 
diagnose SAIS. These would include positive painful arc (Cyriax & Cyriax 1982), 
positive impingement sign (Neer & Welsh 1997) and tender palpation of the 
greater tuberosity. Although the sensitivities and specificities of these 
orthopaedic tests varies, in practice a diagnosis of impingement syndrome is still 
based on findings of a clinical examination for a majority of patients (Dinnes et al 
2003). Due to the subjective nature of these tests by various clinicians having 
different assessment and interpretative skills, there has been variation in testers’ 
expertise (Hanchard 2005). 
 
2.5.2 Neer and Welsh’s (1977) Classification of Impingement Syndrome 
The three stages of impingement suggested by Neer & Welsh (1977) are the 
most widely reported (Hanchard et al 2004, Lewis et al 2005). This classification 
was borne out of the many propositions regarding the aetiology of SAIS.  
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Stage 1: Reversible subacromial edema and haemorrhage of the bursa and cuff 
occurs, usually in the under-25 age group, because of overuse (Fongemie et al 
1998, Hanchard et al 2004).  
 
Stage 2: Irreversible impingement by conservative treatment and typically found 
in the 25–40 age groups and represents irreversible changes, such as fibrosis 
and tendinitis. Accordingly, Hawkins & Kennedy (1980) suggest there may be a 
catching sensation with the reversal of elevation or extension.  
 
Stage 3: Impingement is marked by bony changes and cuff tears, usually in 
those aged over 40 (Neer & Welsh 1977).  
 
According to Lewis et al (2005), although the stages are clinically distinct, they 
may represent a continuum, with some cases overlapping. Furthermore, three 
important arguments have been made about this classification (Hanchard et al 
2004). Firstly, it has been suggested that the onset of stage I is not strictly limited 
to those less than 25 years old, but could occur at any age, given the right 
conditions such as excess overhead activity (Zuckerman et al 1991). Secondly, 
as discussed by Hanchard et al (2004), when problems do occur in the under 
25s, underlying instability should be specifically investigated. This suggestion is 
supported in Parker & Seitz’s (1997) consecutive series of 50 patients with 
“shoulder impingement/instability overlap syndrome” whose ages ranged up to 
38 years with mean age of 26. Thirdly, a RCT has demonstrated that stage II is 
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responsive to appropriate conservative treatment such as cortisone injection; 
and it is possible that components of stage III involving partial thickness cuff may 
also respond positively to conservative treatment (Brox et al 1997). These 
findings support the assertion that SAIS is reflective of a spectrum of soft tissue 
pathologies, rather than a diagnostic label relating to pathology in a specific 
structure (Lewis 2010). In a review of rotator cuff tendinopathy, Lewis (2010) 
concludes that a considerable body of research is necessary to understand fully 
the pathohistology of rotator cuff tendinopathy and its relationship with bursal 
pathology. 
 
Recently, Cook & Purdam (2009) presented a generic model to explain the 
continuum of tendon pathology based on existing knowledge of the clinical, 
histological and imaging framework of tendon pathology. Lewis (2010) suggests 
that due to the regional anatomical and/or biomechanical considerations of 
tendons, variation of this generic model may be required for the management of 
rotator cuff tendons. Adopting Cook & Purdam generic tendon model, Lewis 
(2010) proposed a new model to explain the pathoaetiology and management of 
rotator cuff tendons and subacromial bursa. A brief description of this model is 
discussed below. 
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2.5.3 Lewis (2010) New Model for Rotator Cuff Tendinopathy 
According to Lewis (2010), this new model consists of the underloaded tendon 
stage, normal tendon overload, underloaded/normal tendon overload, reactive 
tendinopathy tendon disrepair and tendon degeneration. 
 
In practice, patients who present with any of the underloaded, normal tendon or 
underloaded/normal tendon stages of tendinopathy, are not likely to present to 
physiotherapy or musculoskeletal clinic requiring intensive treatment because 
pain is likely to resolve with rest, gentle exercises, pain medication, and natural 
resolution. However, if pain is persistent and interfering with daily activities such 
as lifting, then physiotherapy or cortisone injection to the painful shoulder might 
be considered. 
 
In the reactive and disrepair stages, the subacromial bursa has been implicated. 
Some authors (Gotoh et al 1998, Sakai et al 2001) have reported abnormal 
neuropeptite (substance P) and cytokine levels in the reactive stage; with 
increased swelling within the tendon, and bursal effusion. This is similar to the 
disrepair stage characterized by significant areas of swelling and tendon 
degeneration (Lewis 2010).  
 
Pain may be present in both stages, and it indicates that the subacromial bursa 
is involved (Lewis 2010). The use of cortisone injection has been suggested to 
help relieve pain and inflammation caused by the bursa inflammation and tendon 
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cell proliferation/protein production or intratendinous swelling (Lewis 2010). More 
importantly, it is being found that pain-relieving injections that reach the bursa 
produce superior pain relief than those that target other structures (Henkus et al 
2006, Marder et al 2012). Lewis (2010) also suggested relative rest, cryotherapy, 
manual therapy, taping, use of NSAIDs (ibuprofen), modified shoulder activity 
below 90 degrees and dietary changes to help reduce pain and improve shoulder 
function. However, evidence for this is equivocal. Surgery is usually considered 
as the last option if conservative treatments such as physiotherapy and cortisone 
injection have been unsuccessful. 
 
The tendon degenerative stage is characterised with significant structural tendon 
failure, with diagnostic imaging evidence of large partial-thickness, full-thickness 
and massive rotator cuff tears. Evidence exists that even in the presence of 
significant structural pathology (partial or full thickness tear), shoulder range of 
movement and muscle power may be improved when pain has subsided (Ben-
Yishay 1994, Brox et al 1997 & Steenbrink et al 2006). Surgical consideration to 
repair the rotator cuff should be based on the individual patient’s functional ability 
and requirements, size of the cuff tear and the amount of fat infiltration into the 
muscle because the presence of fatty streaks has been associated with negative 
surgical outcomes (Goutallier et al 2003,  Liem et al 2007). 
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2.5.4 Aetiology of Subacromial Impingement Syndrome 
2.5.4.1 The Subacromial Space 
The space between the undersurface of the acromion and the superior aspect of 
the humeral head is termed the impingement interval (Fongemie et al 1998) or 
supraspinatus outlet (Neer & Poppen 1987) and the subacromial space (Neer 
1972). Using radiographic evidence it measures approximately 1.0 to 1.5 
centimetres (Umer et al 2012). The subacromial space is defined inferiorly by the 
humeral head and superiorly by the anterior edge and under surface of the 
anterior third of the acromion, coracoacromial ligament and the acromioclavicular 
joint (Neer 1972, Umer et al 2012). It is surrounded by the tendons of the rotator 
cuff and long head of the biceps tendon, the bursa and the coracoacromial 
ligament (Lewis et al 2001).  This space is normally narrow and when the arm is 
abducted or elevated, the greater tuberosity moves closer to the acromion, 
narrowing the space further. SAIS has been suggested to result from pathology 
of any of the contents of the subacromial space (Lewis et al 2001, Hanchard et al 
2013). However, it has been argued that the aetiology and pathogenesis of SAIS 
remains unclear (Lewis et al 2001, Lewis et al 2005). Recently, Lewis (2010) 
proposed a new model to explain the pathoaetiology and management of rotator 
cuff tendons and subacromial bursa. This new model suggests that pain and 
inflammation caused by SAIS is due to the bursa inflammation and tendon cell 
proliferation/protein production or intratendinous swelling of the rotator cuff 
tendons. 
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2.5.4.2 Factors Associated with Subacromial Impingement Syndrome 
Neer (1972, 1983) argued that 95% of all rotator cuff lesions and 100% of 
impingement pathology are attributed to friction between the acromion and the 
surrounding structures within the subacromial space. Neer (1972,1983) further 
described the “impingement sign”, a clinical procedure used to reproduce 
symptoms, and the “impingement test”, a 10 cc (10 ml) injection of 1.0% 
xylocaine into the subacromial space, to reduce symptoms such as inflammation 
and pain (Lewis et al 2001).  
 
However, Neer’s concept of SAIS has been challenged and the literature (Jobe 
1997, Kibler 1998, Ogata & Uhthoff 1990, Riand et al 1998) suggests that the 
aetiology of SAIS is multifactorial (Lewis et al 2001). Broadly speaking, it is 
divided into intrinsic (intratendinous) and extrinsic (extratendinous) factors 
(Bigliani & Levine 1997, Lewis 2008), and can be further characterized into 
primary (intrinsic or extrinsic) and secondary aetiology, occurring because of 
another process such as shoulder instability or neurological injury. The intrinsic 
(intratendinous) factors include muscle weakness and degeneration of the rotator 
cuff due to increasing age, trauma, overuse, tension overload, and the extrinsic 
(extratendinous) factors are inflammation of the rotator cuff tendons and the 
bursae surrounding the subacromial space (Neer 1972, Fu et al 1991, Banas et 
al 1995, Bigliani & Levine 1997, Paletta et al 1997, Cook & Purdam 2009). Also, 
os acromiale (an unfused distal acromial epiphysis) (Neer 1972, Bigliani & 
Levine 1997), acromial morphology (Solem-Bertoft et al 1993, Ludewig & Cook 
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1996, Wang et al 1999), the attachment of the coracoacromial ligament (Farley 
et al 1994, Soslowsky et al 1994) and changes in the acromioclavicular joint 
(Edelson 1995) have been implicated as extrinsic factors. 
 
Examples of secondary aetiology include weak or dysfunctional rotator cuff and 
scapular musculature (Warner et al 1990, Ludewig & Cook 2000), and capsular 
laxity or tightness (Tyler et al 2000). 
 
The predominance of joint side rotator cuff pathology has led a number of 
investigators to argue that impingement also occurs on the articular side of the 
tendon. This involves pinching of intra-articular (internal joint) structures at the 
extremes of movement (Hanchard et al 2013). The model is known as internal 
(undersurface) impingement and may be subcategorised as anterior-superior or 
posterior-superior impingement. The aetiology of anterior superior impingement 
is not clear and it occurs rarely compared to posterior-superior impingement 
(Garofalo et al 2010). Anterior-superior impingement is thought to be caused by 
trauma or degenerative changes and is related to the biceps pulley lesion (which 
is made up by the superior glenohumeral ligament and coracohumeral ligament) 
and the instability of the long head of the biceps tendon (Habermeyer et al 2004, 
Garofalo et al 2010). Paley et al (2000) have suggested that posterior internal 
impingement occurs when the articular side of the supra or infraspinatus tendons 
are entrapped with the posterior/superior glenoid labral complex in a position of 
shoulder abduction and external rotation. This type of impingement however is 
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commonly associated with athletes who engage in overhead activities such as 
throwing (Cavallo & Spear 1998, Paley et al 2000). This phenomenon was 
originally identified by Walch et al (1992) in an arthroscopy study involving 17 
athletes with unexplained shoulder pain on throwing. They found that with the 
glenohumeral joint at 90 degrees of abduction and external rotation, the 
supraspinatus and infraspinatus tendons rotate posteriorly rubbing on the 
posterior-superior glenoid lip, and become pinched between the humeral head 
and the posterosuperior glenoid labrum (Walch et al 1992). This argument is also 
based on the findings of Edelson & Tietz (2000) who investigated a cohort 1232 
shoulders in clinical impingement test positions and the work of Jobe (1996) on 
shoulder impingement. Hanchard et al (2013) have argued that it is unclear to 
what extent internal impingement is limited to overhead sporting activities and 
whether instability is a prerequisite (Jobe 1996). Lewis (2008) has emphasized 
that definitive evidence for internal impingement is incomplete and until available, 
clinicians should be cautious interpreting this model (Claver 2009). 
 
Research findings suggest that controversy exists regarding the pain-generating 
mechanisms in patients with impingement syndrome (Johansson 2002). These 
potential mechanisms have been suggested to occur singularly or in combination 
(Lewis et al 2001, Michener et al 2004). Therefore, it is unclear as to the role of 
each individual mechanism, the relationships between these factors, or the 
association with functional loss and disability (Lewis et al 2001, Michener et al 
2004). However, recent research suggests that mainly the bursa inflammation 
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and tendon cell proliferation/protein production or intratendinous swelling causes 
the pain-generating mechanisms in patients with SAIS (Henkus et al 2006, Cook 
& Purdam 2009, Lewis 2010). Therefore, the role of each individual mechanism, 
the relationships between these factors, and the association with functional loss 
and disability, although previously unclear, is now becoming obvious. 
 
2.5.5 Diagnostic Difficulties 
Interpreting the evidence concerning the diagnosis of shoulder pathology is 
challenging because it has been reported that there is great variation in the 
diagnostic criteria applied (Green et al 1999, Stevenson 2006, Lewis 2008). In a 
majority of studies, diagnosing SAIS is based largely on the presence of a 
positive impingement sign such as Neer’s or Hawkins Kennedy (Kuhn 2009), 
despite recent studies assigning them low specificity values. The tests are 
designed to apply mechanical compression to the tissue of interest however, it is 
inconceivable that they would not stretch or compress other structures during the 
procedure (Lewis 2010). In general the tests that have a high sensitivity (ability of 
a test to discover pathology when it is present) have a low specificity (ability to 
rule out pathology when it is not) and vice versa (Claver 2009). Most of the 
difficulties encountered in making a clinical diagnosis of this condition come from 
the fact that this is a syndrome rather than a discrete pathology. No one test or 
finding in isolation is in itself diagnostic; instead, in practice we tend to rely on 
common patterns of presentation (Murrell & Walton 2001, Park et al 2005). 
Several investigative procedures such as x-ray, ultrasound, or magnetic 
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resonance imaging (MRI) have been suggested to demonstrate SAIS (Kieft et al 
1990).  
 
Dinnes et al (2003), in a systematic review, found that overall sensitivity and 
specificity of ultrasound scan for full-thickness rotator cuff tears was 87% and 
96% respectively. For MRI the overall pooling for full-thickness tears 
demonstrated similar values (89% and 93%). However, MRI pooled sensitivity 
estimates for partial thickness were much lower (44%) even though specificity 
remained high at 90%. Ultrasound sensitivity was slightly higher (67%) for 
partial-thickness tears. Dinnes et al (2003) therefore argued that Ultrasound is 
the most valuable test to rule out a partial-thickness tear. However, they 
uncovered no studies that directly compared the test characteristics of 
ultrasound scan and MRI. X-rays are not routinely indicated in the diagnosis of 
shoulder impingement syndrome, as degenerative changes in the 
acromioclavicular joints and rotator cuff are common (NHS Radiographic 
Standard Operating Protocols 2008). Tennent et al (2003), in a review of the 
special tests associated with shoulder examination for rotator cuff, suggest that 
clinical examination remains a fundamental part of the diagnosis of shoulder 
pathology. Because of the difficulties in interpreting the evidence concerning the 
diagnosis of shoulder pathology, the CSP has recommended guidelines for 
assessment/diagnosis of shoulder impingement syndrome (Hanchard et al 
2004). This will be discussed in the next section. 
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2.5.6 Clinical Assessment of Subacromial Impingement Syndrome 
The clinical manifestation of SAIS varies widely.  
 
2.5.7 Subjective Assessment of Subacromial Impingement Syndrome 
This includes age, pain and function. 
2.5.7.1 Age 
Shoulder assessment should begin with questioning about the patient's age 
because it can give some indication of the possible stage of SAIS according to 
Neer & Welsh's (1997) classification. However, patients with SAIS have similar 
age ranges with those of other shoulder pathologies such as adhesive capsulitis 
and acromioclavicular joint dysfunction (Hanchard et al 2004). Frost et al (1999) 
have shown that the incidence of structural rotator cuff tendon pathology 
including full thickness tears increases with age. However, large numbers of 
people with full thickness tears may have asymptomatic shoulders and full 
function (Frost et al 1999). In a study of 420 cadaver scapulas, Nicholson et al 
(1996) concluded that incidence of acromion bony spurs increased with age. 
Different authors have reported different ages with patients with posterior 
superior glenoid impingement. While Cavallo & Speer (1998) reports that it 
occurs in patients under 35 years, Jobe (1996) reported age ranges of 20-55, 
with a mean age of 36 years. The inequality between these author's accounts 
may be due to differences in patient populations with the mechanism of injury 
related to a sporting activity or not (Hanchard et al 2004). 
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2.5.7.2 Pain 
Some SAIS patients experience only mild discomfort whereas others experience 
severe acute or chronic pain (Bokor et al 1993). Pain often radiates from the 
front of the shoulder to the side of the arm (Lewis et al 2001), with possible sharp 
or catching pain during movement (Hanchard et al 2004). Classically, there is a 
painful arc during forward or downward movement of the arm, or both, as the 
humeral tuberosities pass under the coraco-acromial arch (Hanchard et al 2004, 
Neer 1983). The presence of a painful arc of movement between 60 and 120 
degrees is suggestive of supraspinatus tendinopathy (Cyriax & Cyriax 1982). 
Pain is also aggravated with placing the arm behind the back (American 
Academy of Orthopaedic Surgeons 2008), arm elevation or overhead activities 
associated with daily living (Lukasiewicz et al 1999, Ludewig & Cook 2002, Lewis 
et al 2005). Night pain, causing difficulty lying on the affected side is commonly 
present in SAIS, and is particularly associated with rotator cuff tears (Zuckerman 
et al 1991), but it is also a common feature of adhesive capsulitis (Hanchard et al 
2004). However, if linked with age (> 65), night pain and weak external rotation 
can be suggestive of rotator cuff tears (Litaker et al 2000, Hanchard et al 2004).  
 
In practice, shoulder pain is generally measured using the numeric pain scale 
(NPS) and visual analogue pain scale (VAS). Although both scales are well 
validated, the NPS scale can be administered verbally by telephone or by self-
completion through the post, compared to the VAS (Jensen 1986). The NPS is a 
single 11-point numeric scale (with 0 as “no pain” and 10 as the “worse 
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imaginable pain”) to measure pain intensity in adults (Hawker et al 2011). It 
allows patients to measure their level of pain accordingly using a whole number 
(0-10 integers) that corresponds to their pain intensity (Rodriguez 2001). A 
systematic review that compared NPS, verbal rating scales (VRS), and VAS for 
assessment of pain intensity in adults found that NPS had better 
responsiveness, easier to use, and most applicability compared to VAS/VRS 
(Hjermstad et al 2011). Since day time and night time pain as usually associated 
with SAIS (Zuckerman et al 1991, Hanchard et al 2004), this study used NPS to 
record them at baseline and follow-up periods as part of the patient reported 
outcome measures (PROMs) (see Appendix 5).  This is because it is a self-
assessment measure that has enhanced the patient’s participation during 
telephone follow-up such as cortisone injection outcome. This is consistent with 
previous authors (Akgun et al 2004) who in a RCT that evaluated the effects of 
subacromial injections in SAIS patients used a similar pain scale to measure 
shoulder pain at day time, and night time causing disturbance of sleep.  
 
2.5.7.3 Function 
Shoulder function should be measured subjectively before and after treatment to 
evaluate success of treatment outcomes such as cortisone injection. There are 
numerous measurement tools such as Shoulder Pain Disability Index 
questionnaire (SPADI), Disabilities of the Arm, Shoulder and Hand questionnaire 
(DASH), American Shoulder and Elbow Surgeon questionnaire 
(ASES), Shoulder Disability Questionnaire (SDQ-UK), Constant Murley score 
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and Simple shoulder test (SST) that can be considered when evaluating 
outcome from shoulder interventions. However, SPADI was choose for this study 
because it is a self-assessment measure that has provided the benefits of 
emphasising the patient's involvement in the process and enhancing telephone 
follow-up such as cortisone injection outcome. SPADI is a self-report 
questionnaire designed to measure pain and disability specifically associated 
with shoulder pain of musculoskeletal origin (Roach et al 1991). It has thirteen 
items covering two domains (pain and disability), which are scored on a 
numerical rating scale between zero (no pain/difficulty) and ten (worst pain 
imaginable/so difficult it requires help). The pain dimension consists of five 
questions concerning the severity of a patient’s pain. Functional activities are 
measured with eight questions designed to assess the degree of difficulty a 
patient has with different activities of daily living (Roach et al 1991). Each domain 
carries equal weighting in the overall score that is expressed as a percentage 
where zero represents no pain or disability and 100% represents maximum pain 
and disability. A recent systematic review by Thoomes-de Graaf et al (2016) has 
recommended the use of SPADI over the DASH, SDQ-UK and SST for 
measurement of shoulder pain and functional limitation for English, Norwegian 
and Turkish users because it more user friendly and easier to understand. A 
study that compared the responsiveness of Shoulder Disability Questionnaire 
(SDQ), SPADI and Western Ontario Rotator Cuff (WORC) index in SAIS 
confirmed that both the SDQ and SPADI scores were more suitable for 
assessment of SAIS compared to WORC (Dogu et al 2013). However, the 
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authors reported that WORC is better for psychological impact assessment of 
SAIS. 
 
A minimally important clinical difference (MICD) is the smallest change in an 
outcome that a patient would identify as important following an intervention 
(Jaeschke et al 1989). A MICD for the SPADI is 8-13% (Roy et al 2009). In 
practice, it is easy to administer and requires minimal time for a patient to 
complete and Roy et al (2009) reports that it is not only very reliable, but a valid 
region-specific measure for the shoulder. It is also able to discriminate between 
patients whether they are improving or not (Roy et al 2009, Breckenridge & 
McAuley 2011). This study used SPADI as both baseline and follow-up 
measures. This is consistent with recent RCTs that used SPADI as the primary 
outcome to compared corticosteroid injection with manual physical therapy in the 
management of patients with shoulder impingement syndrome (Rhon et al 2014, 
Roddy et al 2015). 
 
2.5.7.4 Objective assessment of Subacromial Impingement Syndrome 
This includes physical inspection, physical tests, measurement of shoulder range 
of movements (ROMs) and assessment of instability. Physical inspection of the 
shoulder and scapular muscle bulk, cervical, upper thoracic and static scapular 
posture and scapulohumeral rhythm is vital. Physical tests of patients with SAIS 
include palpation of the rotator cuff tendons such as supraspinatus, 
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infraspinatus, teres and subscapularis, which can be challenging because it is 
difficult to identity their individual tendons.  
 
During measurement of shoulder movement, it is important to make a differential 
diagnosis due to the complexities of shoulder pathologies such as SAIS, SAIS 
secondary to instability, intracapsular causes of impingement, ACJ arthritis and 
adhesive capsulitis (Hanchard et al 2004). This is because none of these is 
mutually exclusive (Hanchard et al 2004). Clinically shoulder ROM is usually 
measured by universal goniometer or visual inspection (Hanchard et al 2004). 
Although few studies have evaluated these methods their reliability in shoulder 
pain patients has been reported as high (Hanchard et al 2004). Although this 
study will not be investigating shoulder ROM using a goniometer, it will measure 
shoulder function subjectively using the SPADI measure both before and after 
cortisone injection therapy, because shoulder function is a predictor of shoulder 
ROM. 
 
There are basically three types of shoulder/scapular instability (dislocation or 
subluxation) namely: anterior, which may result from repeated small (micro) 
trauma to the anterior shoulder capsule; multi-directional that is associated with 
generalised musculoskeletal laxity (Parker & Seitz 1997) and posterior, which is 
an isolated finding, and is not common. A number of tests for these problems 
include load and shift, sulcus, anterior apprehension and relocation test for 
anterior instability (Hanchard et al 2004, Hanchard et al 2013). In this study, a 
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participant who tested positive following any of these manoeuvres was excluded 
because the study is investigating patients with SAIS patients who do not have 
dislocation or obvious subluxation. 
 
2.5.7.5 Tests of Rotator Cuffs and Long Head of Biceps 
The rotator cuff muscles - supraspinatus, infraspinatus, subscapularis and teres 
minors and the long head of biceps constitute the contractile tissues around the 
shoulder. Clinical evaluation of these structures includes active and resisted 
active shoulder movements, done in mid-range in order to minimise on non-
contractile tissues such as (joint capsule, ligaments, bursae, blood vessels, and 
cartilage) and increased specificity (Hanchard et al 2004). Table 5 below 
summarises the tests of rotator cuffs and long head of biceps (Hanchard et al 
2004). 
 
Table 5: Summary of Tests of Rotator Cuffs and Long Head of Biceps 
Muscle Action 
Supraspinatus Abduction 
Infraspinatus External rotation 
Subscapularis Internal rotation 
Teres minor Adduction 
Biceps Elbow flexion 
 
During testing of contractile tissues around the shoulder, pain is assumed to 
indicate a minor lesion (tendon strain), combined pain and weakness a more 
significant lesion such as a partial tear, and painless weakness either a 
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neurologic problem (such as suprascapular neuritis) or a complete cuff tendon 
tear (Cyriax 1982). 
 
In this study, a participant that tested positive (i.e. pain present during testing) 
following any of these manoeuvres was included. Other tests that capture pain 
during shoulder manoeuvre are specific impingement tests. 
 
2.5.7.5.1 Specific Impingement Tests (Hanchard et al 2004, Lewis 2005, 
Hanchard et al 2013) 
 
Generally, the tests and signs used to identify signs of impingement include 
Neer's sign, Hawkins-Kennedy and the painful arc. These tests will be used to 
recruit a homogeneous group of subjects with SAIS. 
 
2.5.7.5.2 Neer's Sign (1983) 
This test is done with the patient in a sitting or standing position. The clinician 
stabilises the clavicle and the scapula with one hand. With the patient’s arm 
internally rotated, the clinician passively flexes the arm with the other hand. This 
procedure compresses the greater tuberosity against the antero-inferior border of 
the acromion constricting the subacromial structures, and reproduction of pain 
and/or apprehension indicates a positive test.  
 
Neer (1972) in a cadaveric study observed that impingement could occur 
between the acromion and supraspinatus, infraspinatus and the long head of 
biceps when the arm is in the test position in approximately 10% of the 
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specimens. He however warned that while the sign could signify impingement, 
there were other conditions such as capsulitis that could also reproduce pain 
during the manoeuvre (Neer 1983, Neer & Welsh 1997). He advised that full 
elevation and external rotation should be present to eliminate the presence of 
frozen shoulder and reduce that chance of recording false positive findings. He 
therefore recommended a re-assessment of the sign following an injection of 
local anaesthesia to the subacromial injection space and, if pain was relieved (a 
positive Neer's test), a diagnosis of subacromial impingement could be 
confirmed. Confirmation of subacromial impingement using Neer's sign has been 
confirmed by other authors (Valadie et al 2000, Kim & McFarland 2004).  
 
2.5.7.5.3 Hawkins-Kennedy Test (1980) 
This test is performed with the patient either sitting or standing. The clinician 
positions the patient’s arm at 90 degree of forward flexion and then internally 
rotates the shoulder. Reproduction of anterior shoulder pain and/or apprehension 
is a positive sign for the supraspinatus, subscapularis and/or long head of biceps 
tendon pathology (Placzek & Boyce 2006). However, pain could be felt in 
superior shoulder indicating ACJ pathology, whereas posterior shoulder pain 
may indicate infraspinatus, teres minor and/or posterior joint capsule pathology 
(Placzek & Boyce 2006). Some authors (Calis et al 2000, MacDonald et al 2000), 
have reported that a positive test response cannot be confidently ascribed to 
impingement. However, if the result is negative, impingement is very unlikely 
(Hanchard et al 2004). 
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2.5.7.5.4 Painful Arc 
The patient actively abducts the arm. The presence of painful arc of movement 
between 60 degrees and 120 degrees suggests SAIS (Cyriax & Cyriax 1982). 
Although a positive painful arc suggests impingement, absence of an arc sign 
does not rule it out completely (Hanchard et al 2004).  
 
Several authors such as Hegedus et al (2008) have investigated physical 
examination tests of the shoulder. A systematic review by Hegedus et al (2008) 
identified 45 such studies. Pooled sensitivity and specificity for the Neer’s test 
was 79% and 53% respectively and for the Hawkins-Kennedy test was 79% and 
59% respectively. Park et al (2005) in a composite examination found that a 
combination of Hawkins-Kennedy sign, painful arc and infraspinatus muscle test 
yielded the best post-test probability (proportion of patients with that particular 
test result who have the target disorder) at 95% for any degree of impingement 
syndrome. These findings are similar with the Murrell & Walton (2001) who found 
that supraspinatus weakness, weakness in external rotation and a positive 
Neer’s or Hawkins-Kennedy impingement sign were the most diagnostic for 
rotator cuff disease, yielding a 98% likelihood of a partial or full thickness rotator 
cuff tear for patients who tested positive for all three or were positive for two and 
were aged 60 or older. A systematic review by Hanchard et al (2013) concluded 
that there is insufficient evidence upon which to base selection of physical tests 
for shoulder impingement in primary care. This is because the clinical trials that 
attempt to establish criterion based validity of these tests are hampered by the 
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accuracy of the reference standard (Claver 2009). However, a more recent 
systematic review (Diercks et al 2014) on guideline for diagnosis and treatment 
of subacromial pain syndrome has recommended a combination of the Hawkins-
Kennedy test, the painful arc test, and the infraspinatus muscle strength test 
should be used. 
 
The above tests (Neer's sign, Hawkins-Kennedy and the painful arc) have been 
widely used in both clinical practice and shoulder research (Lewis 2005). 
Participants with a positive sign of these tests were included in this current study. 
 
2.5.7.6 Specific Tests for Complete Rotator Cuff Tears 
Tests for cuff tears include the drop-arm, lift off, drop sign and external rotation 
lag sign. Participants with a positive sign of these tests were excluded in my 
study. Other tests used to exclude participants from this study included cervical 
spine tests such as Spurling’s test. 
 
2.6 Context of Treatment 
Treatment of patients with SAIS using subacromial injections primarily takes 
place in the community or primary care where most people with shoulder pain 
are diagnosed and managed (Hanchard et al 2013). 
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2.6.1 Current Musculoskeletal Practice – National Health Service 
With the disbanding of the Primary Care Trusts (PCTs) in April 2013 and the 
setting up of Clinical Commissioning Groups, most National Health Service 
(NHS) Trusts in collaboration with GPs have commissioned their musculoskeletal 
services from community providers in order to deal with the backlog of patients 
awaiting specialist musculoskeletal treatments and reduce waiting times 
(Suckley 2012). These patients awaiting specialist musculoskeletal interventions 
include those where previous physiotherapy treatments such as manual 
mobilization or exercise have failed to resolve their pain. Consequently, these 
patients might need other interventions such as injection therapy. This 
arrangement has increased the use of Extended Scope Practitioners (ESPs) 
(working in collaboration with rheumatologists, orthopaedic and spinal 
consultants) to provide such services. ESP’s therefore perform aspects of care 
such as assessing, diagnosing, treating and discharging patients that originally 
may have been performed a GP (Suckley 2012).  
 
2.6.2 The Role of Extended Scope Practitioner in Musculoskeletal Practice 
An MSK ESP is a specialist physiotherapist that has extended their scope of 
practice beyond the recognised scope of physiotherapy practice to include the 
provision of cortisone injection and requesting investigations such as magnetic 
resonance imaging (MRI) scan, ultrasound scan, x-ray and blood tests (Cumbria 
Partnership NHS Foundation Trust 2013). Although the Chartered Society of 
Physiotherapy (CSP) does not provide a definition for an ESP, it states that an 
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ESP is someone who has extended their scope of practice beyond immediate 
post graduate level to include training, supervision and working alongside 
rheumatologists and orthopaedic consultants. 
 
ESPs should be able to manage a wide range of musculoskeletal conditions 
including common and long term, chronic conditions such as shoulder pain. They 
should also be able to identify patients with urgent musculoskeletal pathologies 
such as suspected fractures, infections, tumours or those needing emergency 
surgeries (acute rupture tendons). They also need to recognise musculoskeletal 
conditions which do not fit a musculoskeletal diagnosis and when the need is 
therefore to refer onward to the acute hospital. 
 
Most ESPs hold a postgraduate qualification such as Master of Science (MSc) or 
have a Certificate in Injection Therapy from a recognised training University. 
Since the introduction of injection therapy by the CSP in 1995, many of these 
ESPs provide soft tissue and joint injections to patients with musculoskeletal pain 
such as SAIS (Lewis 2011). In today’s current healthcare climate, where GPs 
and funding providers fund two or three treatment sessions, notwithstanding the 
condition or needs of the patient, cortisone injection is even more relevant. It 
takes centre stage with a maximum of three treatment sessions for injections 
normally recommended within timescales of varying length (Haslock et al 1995, 
Saunders & Longworth 2012). However, this is guided by previous treatment 
outcomes, patient experience and clinical judgement. 
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2.6.3 Community-Based Musculoskeletal Specialist Services 
In 2013, the Government handed over health-care commissioning and control of 
£70 billion of the NHS budget to GPs (Department of Health 2010, Suckley 
2012). This move has made services such as musculoskeletal services that 
originally would have been managed in hospitals available in the community, so 
that patients can easily access them (Suckley 2012). In the UK, it is estimated 
that every year, over £15 billion of the NHS disbursement is for GP referrals to 
hospitals (Suckley 2012). A review commissioned by The Kings Fund that 
investigated GP referrals suggested a range of different referral management 
systems (Imison & Naylor 2010) such as primary-care-based musculoskeletal 
interface clinics known as Clinical Assessment and Treatment Services (CATS) 
(Suckley 2012). These specialist musculoskeletal services, led by GPs with 
special interest in musculoskeletal medicine (GPswSI) or ESPs are mainly 
established to reduce the number of referrals to hospitals by managing most 
within primary care (Suckley 2012). They achieve this by triaging, assessing and 
treating patients in the community. These services have provided more capacity 
for physiotherapists who have extended their scope of practice to include 
cortisone injection as one of the main treatment options in managing 
musculoskeletal pain. 
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2.6.4 Current Treatment Provision 
2.6.4.1 Physiotherapeutic Interventions for SAIS in General 
Physiotherapy is aimed at reducing pain, strengthening weakened muscles and 
preventing functional disability (Bennell et al 2007) using manual and exercise 
therapy, laser, cold or heat therapy, ultrasound therapy, electromagnetic fields, 
transcutaneous electrical nerve stimulation (TENS), deep transverse frictional 
massage, acupuncture and advice on rest (Green et al 2003, Michener et al 
2004).  The CSP (Hanchard et al 2004) and a Cochrane review (Buchbinder et al 
2003) have both concluded that the most effective treatment for musculoskeletal 
shoulder pain is not known. However, the CSP has recommended advice, rest, 
non-steroidal anti-inflammatory drugs (NSAIDs), cortisone injection and a 
programme of pain-free shoulder exercise as an effective form of physiotherapy 
but acknowledge that there is no evidence for any one type of physiotherapy 
treatment over another. 
 
2.6.4.2 Physiotherapy Intervention in Subacromial Impingement Syndrome 
 
Physiotherapy is important in the management for SAIS (Glazier et al 1998); 
however, subacromial injection is now commonly used in the initial treatment of 
patients with pain and inflammation (Harrison & Flatow 2011). Where 
physiotherapy has failed to improve symptoms of SAIS or the shoulder is acutely 
painful, the most commonly available treatment option is subacromial cortisone 
injection (Hanchard et al 2004 & Diercks et al 2014). Where corticosteroid 
injection is used as an adjunct to physiotherapy, it may help to reduce the 
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number of physiotherapy sessions substantially (Hanchard et al 2013). Based on 
a review of evidence of the causative factors of SAIS and the justification for 
surgery, Lewis (2011) and (Hanchard et al 2004) concluded that surgical 
intervention should be considered only if physiotherapy and/or cortisone injection 
is unsuccessful.  
 
Subacromial injection is mainly directed to improve outcomes of pain and 
function in SAIS patients. Research evidence suggests that in practice, post 
injection shoulder outcomes such as shoulder pain and function can be 
measured subjectively either via a telephone interview or by filling out and 
returning the outcome measures by post (Roddy et al 2015). Therefore, in this 
study shoulder pain and function were recorded subjectively using the SPADI 
and PROMs both as baseline measures before the subacromial injections and as 
outcome measures by telephone contact with the patient. 
 
2.6.4.3 Use of Cortisone Injections in General 
Several international professional bodies such as the American College of 
Rheumatology (2000), Dutch College of General Practitioners (Winters et al 
2008), CSP (Hanchard et al 2004) and Dutch Orthopaedic Association (Diercks 
et al 2014) have recommended the use of injection therapy for the management 
of hip, knee and shoulder disorders. Advocates of cortisone injection, including 
primary care clinicians and musculoskeletal practitioners, say it is safe (Kumar & 
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Newman 1999, Ekeberg et al 2009), easy to use and cost-effective (Dacre et al 
1989, Croft 1998). 
 
According to Saunders & Longworth (2012), in the UK injection therapy is the 
most widely used treatment option in rheumatological disease of the joints and 
soft tissues. Traditionally, rheumatologists, doctors in orthopaedics, 
musculoskeletal and sports medicine, and pain management delivered injection 
therapy (Saunders & Longworth 2012). A UK survey has found that GPs also 
perform joint and soft tissue injections, particularly those of knees, shoulders and 
elbows (Liddel et al 2005). However, most of the injections carried out locally are 
done by only 5-15% of GPs (Gormley et al 2003). Lack of confidence with 
injection techniques, inadequate training, and lack of maintenance of injection 
skills have been suggested as some of the hindrances to performing these 
injections (Liddel et al 2005). 
 
In practice, subacromial injection is the most common in musculoskeletal 
conditions. This is consistent with a study that reported that 1 in 5 injections to 
the peripheral joints and soft tissue is subacromial injection (Longworth 2004). 
Similarly, a Dutch study found that steroid injections into the shoulder accounted 
for 20% of all episodes of shoulder disorders (Van der Heijden et al 1996). 
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2.6.4.4 Delivery of Injection Therapy by Extended Scope Practitioners 
Since 1995, ESPs in the UK were given permission to train and perform soft 
tissue and joint injections (Saunders & Longworth 2012).  These injections, for 
example cortisone injections, are administered to the intra-articular, extra-
articular tissues and joints spaces such as the shoulder joint and subacromial 
space. The primary aims of these injections are to relieve pain and inflammation; 
and improve joint functions such as elevation. However, injection therapy can be 
used as an adjunct to manual therapy (Saunders & Longworth 2012). The 
general effects of these injections are to suppress inflammation in joints and soft 
tissue, and to break up the cycle of inflammatory response in low-grade re-injury 
of soft tissue (Saunders & Longworth 2012). The reported side effects of 
cortisone injection include post injection pain, tendon rupture, steroid 
arthropathy, subcutaneous atrophy/skin depigmentation, facial flushing and 
alteration in glycaemic control (diabetics). However, they rarely occur, their 
effects are normally mild and temporary (Kumar & Newman 1999, Saunders & 
Longworth 2012). For example, only 2 - 10 in every 100 patients having 
cortisone injection will experience post injection flare of pain; and only 1:17000 - 
77000 patients will report joint sepsis (Kumar & Newman 1999).   
 
There are several types of cortisone injection such as Triamcinolone acetonide 
(Kenalog), Methylprednisolone acetate (Depo-Medrone) and Hydrocortisone 
acetate. The choice of cortisone injection is often based on the clinician's 
knowledge with a certain compound and their experience of its effectiveness 
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(ACPOMIT 1999). Local anaesthetic such as Lidocaine is commonly used in 
combination with cortisone injections for the management of shoulder pain 
(Nelson et al 1995). The therapeutic effects of the Lidocaine are to provide 
immediate inflammatory pain inhibition and increase the volume of the cortisone 
(Nelson et al 1995). 
 
Cortisone injections are carried out under the Patient Group Directions (PGDs) to 
ensure standardisation of the volume, dose and strength of steroid and local 
anaesthetic used during subacromial injections (Saunders & Longworth 2012). 
PGDs are written instructions for ESPs to inject patients with local inflammatory 
joint or soft tissue conditions in a musculoskeletal clinic without the presence of a 
medical colleague and to enable professional autonomy (ACPOMIT 1999). This 
is a supply and administration frame, and not a prescribing tool for the ESP. A 
doctor and a pharmacist must define in writing the named medicine to be 
supplied and/or administered. The PGD must be written in a specific manner in 
order to be legally acceptable.  
 
Injection therapy by ESPs has been demonstrated to improve pain in patients 
with musculoskeletal and orthopaedic conditions such as SAIS (Hattam 1999). 
Several authors (Daker-White et al 1999) have reported that as well as 
generating lower initial direct hospital costs, ESPs have been shown to provide 
effective injection therapy that is comparable to orthopaedic surgeons. A recent 
randomised control and economic analysis trial found that corticosteroid injection 
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for shoulder pain, provided by a trained and experienced physiotherapist is not 
only clinically effective and less expensive, but also comparable with those 
delivered by an orthopaedic surgeon (Mark et al 2016). The study involved 64 
participants who were randomised to two groups (physiotherapist 33, 
orthopaedic surgeon 31).  At 6 and 12 weeks follow-up there were no statistically 
significant differences between groups on SPADI outcomes, perceived 
improvement, adverse events, satisfaction, quality of life and costs. The authors 
suggested that policy makers and service providers should consider 
implementing this model of care. This study compares favourably with Chambers 
et al (2005) who in a retrospective study that compared the accuracy and 
efficiency of subacromial injection through an anterior approach by a consultant, 
registrar and a specialist physiotherapist, found that the injections of the 
specialist physiotherapist (ESP) were comparable to those of the consultant and 
generally better than the registrar's. Similarly, Dogu et al (2012) reported that 
blind subacromial injections performed by experienced clinicians in patients with 
SAIS not only produced improvements in shoulder pain and function but were 
applicable to routine clinical practice. 
 
2.6.5 Critical Appraisal of Evidence Use of Cortisone Injections in 
Subacromial Impingement Syndrome 
 
From the quantitative literature review seven systematic reviews (Van der 
Heijden GJ et al (1996), Johansson et al 2002, Buchbinder et al 2003, Arroll & 
Goodyear-Smith 2005, Koester et al 2007, Gaujoux-Viala et al 2009, Mohamadi 
et al 2016), were identified that evaluated the effects of cortisone injection in the 
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treatment of SAIS. Seven RCTs (Adebajo 1990, Blair 1996, Winter et al 1997, 
Plafki et al 2000, Akgun et al 2004, Penning et al 2012, Min et al 2013) were 
identified that evaluated the effects of cortisone injection in the treatment of 
SAIS. 
 
Cortisone injection is common in the treatment of shoulder pain due to SAIS 
(National Institute for Clinical Excellence [NICE] 2015, Ellegaard et al 2016). 
Although the reports of some studies (Goupille & Sibilia 1996, Van der Heijden et 
al 1996) on the efficacy of subacromial corticosteroid injections were 
inconclusive, with passage of time several authors have confirmed its 
effectiveness and recommended its use for SAIS (Hanchard et al 2004, 
Dorrestijn et al 2009, Hanchard et al 2013, Diercks 2014, NICE 2015).  
 
Three separate RCTs (Adebayo 1990, Blair 1996, Plafki 2000) investigating the 
effects of subacromial injection to non-steroidal anti-inflammatory medication 
(NSAID) or placebo for rotator cuff disease, have reported that cortisone injection 
was more beneficial in improving clinical outcomes of shoulder pain and function.  
However, Blair et al (1996) found no statically significant difference between the 
cortisone and placebo group with regards to daily activities. Although the study 
was double blind, the analysis and loss to follow-up were questionable 
(Buchbinder 2003).  The Adebajo (1990) trial was double-blind (participants and 
outcome assessment), no loss to follow-up was reported and an intention to treat 
analysis (that is participants were analysed in the group they were originally 
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randomised to) was performed. Compared to the Adebayo 1990, where the 
follow-up period was over a 4 weeks’ period; in the Blair 1996 study it was up to 
28 – 33 weeks, while in the Plafki et al (2000) study participants were followed 
up after six months. The different up-follow periods in these 3 studies could limit 
the possibility of pooling their result findings for a meta-analysis. Although the 
Plafki study was double blinded, treatment was stopped in the placebo group 
after first the 10 participants failed to improve, and four of them had worsening 
symptoms. In this study, the fact that group 1 (the placebo arm) only had 10 
participants while the other intervention groups had 20 participants each warrant 
cautious interpretation of the study. 
 
In a RCT that respectively compared intra-articular and subacromial injections to 
manipulative and non-manipulative physiotherapy for shoulder complaints, 
Winters et al (1997) reported that an average of 1.8 injections of triamcinolone 
acetonide produced a statistically significant better outcome of pain relief of up to 
11 weeks compared to the physiotherapy groups. This compares favourably with 
Akgun et al (2004) who, in a randomised controlled study, investigated whether 
cortisone injection would provide additional benefit when combined with previous 
medication and exercise regime. They found that subacromial cortisone injection 
produced added benefit by relieving pain which affected sleep as well as day 
time activities. 
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Penning et al (2012) in a RCT of 159 patients with subacromial impingement 
found corticosteroid injections were more effective in reducing shoulder pain than 
hyaluronic acid injections and placebo in the first 3 to 12 weeks post treatment. 
At 26 weeks, although the cortisone group showed better reduction in shoulder 
pain compared to the hyaluronic acid group, it was found to be no more effective 
than the placebo group.  According to Van der Windt et al (1996) 50% of patients 
referred to primary care with new episodes of shoulder pain would experience 
complete resolution at 6 months rising to only 60% after a year (Van der Windt et 
al 1996). Penning et al (2012) found no significant adverse effects (such as 
tendon rupture) in their study, therefore they recommended the use of cortisone 
injection for fast initial pain relief in the treatment of patients with SAIS. 
 
Min et al (2013) in a double-blind RCT compared the effects of subacromial 
injection using corticosteroid versus NSAID in patients with shoulder 
impingement syndrome. The study had 32 participants and the steroid group 
received an injection of 40 mg triamcinolone; and the NSAID group received 60 
mg ketorolac. Clinical outcomes were arc of motion, visual analogue scale (VAS) 
for evaluating pain, and the UCLA (The University of California at Los Angeles) 
shoulder rating scale at four weeks follow-up. At one month follow-up both 
groups had increased range of motion and decreased pain (p=0.03). At 4 weeks 
although both groups continued to improve, the NSAID group had greater 
improvements in the UCLA shoulder rating scale than the steroid group. Due to 
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the small sample and short follow-up period, it is reasonable to argue that the 
results of this study should be interpreted with caution. 
 
Van der Heijden GJ et al (1996) in a systematic review that investigated the 
benefits of steroid injection in shoulder disorders concluded that the evidence for 
its efficacy was scarce and that there were few studies of adequate 
methodological quality. Most of the studies had small sample sizes and were not 
adequately powered. The poor methodological issues were due to 
incomparability of co-interventions, lack of information about randomization, 
outcome measures included, poor blinding of therapist, patients and outcome 
measurement. Similarly, Koester et al (2007) in a systematic review compared 
subacromial corticosteroid injection with placebo in patients with rotator cuff 
disease. The review which included nine RCTs concluded that the evidence to 
support the efficacy of subacromial corticosteroid in managing rotator cuff 
disease was scarce. 
 
On the contrary Johansson et al (2002) in a systematic review that investigated 
the interventions for subacromial pain found that corticosteroid injection was 
superior over NSAIDs, acupuncture, ice, heat and exercise. The review had 17 
studies on subacromial pain and although the health benefits such as reducing 
pain and improving function were short-term, the results were supported by large 
effect sizes, which are defined by (Coe 2002, Ken & Kristopher 2012) as strength 
of the mean difference between two groups. 
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Based on a systematic review to evaluate the evidence for corticosteroid 
injections for shoulder pain, Buchbinder et al (2003) pooled the results of three 
RCTs. They concluded that steroid injection into the subacromial area was more 
beneficial compared to placebo. However, they argued that the effect may be 
small and may not be more substantial compared to patients who took NSAIDs. 
In practice, however, patients might consider cortisone injections for SAIS not 
only because of its fewer repetitions, but also because it has less gastrointestinal 
side effects compared to oral NSAIDs. All NSAIDs including ibuprofen, naproxen, 
and diclofenac are primarily associated with damage to the gastrointestinal tract 
(GIT) such as severe abdominal (GIT) bleeding and ulceration (Ciccone 2007).  
 
Contrary to this a more recent systematic review of seven RCTs by Arroll & 
Goodyear-Smith (2005) found that the relative risks for intra-articular steroid 
injection for rotator cuff tendonitis was low. They found cortisone injections were 
more effective in reducing pain compared to placebo, with an improvement of up 
to 9 months. Based on the review of three RCTS that investigated the 
effectiveness of cortisone injection versus NSAIDs for patients with rotator cuff 
tendonitis, the authors favoured the use of cortisone injection over NSAIDs for 
rotator cuff tendonitis (also called SAIS). Subsequently a meta-analysis of RCTs 
by Gaujoux-Viala et al (2009) was undertaken to assess the efficacy and safety 
of steroid injections for shoulder and elbow tendonitis. The authors found that 
although the effects of steroid injections were comparable to NSAIDs, they were 
more effective than pooled other treatments in shoulder tendonitis and are well 
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tolerated, with rare and minor side effects such as transient post injection pain 
and skin modification. The study involved 20 RCTs (744 patients treated by 
injections and 987 patients treated by controls; 618 shoulders and 1113 elbows).  
 
Similarly, Mohamadi et al (2016) in a recent systematic review and meta-analysis 
of 11 RCTs compared cortisone injections with injection of local anaesthesia or 
placebo in adults with rotator cuff tendinosis. The review identified 11 RCTs and 
it involved 726 adults. All the trials included in the review used VAS scale to 
measure pain at 1, 2 and 3 months after the injections. The review showed that 
cortisone injections provided moderate pain relief for patients with rotator cuff 
disorders up to two months after the injection, but the effect wore off after three 
months. The authors however, cautioned about the varying methodological 
quality, interventions and heterogeneity of populations in the trials. Given the 
short term health benefits of cortisone injection from this review, it might be 
necessary to consider other treatments such as physiotherapy along with a 
steroid injection particularly where SAIS secondary to instability is concerned 
(Kamkar et al 1993).  
 
Hanchard et al (2004) undertook a comprehensive systematic review that 
investigated the effectiveness of physiotherapy interventions used in the 
management of shoulder impingement syndrome. They recommended the use of 
steroid injection to facilitate the management of SAIS particularly in cases were 
pain is the most limiting factor. This is supported by the recent NICE (2015) 
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guidelines on the management of SAIS. For example, in practice, corticosteroid 
injection is indicative where symptoms prevent patients with SAIS from 
participating in physiotherapy. There are instances where patients with SAIS 
have received a cortisone injection and subsequently they are then referred to 
physiotherapy for strengthening of the affected area. However, this is not 
standard practice, as there are patients that may not be routinely referred for 
physiotherapy after subacromial injection rather they are advised on exercises to 
do at home.  
 
Furthermore, a recent Dutch review for the diagnosis and treatment of 
subacromial pain by Diercks et al (2014) concluded that corticosteroid injections 
are more effective than placebo injections, physiotherapy, or no treatment in 
reducing pain and improving shoulder function. However, in the short term they 
found that cortisone injections were not superior to NSAIDs in reducing pain. 
 
2.6.6 Issue of Needle Placement in Subacromial Injections 
Subacromial injections can be performed using the anterior (front), lateral (side) 
and posterior (back) approaches (Sardelli & Burks 2008, Saunders 2010, Bloom 
et al 2012, Marder et al 2012, Saunders & Longworth 2012). It has been reported 
that some practitioners support either a lateral (Saunders 2010) or a posterior 
(Marder et al 2012, Saunders & Longworth 2012) approach to the subacromial 
injection. However, anecdotal evidence suggests that in practice, clinicians, 
including ESPs, commonly use the lateral and/or posterior approaches, with 
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most using the latter method. Whereas a lateral route to subacromial injection 
involves placing the needle underneath mid-way between the anterior and 
posterior margin of the acromion, in a posterior route, the needle is placed 1cm 
directly below the posterior lateral margin of the acromion (Kang et al 2008). 
From an anatomical view point, the posterior approach provides easier access 
particularly in patients with humeral heads anteriorly translated. However, a 
longer needle may be needed to access the subacromial bursa (Innes 2012). 
Although the choice of needle placement is based on preference, experience or 
anatomy, the evidence establishing superiority of one method over the other in 
normal practice is not only scarce, but is still controversial. 
 
2.6.7 Evidence on Needle Placement in Subacromial Injections 
 
From the quantitative literature search, three non-RCTs (Eustace 1997, Yamakado 
2002, Esenyel 2003), evaluated the effect of one approach of cortisone injection in 
treatment of SAIS. Four RCTs (Henkus et al 2006, Kang et al 2008, Goel et al 
2012 and Marder et al 2012) and one non RCT (Sardelli & Burks 2008) directly 
evaluated the effects of different approaches of cortisone injection in treatment of 
SAIS.  
 
Several studies, cadaveric and clinical have been published that investigate 
needle placement in subacromial injections with mixed results, using different or 
single injection approach. 
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2.6.8 Critical Appraisal of Evidence on Different Approaches to Needle 
Placement in Subacromial Injections 
 
From the quantitative literature search, four RCTs (Henkus et al 2006, Kang et al 
2008, Goel et al 2012 and Marder et al 2012) and one non RCT (Sardelli & Burks 
2008) directly evaluated the effects of different approaches of cortisone injection in 
treatment of SAIS using magnetic or radiographic reference.  
 
Henkus et al (2006) examined 33 subacromial injections using MRI evaluation, 
with participants randomly allocated to posterior and anteriomedial routes of 
injection. An orthopaedic surgeon carried out the injections. Injection outcomes 
were measured immediately after the injection and 6 weeks after using the 
Constant Murley and VAS scores. The VAS has been explained in point 2.5.7.2. 
The Constant Murley Score (CMS) is a measure of shoulder pain, function and 
range of movement (Constant & Murley 1987). Although the score is easy to use 
and applicable to patients with SAIS, the objective component of the scale that 
measures range of shoulder movement is not applicable to shoulder studies that 
measure patient’s outcome subjectively over the telephone or by post. Henkus et 
al (2006) reported that 13 out of 17 (76%) of the injections got into the 
subacromial bursa with a posterior route and 10 out 16 (69%) with an 
anteriomedial approach. They found no significant statistical differences between 
the two approaches in terms of accuracy. However, injections that reached the 
subacromial bursa produced significant reduction in pain (P = 0.004) and 
improvement in shoulder function over those that target other structures such as 
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the subdeltoid bursa. A limitation of this study was the small sample size and the 
sample size calculation was not discussed therefore it is difficult to comment on 
how they arrived at the number of patients in the study. Since one orthopaedic 
surgeon carried out the injections, the possibility of intra-rater reliability bias 
(consistency of a single examiner in the application of an instrument over time) 
could not be eliminated. 
 
Kang et al (2008) in a study that used radiographic contrast dye to investigate 58 
patients with impingement syndrome, found no significant statistical difference 
using an anterior, lateral or posterior approach of subacromial injection. The 
authors found no significant difference in outcomes of pain, function and patient 
satisfaction at three months with accurate injections. However, the accuracy rate 
of needle placement was 70% among the three different approaches. This is 
consistent with Henkus et al (2006) that compared posterior and anteriomedial 
routes of subacromial injection, and reported no significant statistical difference, 
yet accuracy rates were 70%. Although participants in the Kang et al study were 
properly randomised to the injection site and the treating surgeon was blinded to 
the results of injection accuracy, the use of a single experienced radiologist to 
review the films might have introduced assessment bias - limiting intra-rater 
reliability. The authors reported the use of composite interventions of NSAIDs, 
physical therapy and cortisone injection/local anaesthetic on each patient. 
Although this is common in normal clinical practice, however, from the study’s 
findings it was difficult to single out the contributions of the additional effects of 
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cortisone injection alone. They reported that the major variable under 
investigation was injection accuracy. In clinical practice, clinicians, including 
ESPs, provide subacromial cortisone injections with or without a local anesthetic 
as a treatment choice, with many stipulating exercise after a period of relative 
rest (a week or more) following the injection. However, these exercise 
prescriptions are not routine and standardised (Innes 2012). To avoid potential 
tendon damage, it has been recommended that resisted exercise should be 
avoided 2 weeks after shoulder cortisone injection (Hanchard et al 2004). 
 
Sardelli & Burks (2008) in a study of 30 shoulders, measured the distances to 
the subacromial bursa of injection placement from anterior, lateral and posterior 
routes using arthroscopy. They found that the average distance for anterior 
approach was 2.9 +/-0.6cm, lateral route was 2.9 +/- 0.7cm and posterior route 
was 5.2+/- 1.1cm. This demonstrated that needle placement from the posterior 
approach to the subacromial bursa was almost twice as much as those of 
anterior and lateral routes. They reported that the distances from both the 
anterior and lateral approaches to the subacromial bursa were almost the same 
and within the zone of a standard 22- or 25-gauge needle. However, needle 
placement from the posterior approach using a 22- or 25-gauge needle may not 
reach the subacromial bursa. Therefore, Sardelli & Burks (2008) recommended 
that practitioners using the posterior portal to the subacromial bursa should apply 
a longer needle to enhance the accuracy of placement. They concluded that 
standard-length needles would demonstrate accuracy from the anterior and 
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lateral portals. However, in practice clinicians, including ESPs use standard 
length needles of 21-gauge, for the posterior, as well as lateral and anterior 
approaches (Saunders & Longworth 2012). This is to enhance standardisation of 
injection procedures using PGD (Saunders & Longworth 2012). The result of the 
Sardelli & Burk’s (2008) study should be interpreted with care given the small 
sample number. The study used an arthroscopic model to evaluate needle 
accuracy to the subacromial, therefore its findings are limited in demonstrating 
clinical efficacy of needle placement in SAIS. Nevertheless, the study’s finding 
should provide some motivation for conducting the appropriate and necessary 
RCTs for investigating the effectiveness of needle placement in SAIS patients 
using anterior, lateral or posterior approaches of subacromial injection. 
Participants in the study were not randomised to the injection site this might have 
introduced allocation or measurement bias. The use of a single experienced 
orthopaedic consultant to complete the arthroscopic evaluation of the needle 
distance might have introduced assessment bias - limiting intra-rater reliability. 
 
Goel et al (2012) undertook a prospective RCT to investigate the accuracy of 
posterior and anteriolateral approaches of subacromial injection in patients with 
SAIS. The study involved 50 patients (23 women and 27 men) with an average 
age of 64.5 years and the authors used VAS and the CMS to assess shoulder 
pain and function respectively. Randomisation to the two study groups occurred 
after patients had given informed consent to participate in the study. Random 
allocation was by sealed envelopes. A consultant Radiologist blinded to the 
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method of the injection carried out the evaluation of needle accuracy and 
effectiveness of the 2 groups. Both the VAS and CMS were measured at 
baseline and 30 minutes post injection. The authors found a statistically 
significant difference (p ˂0.05) in favour of the posterior group 78% compared to 
the anterolateral approach 63.6%. Although the study used concealed random 
allocation and the treating consultant or registrar was blinded to the results of 
injection accuracy, the use of a single experienced clinician to review the films 
might have introduced experiment or treatment bias - limiting intra-rater 
reliability. The finding of this study is in contrast with some previous authors 
(Partington et al 1998, Esenyel et al 2003, Yamakado 2002) who favoured lateral 
approach with similar percentage margins with the Goel et al (2012) study. For 
example, while Yamakado (2002) demonstrated a 70% success, Partington et al 
(1998) and Esenyel et al (2003) have both reported accuracy rates of 83% and 
87%, respectively through anteriolateral route. 
 
Marder et al (2012) investigated 75 patients with rotator cuff syndrome to 
compare the accuracy of anterior, lateral and posterior approaches of 
subacromial injections to the bursa area using radiopaque contrast. An 
orthopaedic surgeon performed the injections. The authors reported different 
degrees of accuracy using the three approaches. The lateral route was 92% (p = 
0.006), the anterior route was 84% and the posterior route was least with 56%. 
At one hour, injections that reached the bursae (intrabursal) produced 
significantly greater pain relief in patients than in those whose injections were 
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extrabursal. They concluded that the anterior and lateral approaches of injections 
into the subacromial area were more accurate in women, but not in men, 
compared to the posterior approach. However, the authors reported that the 
accuracy of injection was approximately 90% irrespective of whether the injection 
was from an anterior, lateral or posterior approach. A limitation of the Marder et 
al study is that a single orthopaedic consultant (who traditionally had used the 
posterior approach) performed all injections (Brett 2012).  
 
Similarly, Yamakado (2002) in a study of accuracy of subacromial injection into 
the shoulder demonstrated a 70% success rate in targeting the subacromial 
bursa in 53 patients through lateral approach. Partington et al (1998) and 
Esenyel et al (2003) have both reported accuracy rates of 83% and 87%, 
respectively through anteriolateral route. However, the Partington et al study 
used cadaveric shoulders. Although the Esenyel et al study did not compare the 
anteriolateral route with posterior approach, the percentage of improvement of 
the anteriolateral route was significant to prove its efficacy. The question 
therefore is why do clinicians traditionally adopt the posterior approach if it has 
least accuracy. Marder et al (2012) showed that sample size was adequately 
powered based on sample calculations of previous studies (Yamakado 2002, 
Kang et al 2008). However, in the Marder et al (2012) study post injection 
outcomes for measures of accuracy and level of pain were measured at 10 
minutes and between 30 minutes to one hour respectively by a radiologist. This 
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follow-up regime is in contrast with normal MSK or GP clinical practice where 
follow-up periods are much longer that is 4 - 12 weeks. 
 
In concluding this section of the evidence of needle placements in subacromial 
injections, four studies (Henkus et al 2006, Kang et al 2008, Sardelli & Burks et 
al 2008, and Marder et al 2012) investigated needle placements in patients with 
SAIS. They did so by assessing the accuracy of anterior, lateral and posterior 
approaches of subacromial injections in patients with SAIS either by using a MRI 
(Henkus et al 2006), radiographic contrast dye (Kang et al 2008), arthroscopy 
(Sardelli & Burks 2008) or radiopaque contrast (Marder et al 2012) as a 
reference. Although the injections were performed by experienced clinician, they 
were done with the aid of a diagnostic evaluation, however, in normal practice, 
clinicians such as ESPs and GPs do not inject the shoulder using an imaging 
reference. In all four studies, a single orthopaedic surgeon performed all the 
injections. The lack of inter-rater measures in these studies, could compromise 
their intra-rater reliability. The results of two of the studies (Henkus et al 2006, 
Kang et al 2008) indicate that there is no evidence supporting the use of either 
anterior, lateral or posterior approaches over each other. In contrast, the Goel et 
al (2012) study favoured lateral approach compared to posterior route. Further 
still, Marder et al (2012) have demonstrated that subacromial injection using 
anterior and lateral routes were more accurate in women compared to the 
posterior route. Sardelli & Burks (2008) have recommended that compared to 
lateral and anterior approaches a longer needle length is necessary to enhance 
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the accuracy of from the posterior because it had least accuracy. Therefore, the 
results of the four studies that were critically evaluated indicate that there is no 
consensus regarding the evidence establishing superiority of any one method of 
injection approach over the other in clinical practice.   
 
2.7 Discussion of the Qualitative Literature Review Findings 
This section focuses on the qualitative literature review on shoulder pain and 
SAIS. It discusses the importance of investigating the experiences of patients 
with SAIS receiving subacromial injection from a qualitative perspective. The 
benefits of qualitative study in musculoskeletal conditions, the ontological and 
epistemological positions of using semi-structured interview methods as a means 
of exploring the lived experiences of patients with SAIS being treated with either 
posterior or lateral route of subacromial injection are also discussed.  
 
Generally, SAIS has been treated conservatively with a focus on improving 
clinical outcomes of pain, function and disability. However, the experiences, 
perceptions, and preferences of SAIS patients are often neglected, and this can 
have a profound influence on treatment outcomes (Australia Physiotherapy 
Association 2003, Walker & Sofaer 2003). Currently there is increased pressure 
on healthcare practitioners, including ESPs, to demonstrate that their practice is 
evidence-based. The emphasis to document improvements in a patient’s health 
status helps in justifying funding needs, hence the necessity for research that 
focuses on the holistic model of patient care cannot be overemphasised. 
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Therefore, clinicians such as ESPS have to adopt an approach that moves away 
from focusing solely on measuring pain, muscle function and disability toward a 
greater emphasis on assessment of the individuals' experiences before, during 
and after treatment (Copeland et al 2008 and Shaw et al 2010).  
 
Conservative management of SAIS is multifactorial and consists of rest, NSAIDs, 
corticosteroid injections, acupuncture, manual and exercise therapy. While 
several authors have demonstrated short-term benefits of cortisone injection in 
the treatment of SAIS, the research literature demonstrates paucity in the 
subjective experience of SAIS patients receiving subacromial injections either 
through a lateral or a posterior approach. A systematic review commissioned by 
the UK department of Health that searched for studies on patient’s experience of 
conservative treatment found none (Maund et al 2012). 
 
2.7.1 Patient Experience on Subacromial Cortisone Injection 
The results of the qualitative literature search (from 1980 to 2016) found just one 
study (Nyman et al 2012) that investigated the experiences of patients with 
supraspinatus tendinitis who had received either physiotherapy and cortisone 
injection or had undergone open or arthroscopic shoulder surgery. The study 
involved 26 participants aged 43-63 and interviews were through focus groups. 
However, only three of the participants received cortisone injection. The 
interviews occurred between 2005 and 2007, and participants were divided into 
six focus groups: three before and three after treatments. The groups were also 
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chosen according to the type of treatment the respondents had received. Data 
analysis was through a thematic method. The main themes that emerged from 
the interviews were in two categories the before and after intervention themes. 
The pre-intervention themes consist of patients concern with pain disturbing their 
sleep, daily activities, reaction of their work colleagues to their condition and lack 
of understanding of their problem. The post intervention experiences of the 
participants were professionalism of physiotherapists, the therapeutic 
relationship they enjoyed during treatment, time taken before they were treated, 
treatment expectations and the environment of their treatment. The findings of 
the study compare favourably with other shoulder studies (Jones et al 2013, 
Chester et al 2016) that reported that patient expectations and experiences of 
their treatment and care contributed to their overall clinical outcomes.  
 
Although this study provides information on patients’ experiences of shoulder 
problems before and after intervention using focus groups interviews, only three 
out of the 26 participants who were interviewed were treated with cortisone 
injection after having physiotherapy. While the study’s findings are generalisable 
to patients with supraspinatus tendonitis receiving physiotherapy or surgical 
interview, they are not generalisable to SAIS patients receiving cortisone 
injection because of the small number (3 out of 26) of those involved in the 
study. However, the study provides a good platform to conduct future qualitative 
interviews regarding SAIS patients’ experiences of receiving subacromial 
injection. This view is supported the Department of Health (DOH 2009) 
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document that recommends patient centred treatment. This was the motivation 
as to why I undertook this current research. 
 
The Department of Health (DOH 2009) in its report of reforms of “NHS 2010-
2015: from good to great” (DOH 2009) specifies that NHS services must be more 
productive, patient centred and closer to people’s home. The document 
acknowledges that there are shortcomings in musculoskeletal service’s 
pathways due to inappropriate referral down a less effective route and/or delayed 
referral to more appropriate care and seeks to address these by ensuring more 
patient and public involvement – taking into account their views and experiences 
(DOH 2009). This is to ensure that decisions made regarding resource allocation 
are patient-led rather than provider and/or bureaucracy-led, one that is prompt 
and equitable, cost effective and a rational service for all (DOH 2009). This 
includes referrals to clinical specialists such as ESPs who can provide treatment 
options including cortisone injection to patients in a timely fashion and closer to 
their homes.  
 
Currently, specialist musculoskeletal services are commissioned by GPs mainly 
to enhance patient experience by reducing waiting times. This is because 
previously patients, including those with shoulder pain, have had to wait longer 
periods to access these services (including provision of injection therapy) – 
leading to delayed referral along the specialist musculoskeletal pathway. Such 
delay can negatively influence the overall experience of patients, as well as 
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leading to patients developing chronic symptoms thereby reducing the 
effectiveness of future interventions such as cortisone injection (DOH 2009). 
However, a prompt referral to an appropriate clinical pathway such as extended 
scope musculoskeletal service, could achieve better clinical outcomes in 
improving the patient’s condition by arresting progression of painful symptoms – 
leading to a better patient experience. Therefore, it is necessary to examine the 
impact that the current referral pathway would have on patient experience in 
relation to cortisone injection. 
 
In conclusion, since SAIS is so common and causes so much cost and disability, 
it is therefore important it be treated effectively. Research evidence also 
suggests that generally, the lateral and posterior approaches are used by ESPs 
for subacromial injection. However, the posterior approach is most commonly 
used. In normal practice, the evidence establishing superiority of the lateral 
approach over the posterior route in subacromial injection is still controversial. 
Therefore, it is uncertain if a lateral approach to subacromial injection is more 
effective over a posterior route in improving outcomes of pain and function in 
SAIS. The evidence in the subjective experience of SAIS patients receiving 
subacromial injections is very scare. To my knowledge and despite extensive 
literature search, no study has both compared the effectiveness of the lateral 
versus the posterior approach in subacromial cortisone injection in normal 
clinical situations and the experiences of the patients receiving these treatments. 
This study will therefore address these issues.  
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2.8 The Research Question 
To address the gap in the current knowledge on which of the needle approaches 
whether lateral or posterior to subacromial injection is more effective in the 
treatment of SAIS patients and their experiences of receiving these injections the 
following research questions were formulated.  
1. Is lateral approach to subacromial injection more effective at improving 
shoulder pain and function in patients with SAIS compared to a posterior 
approach?  
2. What are the experiences of patients with SAIS receiving these 
subacromial injections? 
 
2.9 Null Hypothesis of the Study 
There is no significant difference in the effectiveness of lateral approach 
compared with posterior approach to subacromial injection at improving shoulder 
pain and function in patients with SAIS. 
 
2.10 Alternative Hypothesis of the Study 
Lateral approach to subacromial injection is more effective at improving shoulder 
pain and function in patients with SAIS compared to a posterior approach. 
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2.11 Aims of the Study 
2.11.1 Primary Aims 
1. To determine the effectiveness of lateral approach to subacromial 
injection compared to posterior approach for the treatment of SAIS 
2. To establish the experiences of patients with SAIS receiving these 
subacromial injections 
 
2.12 Chapter Summary 
This review has critically appraised the current literature on SAIS and its clinical 
presentation, classification, aetiology, diagnostic difficulties and clinical 
assessment. The current trend in National Health Service (NHS) musculoskeletal 
practice, the role of Extended Scope Practitioner (ESP) in musculoskeletal 
practice, current treatment for SAIS, and the issue of needle placement in 
subacromial injections have been presented. The review also critiqued the 
evidence regarding needle placements in subacromial injections in patients with 
SAIS and the experience of those receiving these treatments. There was lack of 
clear evidence establishing superiority of the lateral approach over the posterior 
route in subacromial injection in normal practice with paucity of literature 
investigating the experiences of these patients. Therefore, answering questions 
about the effectiveness of these approaches and the patients’ perspective of 
these treatments are relevant to both patients and clinicians, as this may inform 
and transform practice.  
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The next chapter describes the methodology of the research including the aims 
of research, the research hypothesis and design, study setting and selection 
criteria for both the quantitative and qualitative study, clinicians involvement in 
the study, recruitment of participants, sample size calculation, process of 
randomisation, concealed allocation and blinding. I also provide a discussion on 
the study groups, interventions, treatment procedure, baseline comparability, 
data collection methods and analysis for both arms of the study. Finally, a 
discussion of ethical considerations and input of service users to the research is 
considered. 
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CHAPTER 3 METHODOLOGY 
 
3.1 Introduction 
In the previous chapter, a review of SAIS, the evidence relating to needle 
placement in subacromial injection with adults with SAIS and the knowledge gap 
regarding which approach of subacromial injections is more effective and the 
experiences of those receiving these injections are provided. This chapter will 
describe the methodology used to address these gaps in knowledge. The 
chapter is organised around the research design for both the quantitative and 
qualitative aspects of this research, data collection methods and analysis. The 
chapter concludes with a discussion of ethical considerations and input of 
service users to the research. 
 
3.2 Research Design 
This study used a mixed methods approach that combines both a quantitative 
and a qualitative approach as the research design.  
 
3.3 Mixed Method Design 
A research paradigm that combines both qualitative and quantitative methods, 
that is centred on optimizing treatment outcomes and integrating patient’s 
perception and preferences is better suited to answer the above research 
questions. Several authors have suggested that combining qualitative research 
with quantitative methods greatly enhances the understanding patients provide 
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to treatment interventions (such as injection therapy), and the expectation they 
have concerning treatment outcomes such as pain relief (Verhoef et al 2002, 
Copeland et al 2008, Rowell & Polipnick 2008, Shaw et al 2010). This is in 
tandem with the current Department of Health drive to include patient's 
expectations and their experiences in the design and evaluation of healthcare 
research and services (DOH 2010). A systematic review of qualitative and 
quantitative studies on patients’ expectations of treatment of musculoskeletal 
pain concluded that patients should be more involved in the decision-making 
process of their treatment (Verbeek et al 2004). This is because patients’ 
involvement would enhance shared decision making and improve the quality of 
treatment they receive. The authors however, expressed some concerns with the 
mixed method research; for example, the lack of generally accepted quality 
criteria for evaluating mixed methods research (Creswell & Piano Clark 2007). 
However, the Priority-Sequence approach suggested by Morgan (1993) provides 
an acceptable quality approach for evaluating both qualitative and quantitative 
research methods. The approach by Morgan (1993) allows different but 
complementary information to be obtained in a mixed method research design. 
Furthermore, researchers with different areas of methodological expertise can 
provide potential innovation for guidance and quality criteria to enhance both 
qualitative and quantitative methods (Rauscher & Greenfield 2009, Shaw et al 
2010).  
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The priority-sequence model by Morgan (1993) attempts to address the 
complementary needs aspects of different research methodologies. The author 
proposes that the first research design decision is to decide on which approach, 
either quantitative or the qualitative will be the principal data collection method. 
The next step is for the researcher to select a contrasting complementary 
method that adds additional sets of values to the research design's overall ability 
to meet the project goals. The second research design decision is to determine 
the sequence or order of the two methods. Combining this two-step decision 
making led Morgan to develop four major research designs which include: 
a) A qualitative preliminary study that contributes to a principal quantitative 
study (qual-QUANT),  
b) A quantitative preliminary study to enhance a principal qualitative study 
(quant-QUAL),  
c) A qualitative method that complements a principal quantitative approach 
(QUANT-qual) and  
d) A complementary quantitative study that serves as follow-up to a principal 
qualitative study (QUAL-quant) 
Since this study aims to determine which injection approach is superior to the 
other for SAIS treatment and to establish the experiences of the patients 
receiving these injections, the third design Quant-qual (Morgan 1993) was used 
because it allowed for exploration of the study's objectives from two 
perspectives. The adoption of a complementary design approach enabled the 
demarcation of the data each method generated and ensured analyses were 
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separate. A pragmatic RCT approach was used as the quantitative approach. 
The objective of using the pragmatic RCT design is to provide a valid and 
reliable set of clinically relevant data that is capable of detecting clinically 
important outcomes (such as shoulder pain, function and disability) for patients 
with SAIS (Walker & Sofaer 2003). Using the Priority-Sequence approach 
suggested by Morgan (1993), a qualitative study using semi structured 
qualitative interviews that complements a principally quantitative approach was 
used as the research methodology. Qualitative interviews using semi-structured 
questions were used as the qualitative design. This is to enhance the gathering 
of in-depth, rich data concerning the patient’s experiences of subacromial 
injection. The qualitative method served as a follow-up to the quantitative 
approach. The desired objective of using the mix-method for this study is for the 
qualitative method to provide in depth interpretative data for understanding and 
describing the meanings patients with SAIS ascribe to subacromial cortisone 
injection.  
 
3.4 Stages of the Research 
The study has two phases. Phase 1 involves a randomised control trial and 
phase 2 is a qualitative study using semi structured interview. The flow charts for 
the research design are summarised in Figure 5. 
 
In this chapter, I will outline the RCT first and then go on to outline the qualitative 
aspects of the study. 
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Figure 5: The Flow Chart for the Research Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Setting 
Patients with SAIS attending community MSK treatment  
 
Sample Size 
Potential participants n = 110 
Potential participants at follow-up n = 100 
Identification of Potential Participants 
Shoulder pain patients assessed by ESP’s as suitable for the study 
Eligibility criteria for SAIS & the trial 
 
Recruitment of Potential Participants  
Invitation letter containing patient information sheet and informed consent 
 
Intervention/Experimental treatment 
(Lateral) group n = 55 
Control/Standard treatment 
(Posterior) group n = 55 
Outcome Measures & Follow-Up 
SPADI & PROMs and Follow-up period at 8 & 12 weeks 
 
Following completion of follow-up assessments, 20 
potential participants will be selected by the 
researcher for qualitative interviews 
Quantitative Data 
Analysis& Descriptive 
statistics 
SPSS & t-tests 
Semi-structured Interviews 
Qualitative Data Analysis 
Randomisation/Blinding 
Concealed random allocation/Assessor blinding 
Interventions 
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3.5 Phase 1 
3.6 Methods 
3.6.1 Design: Quantitative – Pragmatic Randomised Controlled Trial 
The study is a two-arm, single blind, pragmatic randomised controlled design as 
defined by Hicks (1999), where the effects on dependent variables (shoulder 
pain and function) were measured by manipulating a single independent variable 
subacromial injection with two conditions (lateral and posterior approaches to 
subacromial injection). 
 
There are many different research designs ranging from a single observational 
case study, a cohort or case controlled design, to experimental studies such as 
non-randomised and randomised controlled trials (RCTs). Each design has its 
own strengths and weaknesses. The choice of methodology may be influenced 
by factors such as the research question, ethical issues, sample size and funding 
(Hicks 1999). Although case studies are likely to demonstrate clinically significant 
improvement in outcomes of pain and function in the individuals, it must not be 
forgotten that they cannot rule out the effect of natural resolution, bias and other 
confounders such as the cause of improvement (Ainsworth & Lewis 2007). 
However, single case studies should provide some motivation for conducting the 
appropriate and necessary trials such as non-RCTs and RCTs (Egger et al 
2007). Non-RCTs can detect associations between an intervention and an 
outcome, however they cannot rule out the possibility that the association was 
caused by a third factor linked to both intervention and outcome (Sibbald & 
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Roland 1998). RCTs are widely considered as the gold standard for assessing 
the effectiveness of different interventions such as shoulder injections, because 
they allow us to be confident that a difference in outcome can be directly 
attributed to a difference in the treatments, rather than some other confounding 
factors (age and gender) (McGovern 2001, Aveyard 2007). However, other 
factors, such as patient's clinical experience of the intervention, have been 
suggested to play a role in determining treatment outcomes (Black 1996). 
Therefore, a study that combines both aspects by investigating the effectiveness 
of the interventions as well as exploring the experiences of patients concerning 
the interventions is important. To achieve this, this study investigated the 
effectiveness of two interventions (lateral versus posterior approach) to 
subacromial injections in SAIS patients was well as the experiences of those 
receiving these injections. 
  
RCTs help to reduce the risks of bias (threats to interval validity), mostly 
selection bias, and are thus best suited for research designs about the 
effectiveness of different interventions (Treweek & Zwarenstein 2009). However, 
it is the opinion of Cochrane, that randomisation does not, of itself, enhance the 
applicability of the results of a trial (external validity) to situations other than the 
exact one in which it was conducted (Cochrane 1972). It is possible for a trial to 
be free of bias but lacking in its application beyond the immediate clinical 
environment in which it was conducted (Treweek & Zwarenstein 2009). This view 
was strongly re-echoed by Rothwell (2005) which it stated: “Lack of 
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consideration of external validity is the most frequent criticism by clinicians of 
RCTs, systematic reviews, and clinical guidelines" (Rothwell, 2005:8). To resolve 
this problem Treweek & Zwarenstein (2009) has suggested the use of well-
designed trials that adopt a pragmatic approach. In this study, a pragmatic RCT 
approach was adopted and the study was undertaken in a normal clinical 
environment within the community where most people with shoulder pain are 
diagnosed and treated (Hanchard et al 2013) to enhance its generalisation.  
 
3.6.2 Pragmatic Versus Explanatory Randomised Controlled Trial  
Schwartz & Lellouch (1967) describe two different types of RCT, explanatory and 
pragmatic. They proposed a distinction between explanatory and pragmatic 
trials. It is their view that many trials (such as explanatory trials) were limited in 
their applicability beyond the artificial, laboratory environment. Explanatory trials 
are aimed at validating a physiological hypothesis by specifically proving a 
causal relationship between administration of a treatment (a drug) and a 
physiological outcome (such as inflammation) (Schwartz & Lellouch 1967). 
Although pragmatic trials provide an explanation between interventions and 
treatment outcomes, they are also intended to inform healthcare decision-
making, with this decision involving the choice between two or more treatments 
and real life outcomes (such as pain, function, and disability). On the other hand, 
explanatory trials provide knowledge about the effects of precisely defined 
interventions applied to selected groups under highly controlled conditions; 
however, they are not applicable in normal clinical situations that lack such highly 
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controlled environments. Pragmatic trials have been offered as a solution in that 
they retain the rigour of randomisation but are still applicable to normal clinical 
practice (Relton et al 2010). It is for these reasons that this study adopted a 
pragmatic approach and took place within a normal clinical environment in the 
community. 
 
The differences between the two approaches are also highlighted in the use of 
efficacy and effectiveness (MacRae 1989, Sheikh et al 2002). Explanatory trials 
deal with efficacy as these studies assess differences in effect between two or 
more conditions under ideal, highly controlled conditions (Alford 2007). Although 
the tight controls of explanatory trials result in maximal internal validity, external 
validity could be lost (Alford 2007) because replicating them under normal clinical 
practice is difficult. Explanatory trials are thought to be well suited to medical 
drug trials, which are usually double or triple blinded, and involve the use of a 
placebo control group (Alford 2007). Pragmatic RCTs utilise effectiveness, which 
assesses differences in effect between two or more conditions in normal clinical 
circumstances, thus retaining internal validity and enhancing external validity 
(Alford 2007). It is the opinion of Alford (2007) that pragmatic RCTs are generally 
more suited to assessing musculoskeletal interventions such as needle approach 
to subacromial injections. Explanatory trials are usually more expensive, take 
more time and involve more personnel, unlike pragmatic trials. These difficulties 
are the reasons why a pragmatic approach was adopted in this research. To 
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achieve this, no extra costs or personnel was involved in the study. For example, 
the study took place within normal clinical hours with the usual staff involved. 
 
3.6.3 Pragmatic Randomised Controlled Trial – Why it is Important 
This study used a pragmatic RCT design to compare the effectiveness of 
posterior or standard approach versus lateral or experimental approach of 
subacromial injections in SAIS patients in a normal community practice where 
most people with shoulder pain are diagnosed and managed (Hanchard et al 
2013). A pragmatic RCT is aimed at determining the effectiveness of two or more 
interventions under the usual conditions or real life settings in which they are 
applied (Califf & Sugarman 2015). Pragmatic trials including RCT are aimed at 
ensuring that the care delivered in the setting in which trials are conducted 
matches the care delivered in the setting to which its results are applied (Loudon 
et al 2015). Pragmatic RCTs are generally linked with clinical practice and they 
incorporate clinical outcomes that are relevant to inform decision makers such as 
patients, clinicians, health commissioners and policy makers about interventions 
that are applicable to a wide range of clinical settings (Califf & Sugarman 2015). 
These trials adopt minimal exclusion criteria in order for the patients to reflect 
those receiving care within the normal population (Califf & Sugarman 2015). This 
study used a pragmatic RCT design to compare both aspects of subacromial 
injections (posterior or lateral) to determine which of them will produce better 
clinically important outcomes (such as shoulder pain and function) for patients 
with SAIS. This is so that decision making by both the patients and healthcare 
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providers regarding subacromial injections for patients with SAIS could be 
enhanced. The study included participants with SAIS drawn from a population of 
patients attending a community (MSK) service and were representative of the 
general population. To enhance the study credibility, the nine dimensions for 
assessing the level of pragmatism in a trial, as proposed in the pragmatic-
explanatory continuum indicator summary 2 (PRECIS-2) tool was adopted 
(Loudon et al 2015). See Table 7 for detailed description.  
 
With the current economic climate and given the pressure to improve healthcare 
delivery within the community, pragmatic RCTs have received wide spread 
support and acceptance from clinicians, researchers and policy makers (Whicher 
et al 2015). Healthcare commissioners and policy makers are very interested in 
pragmatic trials because they are designed to answer important questions 
relevant to them, which is comparative effectiveness of interventions in the 
normal clinical practice (Patsopoulos 2011, McCully 2015). The service where 
this study took place was commissioned by the local Clinical Commissioning 
Group (CCG) to provide cortisone injection as part of the management of 
patients with shoulder pain and they were interested in knowing the clinical 
outcomes. Therefore, they were keen in promoting high quality health research 
which provides the evidence needed to improve healthcare and treatment. 
Consequently, during the planning stages of this study, the local CCG and GPs 
were informed and involved in the study and they supported it.   
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Table 6: The nine dimensions for assessing the level of pragmatism in a trial, as proposed in the pragmatic-
explanatory continuum indicator summary 2 (PRECIS-2) tool 
Dimension Assessment of Pragmatism – PRECIS-2 
Tool 
 What this study did using the PRECIS-2 Tool 
Eligibility To what extent are the participants in the 
trial similar to those who would receive this 
intervention if it was part of usual care? 
This study participants were patients that have been referred to the service 
by their GP with shoulder pain who usually could be treated with 
subacromial injection either via a posterior or a lateral approach. 
Recruitment How much extra effort is made to recruit 
participants over and above what would be 
used in the usual care setting to engage 
with patients? 
The service where thus study took place receives referrals from 33 GP 
practices in the area. Therefore, prior to the study, presentations were 
made to the GP’s in the area via the clinical commissioning group (CCG) 
and to the ESPs and the Physiotherapists at the researcher's place of work 
to inform them of the study and enhance recruitment of participants.  
Setting How different are the settings of the trial 
from the usual care setting? 
All the participants recruited to the study were from a population of patients 
attending a community (MSK) service. 
Organisation How different are the resources, provider 
expertise, and the organisation of care 
delivery in the intervention arm of the trial 
from those available in usual care? 
No extra cost or personnel was involved in this study. The clinicians 
involved in this study and the treatment they provided were similar to the 
care they would normally provide in their clinical practice. 
Flexibility in 
delivery 
How different is the flexibility in how the 
intervention is delivered and the flexibility 
anticipated in usual care? 
The flexibility applied to the intervention in this study was similar to the 
usual care.  
Flexibility in 
adherence 
How different is the flexibility in how 
participants are monitored and encouraged 
to adhere to the intervention from the 
flexibility anticipated in usual care? 
In this study standard after care and post-injection information were 
provided verbally and in the form of information leaflet based usual care. 
Follow-up How different is the intensity of 
measurement and follow-up of participants 
in the trial from the typical follow-up in usual 
care? 
Participants in this study were assessed three times during the study 
period, at 0 (baseline), 8 and 12 weeks. The 0 and 8 weeks’ timeframe is 
common in normal clinical practice and previous authors (Akgun et al 
2004) have used the 12 weeks’ follow-up period. At follow-up, the 
outcomes of the injection were evaluated via a telephone call similar to 
normal clinical practice. 
Primary 
outcome 
To what extent is the trial’s primary outcome 
directly relevant to participants? 
The primary outcome – SPADI and the PROMs that were used in this are 
patient reported outcome measures that are used in normal clinical 
practice.  
Primary 
analysis 
To what extent are all data included in the 
analysis of the primary outcome? 
In this study, all data were included in the analysis of the primary outcome. 
Once a participant is randomised to an arm of treatment, they should be 
analysed in the group to which they were allocated to after randomisation. 
 Adopted from Loudon et al (2015)
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This is consistent with the suggestion by Patsopoulos (2011) that decision 
makers such healthcare providers and policy makers should be included in 
the design of pragmatic trials.  
 
In a recent review literature, Drazen et al (2016) advocate that in pragmatic 
trials, the intervention should be delivered as in normal clinical practice by 
experienced, skilled and trained clinicians.  This is consistent with the 
pragmatic RCT approach that this study used. It involved experienced, trained 
and skilled ESPs working in the community with no extra costs or personnel 
for the research. Pragmatic trials not only compare a new treatment with an 
existing one, but they can also compare existing treatments with alternatives 
(Zwarenstein 2016). This is exactly what took place in this study where a 
posterior (the usual or standard) approach to subacromial injection was 
compared with a lateral (alternative or experimental) approach to determine 
which of them is more effective in the treatment of SAIS. 
 
3.6.4 Study Setting 
The study setting was at a large Community Musculoskeletal (MSK) service. 
Prior to the study, presentations were made to the GP’s in the area via the 
clinical commissioning group (CCG) and to the ESPs and the 
Physiotherapists at the researcher's place of work to inform them of the study. 
They were provided with details regarding the rationale behind the study and 
the participants. All the participants recruited to the study were from a 
population of patients attending a community (MSK) service. This service 
receives referrals from 33 GP practices in the area.  
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3.6.5 Sample Criteria 
Eligibility of participants is a crucial feature and central to the topic of 
inferential statistics, this is because the sample chosen should be 
representative of the population that the results are likely to be applicable to 
(Hicks 1999). Research predictions are better made if the sample is largely 
homogeneous to the population that it is trying to represent; otherwise the 
results are only generalisable to a small subgroup of participants (Hicks 
1999). Since restrictive inclusion and exclusion criteria lead to a more 
homogeneous group of patients, pragmatic trials frequently utilize less 
restrictive criteria (Godwin et al 2003, Alford 2007). This improves the 
external validity (generalisability) as patients with the disorder of interest 
commonly exhibit co-morbidities such as previous injury and diabetes. This 
maximisation of external validity often occurs at the expense of internal 
validity (Alford 2007). In balancing these two competing demands, the SAIS 
criterions when selecting patients with SAIS (Lewis et al 2005) and the study 
suitability criteria for subacromial injection (Saunders & Longworth 2012) 
were adopted from previous studies which have successfully used them. 
Tables 3 and 4 are respectively the participants' diagnosis and study's 
suitability criteria. 
 
3.6.6 Identification of Participants 
Participants were patients that have been referred to the service by their GP 
with shoulder pain. The term SAIS is reflective of a spectrum of soft tissue 
pathologies rather than a diagnostic label relating to specific pathology (Lewis 
2008). However, in practice a diagnosis of SAIS is still based on findings of a 
clinical examination for a majority of patients (Dinnes et al 2003).  At first 
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appointment, a trained ESP identifies them through a face-to-face 
assessment to determine if they have a diagnosis of SAIS and would benefit 
from a cortisone injection. A diagnosis of SAIS was made by the assessing 
ESP according to the inclusion and exclusion criteria in Table 7. 
 
Table 7: Diagnosis Criteria for SAIS 
 
Inclusion Criteria Exclusion Criteria 
Patients aged 18 and above 
Shoulder pain localised to the acromion 
Pain with active arm elevation 
Positive painful arc between 60° and 
120° of abduction 
Positive impingement test-Neer’s sign 
or Hawkins Kennedy 
No evidence of referred pain from 
cervical spine 
 
Patients below 18 years of age 
History of: 
• Current Pregnancy 
• Spinal or shoulder surgery (last 6 
months) or joint replacement 
• Current Spinal or upper limb fracture 
• Previous hydrocortisone injection in 
the last 4 weeks 
• Shoulder dislocation/ instability 
• Current Frozen shoulder 
• Acromioclavicular joint arthritis 
• Os acromiale 
• Bony metastases 
Clinical findings of presence of positive:  
• External rotation lag sign 
• load and shift test 
• Sulcus sign 
• Active compression labral test 
Reproduction of shoulder symptoms 
during active cervical movements 
Reproduction of shoulder symptoms on 
movements of the cervical or thoracic 
spine rather than shoulder movement 
Radiographic evidence of calcific 
periarthritis 
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3.6.7 Suitability Criteria for the Study 
Once SAIS criteria had been met, a further selection was made using all of 
the inclusion and exclusion criteria listed in Table 8 below to select patients 
for the study.   
 
Table 8: Inclusion and Exclusion Criteria for the Study 
Inclusion Criteria Exclusion Criteria 
Patients 18 years and above Patients under 18 years of age 
They fulfil the eligibility criteria for SAIS Did not fulfil the eligibility criteria for SAIS 
Able to give informed consent Failure to consent 
Eligible for lateral and posterior routes of 
subacromial injection 
Not eligible for lateral and posterior 
routes of subacromial injection 
Patients with no contraindication to 
cortisone injection such as: 
• sepsis, fracture sites, prosthetic 
joint and uncontrolled blood 
glucose levels 
Patients with contraindication to 
cortisone injection such as: 
• sepsis, fracture sites, prosthetic 
joint and uncontrolled blood 
glucose levels 
 
 
3.6.8 Clinicians Involvement in the Study 
The researcher as Chief Investigator and two Extended Scope Practitioners 
(ESPs 1 & 2) were involved in this study. Both ESPs (1 & 2) were involved in 
consenting, assessing and injecting patients. The Chief Investigator, who was 
not involved in the patient’s initial assessment and therefore blinded to the 
baseline measurement, was involved in the follow-up assessments at 8 and 
12 weeks. Information about the eligibility criteria was provided to both ESPs 
to aid diagnosis and they, as well as the administrative staff involved in the 
randomisation, received training on the study protocol. For the ESPs the 
training included the selection criteria, consenting of participants and 
adequate documentation of none identifiable participant’s information. The 
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administrative staff were trained on the participant information sheet, patient 
recruitment and randomisation procedure. A standard operating procedure 
(Appendix 1) was developed for this purpose and everyone involved in 
administering the study followed it. 
 
3.6.9 Recruitment of Potential Participants 
When the first musculoskeletal appointment was posted to the patient, a 
separate envelope containing a letter of invitation (Appendix 2) to take part in 
the study was also sent. The invitation pack contained a letter of invitation 
with a Patient Information Sheet (PIS) (Appendix 3) and two consent forms 
(for the quantitative part and the qualitative interview) (Appendix 4). In the 
PIS, it was clearly stated that involvement in the study was voluntary and that 
participants were free to withdraw from the study at any time. Participants 
who were interested in taking part in the study but had further questions were 
encouraged to contact the researcher via a study mobile number or postal 
address. Participants were asked to read the PIS before attending their first 
musculoskeletal appointment if they wished to participate. On attending their 
appointment they had an opportunity to ask questions and were asked to sign 
the consent forms. Potential participants who fulfilled the eligibility criteria 
following screening by the assessing ESP and provided written informed 
consent were then recruited into the study.  
 
3.6.10 Sample Size Calculation 
The primary aim of the study is to detect whether there is a clinically important 
difference between a lateral and posterior approach to subacromial injection. 
Sample size calculation is an important step in the design of a clinical trial; 
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however, the amount of literature that addresses such an important issue is 
scarce (Kieser & Friede 2000). Miaoulis & Michener (1976) in relation to 
determining appropriate sample size have specified three key areas: level of 
precision, level of confidence or risk and degree of variability of the attributes 
in the population. In general the more heterogeneous the population, the 
larger the sample required to obtain the desired level of precision and 
conversely the more homogeneous the population the smaller the required 
sample (Israel 1992, Claver 2009). Sample size also has an economic 
viewpoint with underestimated sample size not having the capacity to produce 
meaningful findings and therefore can be a waste of resources (Claver 2009). 
However, an oversized sample uses more resources than are necessary 
(Claver 2009). In today’s current healthcare climate where there are limited 
resources it is important to have a sample size that is large enough to 
produce a significant result yet still within available budgets and resources 
(Claver 2009). When the sample size is small RCTs are subject to type II 
errors (Keirse & Hanssens 2000, Hicks 2009). These refer to the probability of 
concluding that no difference between the treatment groups exists when, in 
fact, a difference does exist i.e. false negatives (Lochner et al 2001, Hicks 
2009) In this situation, the null hypothesis is false, but erroneously fails to be 
rejected (Lochner et al 2001, Hicks 2009). One way of reducing type II error is 
increasing the sample size (Hicks 2009), which ultimately increases the 
power of the study, defined by Bigby & Gadenne (1996) as the ability of a trial 
to detect a difference in treatments if one exists. The power of a study could 
also be influenced by the statistical significance level (usually set at 5%) and 
knowledge of the minimum clinically important difference (MCID) of the 
primary outcome measure, which can be based on previous studies or expert 
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opinion (Claver 2009). A power level of 80% - 90% is usually considered 
adequate (Murray 1991); this implies that if the clinically important difference 
in treatment truly exists, 4 - 4.5 out of 5 treatments with the specified number 
of patients in the treatment groups will show a statistically significant 
difference (Claver 2009). A large sample size has another advantage in that it 
increases the likelihood of the sample being representative of the population 
being studied (Hicks 1999). According to Alford (2007), pragmatic clinical 
trials generally require larger sample sizes due to the heterogeneity of the 
sample population. In SAIS where the attributes of the population are diverse 
and the prognostic factors not well established, a larger sample offers the 
possibility of achieving the desired level of precision and ensuring that the 
study is sufficiently powered (Claver 2009). Sample size calculations are 
frequently performed using formulas and figures or with the aid of computer 
software. In this study, the former was adopted. 
 
The sample size calculations were based on work by Roach et al (1991) who 
estimated the MCID for the Shoulder Pain and Disability Index (SPADI) to be 
a change in score of 13 points at 90% power level. Identification of a MCID 
between treatments groups is important in deciding the treatment effect-size 
and therefore the sample size (Samsa & Matchar 2001). SPADI is one of the 
primary outcome measures to be used in this study. It is a self-report 
questionnaire designed to measure pain and disability specifically associated 
with shoulder pain of musculoskeletal origin (Roach et al 1991). 
 
Based on data from a previous shoulder study (Ekeberg et al 2009) that 
estimated the standard deviation of change in SPADI to be 20 points, the 
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power level was set at 90% and statistical significance at 5% to detect a 
MCID of 13 points. Using these figures, a sample size of 100 is estimated. To 
account for a 10% rate of loss at follow-up the study included 110 
participants. This value was achieved using formula and figures listed in 
Bland (2000 p, 338 – 339) as shown in Table 9. 
 
Table 9: Sample size calculation using formula and figures listed in Bland 
(2000 p, 338 – 339) 
 
According to Bland (2000), for comparison of two means for equal sized groups, n1 = n2 = 
n, the equation becomes:  
(µ1- µ2)2 = ƒ(α, P) 2σ2/n 
Using the Bland (2000) table, if power P = 0.90 = 90%, α = 0.05 =5%, the conventional 
values of ƒ (α, P) is 10.5. 
P = power of the test = 90% 
α = significance level = 5% 
n = the sample size in each of the groups  
µ1 = population mean in treatment Group 1 – Lateral Group 
µ2 = population mean in treatment Group 2 – Posterior Group 
µ1 − µ2 = d =13 
d = the difference the researcher wishes to detect (clinically important difference) 
σ = population variance standard deviation (SD) = 20 
Since d = µ1 – µ2 = 13, ƒ(α,P) = 10.5, σ = 20 
(µ1- µ2)2 = ƒ(α, P) 2σ2/n becomes  132 = 10.5 x [2 x 202]/n  
which gives n = 10.5 x [2 x 202]/132 = 49.70 
Hence, the researcher needs 50 patients in each group. Therefore, the researcher needs 
100 patients. To account for a 10% rate of loss at follow-up, this study will include 110 
participants. 
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3.6.11 Randomisation & Allocation Concealment 
After recruitment into the study the participants were randomly assigned to 
the two study groups: the experimental group was treated with cortisone 
injections via the lateral approach; and the control group received cortisone 
injections via the posterior route. The use of random allocation to assign 
participants to the treatment groups has numerous advantages. These 
include, for example, even distribution of random errors i.e. factors that 
obscure the results in a random or unpredictable way (Hicks 1999), even 
distribution of intrinsic prognostic factors among the groups and control of 
selection and evaluation bias (Bigby & Gadenne 1996). The success in 
splitting the major confounders and prognostic variables will be judged using 
baseline characteristics. Further measures of restricted randomisation such 
as blocking were considered. In block randomisation, participants are 
randomised into treatment groups that result in equal distribution of sample 
sizes (Suresh 2011). This approach is simple, easy to apply and ensures a 
balance in sample size across groups over time; and the block size is 
determined by the researcher and they are in multiple of the treatment groups 
(for example, with two treatment groups, block size could be 4, 6, 8, 12, 16, 
...30 etc) (Suresh 2011). In this study the researcher used a block size of 30 
generating equal numbers of participants in each group (lateral or posterior). 
 
The use of randomisation to allocate subjects to either group helps to 
minimise systematic differences between the groups that may potentially 
distort the results, balancing both known and unknown prognostic factors 
such as age, sex, race (Sibbald & Roland 1998). Alford (2007) suggests that 
random allocation of participants to groups is an important feature of RCTs 
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that helps to reduce allocation bias. However, it is not always practicable to 
investigate healthcare interventions using random allocation (McKee et al 
1999). Furthermore, simply by having a random allocation sequence the risk 
of selection bias is not completely removed (Sibbald & Roland 1998). If 
participants or clinicians are aware of the order of the allocation sequence, 
then they can allocate participants to one group or another by deciding 
whether to recruit them into the trial. However, this can be prevented by 
ensuring allocation concealment thus reducing selection bias (Sibbald & 
Roland 1998). 
 
An administrative staff member who was blinded to the hypothesis of the 
study carried out the randomisation process. This took place after the 
participant has agreed to participant in the study using sealed opaque 
envelopes thus achieving concealed random allocation. 
 
3.6.12 Blinding 
In traditional explanatory RCTs such has pharmaceutical trials, blinding of 
participants and therapists (double blinding) is an important aspect (Alford 
2007). It refers to concealment of the allocated treatment group after the 
participant has entered into the trial and it helps to reduce measurement bias 
(Verhagen et al 1998). Unlike explanatory trials, in pragmatic trials it is often 
impractical to blind participants to the nature of the treatment they are 
receiving or therapists to the treatment they are administering. However, it 
may be possible for the assessor to be blinded. Ethical considerations may 
prevent the inclusion of a “no treatment” group (Alford 2007). Comparison of 
different treatment approaches, such as standard treatment (posterior 
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approach) versus experimental treatment (lateral approach) is the preference 
(MacPherson 2004). In pragmatic trials the non-blinding of both patients and 
therapists to treatment approach can be accepted (Roland & Torgerson 1998) 
as this reflects what happens in normal clinical settings, where treatment 
effect may be influenced by the expectations of the patient and the therapist 
(Alford 2007). However, Herbert et al (2005) and Hotopf (2002) argued that to 
minimise the risk of selection or measurement bias by researchers, concealed 
randomisation and blinding of the assessor to outcome is imperative.  
 
In this current study, a pragmatic approach was adopted because it was well 
suited to situations where it was difficult or impossible to blind both 
participants and therapists (Helms 2002). The injecting clinicians were 
therefore blinded to participant allocation in order to minimise experimenter 
bias as defined by Hicks (1999), as expectations of outcome may influence 
what you perceive and how you behave and the assessor was blinded to the 
baseline measures. 
 
3.6.13 Randomisation and Blinding Process 
Randomisation was based on concealed random allocation using sealed 
opaque envelopes. Allocation concealment ensures that participants and 
clinicians cannot know or predict what the next patient’s treatment allocation 
will be (Viera & Bangdiwala 2007). After obtaining consent from the patient, 
the assessing and injecting ESPs immediately telephoned administrative staff 
who performed the randomisation process. Assignment was made by 
sequentially numbered, otherwise identical, sealed envelopes. Envelopes 
were opaque and lined inside with aluminium foil. Each envelope contained 
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an approximately 2-inch by 2-inch paper with a written code L or P 
designating intervention/experimental (lateral approach) or control/standard 
group (posterior approach) respectively. Following the opening of each 
envelope, the administrative staff assigned the patient to either the 
intervention or control group using the label L or P on the sealed envelope. 
Following the notification of the randomisation result by the administrative 
staff, the injecting ESP injected the patients using either lateral approach if 
the envelope was labelled L or posterior approach if it was labelled P. This 
process corresponded to the concealed random allocation design. Through 
such a process, every participant had an equal opportunity of being allocated 
in the intervention or control group. It ensured that there was no order or time 
effect thus minimising systematic bias. Although subacromial injections are 
routinely performed using a posterior approach they can also be given via a 
lateral route because the injecting clinicians have been trained in both 
methods. A detail of participant flow through the study is in figure 6. 
 
Patients in the study had their follow-up outcomes assessed by the Chief 
Investigator. The patient’s study number and their contact details were used 
by the Chief Investigator who was blinded to the baseline measurement to 
contact the patient during follow-up assessment at 8 and 12 weeks. The 8 
weeks’ timeframe is normal clinical practice and the further 4 weeks is to look 
for any additional differences. The 12 weeks’ follow-up period is consistent 
with previous authors (Akgun et al 2004, Kang et al 2008). 
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Figure 6: Flow chart showing movements of patient through the trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligible participants (n = 101) 
Excluded (n = 21) 
Not meeting inclusion criteria (n = 12) 
Do not give consent (n = 9) 
Lost to follow-up (n = 2) 
Failed to attend/withdraw after 
initial assessment (n = 0) 
Follow-up at 8 weeks (n = 40) 
Follow-up at 12 weeks (n = 39) 
 
Allocated to lateral approach (n = 41) 
Received allocated intervention 
(n = 41) 
Did not receive allocated intervention 
(n = 0) 
Followed-up at 8 weeks (n = 39) 
Followed-up at 12 weeks (n = 34) 
 
Allocated to posterior approach (n = 
39) 
Received allocated intervention 
(n = 39) 
Did not receive allocated intervention 
(n = 0) 
Lost to follow-up (n = 5) 
Failed to attend/withdraw after 
initial assessment (n = 0) 
Conceal 
allocation 
Quantitative 
analysis 
Follow-up at 8 
& 12 weeks 
Randomisation (n= 80) 
Analysed (n= 41)  
Completed baseline and follow-up 
appointments (n= 39) 
Analysed (n = 39)  
Completed baseline and follow-
up appointments (n = 34) 
 
Loss to 
follow-up 
Following completion of follow-up 
assessments, 10 patients will be 
selected by the researcher from the 
lateral intervention group for qualitative 
interview 
Following completion of follow-up 
assessments, 10 patients will be 
selected by the researcher from 
the posterior intervention group for 
qualitative interview 
Semi-structured interviews Semi-structured interviews Qualitative Analysis 
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The success of the randomisation process in splitting the major confounders 
such as previous clinical experience was judged by whether the baseline 
characteristics of the study groups were similar. Potential participants were 
partially blinded to the treatment allocation. Although they might know from 
experience whether they are receiving lateral or posterior subacromial 
injection, they did not know however, whether they were receiving the 
experimental or standard treatment. Therefore, they were partially blinded to 
the treatment they received. It is impossible for the injecting ESP to be 
blinded to treatment allocation with this design because they already know 
what the experimental and standard treatment is. However, they do not 
control which patient they inject because of the concealed random allocation 
of potential participants.  
 
3.6.14 The Study Groups 
The research has two-arms; the standard group received a cortisone injection 
through the posterior shoulder and the experimental group via the lateral 
approach. Both arms of the study injections had similar physiological drug 
(cortisone) properties therefore any difference in outcomes should be due to 
the injection approach. To reduce performance bias clinical factors such as 
the volume, dose and strength of steroid and local anaesthetic used during 
subacromial injections were standardised. Subacromial cortisone injections 
were carried out under the Patient Group Directions (PGDs) to ensure 
standardisation of the volume, dose and strength of steroid and local 
anesthetic used (Saunders & Longworth 2012). 
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3.6.15 Interventions 
Intervention (experimental) group: These received a single subacromial 
injection with a 21 gauge (1.5 – 2 inches) Green needle with 40 mg/ml of 
Kenalog (triamcinolonacetonide) and 4 ml of 1% Lidocaine through a lateral 
approach (Figure 5a shows the lateral approach). This is the experimental 
treatment. The procedure includes needle gauge and the injection volume, 
dose and strength of the steroid and local anaesthetic that are standardised 
using recommended values by the PGDs for subacromial injections 
(Saunders & Longworth 2012). This was delivered by a trained and qualified 
ESP during the patient’s outpatient musculoskeletal appointment.  
 
Control (standard) group: These received an identical treatment except for the 
location, which was by a posterior approach (Figure 7b shows the posterior 
approach). This is the routine treatment. 
Figure 7: Diagram to illustrate the difference between the posterior and 
lateral approach of subacromial injection. 
 
        
Figure 7a      Figure 7b 
7a External view of left shoulder showing the location of the lateral shoulder 
injection portal, 7b External view of left shoulder showing the location of the 
posterior shoulder injection portal (Reproduced with permission from 
Wickramasinghe et al 2012). 
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3.6.16 Treatment Procedure 
After obtaining consent from the participants, a routine clinical examination 
was carried out by the injecting ESP before the injection procedure. After a 
diagnosis of SAIS was confirmed and suitability assessment for the trial was 
achieved, the injecting ESP injected each patient by either a lateral or a 
posterior approach according to the label L or P on the sealed envelope. The 
label L or P on the sealed envelope represented the administration of their 
route of injection. The patient's study entry number and contact details were 
then used by the Chief Investigator to contact the patient at 8 and 12 weeks 
follow-up assessment.  
 
Standard after care and post-injection information were provided verbally and 
in the form of an information leaflet based on published recommendations 
(ACPOMIT 1999, Saunders & Longworth 2012). These included rest from 
strenuous activities such as heavy lifting for a period of 1 – 2 weeks and a 
gradual return to normal activities of daily living (Coombes et al 2009). 
Participants were informed of potential post injection side effects such as 
minor bleeding or bruising, post injection flare of pain and skin 
depigmentation/subcutaneous atrophy. They were advised to inform their GP 
in the event of any adverse reactions such as joint infection. All side effects 
were managed by normal clinical procedure by the service manager and the 
service clinical lead. Both groups received either a posterior or a lateral 
subacromial injection and were permitted to continue with their current pain 
medication regime such as paracetamol or ibuprofen. Other forms of 
conservative intervention characteristic in the management of SAIS including 
shoulder stretching and strengthening exercises were allowed. This is 
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reflective of “real life” practice where patients receiving physiotherapy for 
shoulder pain rarely receive a single treatment or intervention in isolation 
(Green et al 2003, Hanchard et al 2004).  
 
3.6.17 Baseline Comparability 
In a controlled trial, random allocation ensures that allocation of patients to 
treatments is left purely to chance (Altman 1985, Trowman et al 2007). It is 
the opinion of Burgess et al (2003) that well-balanced baseline data improves 
the quality of a trial by enhancing its internal and external validity. The authors 
also suggest that the success of randomisation can be measured with 
baseline characteristics of patients. This is because if randomisation is 
properly executed, groups will be similar in baseline characteristics (Burgess 
et al 2003). Where the baseline characteristics of patients that may influence 
outcome are well distributed between the intervention and the control groups, 
any difference in outcome can be assumed to be due to the intervention 
(Hicks 1999, Roberts & Torgerson 1999). In this study, the difference could 
be attributed to the lateral or posterior route of cortisone injection. However, 
imbalance between groups in baseline characteristics that may influence 
outcome (such as age or sex) can bias statistical tests, leading to what is 
sometimes referred to as chance bias (Roberts & Torgerson 1999). Although 
the practice of statistical testing of baseline variables to assess the effect of 
imbalance is common (Alman & Dore 1990), it has been challenged (Altman 
1985). Roberts & Torgerson (1999) argue that baseline tests of imbalance are 
unsuitable unless the researchers suspect that there are problems with the 
randomisation. In RCTs, in order to describe the population in the trial 
adequately, baseline data should include demographic variables such as 
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potential confounders (age, gender). These are known and unknown factors 
that are likely to influence the outcome (including medications being taken by 
participants), modify any benefit of treatment, and those that may predict 
adverse reactions (Burgess et al 2003). In this study, restricted randomisation 
such as blocking was used to help to reduce the chance of imbalance 
(Burgess et al 2003). 
 
3.6.18 Outcome Measures and Follow up 
3.6.18.1 Baseline Assessment 
Baseline characteristics include age, gender, duration of symptoms, dominant 
side affected, previous cortisone treatment, current treatment analgesia and 
current treatment NSAIDS. It also includes the initial SPADI and PROMs 
scores (Table 10 is the breakdown of baseline characteristics).  
Table 10: Baseline Characteristics table 
 
Lateral Group A 
No or mean or % 
Posterior Group B 
No or mean or % 
Age 
 
Gender 
 
Duration of symptoms 
 
Manual occupation 
 
Initial SPADI Score 
 
Initial PROMs Score 
 
Dominant side affected 
 
Previous cortisone treatment 
 
Current treatment analgesia 
Current treatment NSAIDS 
 
  
 
 
3.6.18.2 Primary Outcomes 
When assessing the outcome from shoulder interventions such as cortisone 
injection various measurement tools such as SPADI and NPS can be 
considered because previous shoulder studies have used them (Roy et al 
2009, Bennell et al 2010, Rhon et al 2014). Rhon et al (2014) in a pragmatic 
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RCT that involved 104 patients with shoulder impingement syndrome 
compared the effectiveness of corticosteroid injection with manual physical 
therapy using both SPADI and NPS scores as outcome measures. A physical 
therapy outcome measure is a test or scale administered and interpreted by 
physical therapists that has been shown to measure accurately a particular 
attribute of interest to the patients and therapists and is expected to be 
influence by intervention (Mayo 1994). The primary outcome measures in this 
study were the Shoulder Pain and Disability Index (SPADI) and Patient 
Reported Outcome Measures (PROMs) (Appendix 5 and 6). Both measures 
are routinely used for cortisone injections for patients with shoulder pain as 
baseline and outcome measures. The participants’ shoulder pain and function 
were evaluated using SPADI and PROMs (NPS and shoulder function) during 
their first musculoskeletal appointment. In the PROMs scale, NPS was used 
to measure daytime and night time pain at baseline and at follow-up. Prior to 
the injection therapy, these measures were administered and recorded as 
baseline measures by the injecting ESPs. The Chief Investigator at follow-up 
used them as outcome measures by using the patient’s study number that 
was allocated to them at baseline. 
 
3.6.18.3 Shoulder Pain and Disability Index  
The participants’ shoulder pain and function were evaluated with the shoulder 
pain and disability index (SPADI) score. SPADI is a self-report questionnaire 
designed to measure pain and disability specifically associated with shoulder 
pain of musculoskeletal origin (Roach et al 1991). Thirteen items, covering 
two domains (pain and disability) are scored on a numerical rating scale 
between zero (no pain/difficulty) and ten (worst pain imaginable/so difficult it 
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requires help). The pain dimension consists of five questions concerning the 
severity of a patient’s pain. Functional activities are measured with eight 
questions designed to assess the degree of difficulty a patient has with 
different activities of daily living (Roach et al 1991). Each domain carries 
equal weighting in the overall score that is expressed as a percentage where 
zero represents no pain or disability and 100% represents maximum pain and 
disability. A minimally important clinical difference for the SPADI is 8-13% 
(Roy et al 2009). In practice, it is easy to administer and requires minimal time 
for a patient to complete (Breckenridge & McAuley 2011) and Roy et al (2009) 
reports that it is not only very reliable, but a valid region-specific measure for 
the shoulder.  
 
3.6.18.4 Patient Reported Outcome Measures (PROMs) 
The PROMs contain a numeric pain scale (NPS) (Appendix 5) that was used 
to measure day time and night time pain and this is applicable in clinical 
practice. The NPS is a single 11-point numeric scale (with 0 as “no pain” and 
10 as the “worse imaginable pain”) used to measure pain intensity in adults 
(Hawker et al 2011). It allows patients to measure their level of pain 
accordingly using a whole number (0-10 integers) that corresponds to their 
pain intensity (Rodriguez 2001). The major advantages of the NPS over the 
visual analogue scale are that it can be administered verbally by telephone or 
by self-completion through the post (Jensen et al 1986). The scale is 
considered reliable (accurate and consistent), responsive (able to detect 
clinically significant changes) and valid (actually measures what it sets out to) 
(Hawker et al 2011). The NPS is relatively easy to understand and to apply, 
especially by patients with musculoskeletal disorders (Hawker et al 2011).  
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The PROMs contains a single 11-point NPS that measures day time and 
night time pain in the participants. Since night pain is commonly associated 
with SAIS (Zuckerman et al 1991), it is important to measure it. This is 
consistent with (Akgun et al 2004) who in a RCT that evaluated the effects of 
subacromial injections in SAIS patients used a similar pain scale to measure 
shoulder pain at day time and night time. The PROMs also measure how 
much of specific shoulder function such as lifting is affected using a 6-point 
percentage scale with 0% as full function and 100% as complete loss of 
function. This was considered adequate following expert statistician opinion 
and agreement with my supervisor. 
 
3.6.18.5 Outcome Assessment 
Participants were assessed three times during the study period, at 0 
(baseline), 8 and 12 weeks. This allowed inferences to be drawn about 
immediate and short-term effects. The 8 weeks’ timeframe is common in 
normal clinical practice and previous authors (Akgun et al 2004, Kang et al 
2008) have used the 12 weeks’ follow-up period. At 8 and 12 weeks, the 
outcomes of the injection were evaluated via a telephone call. The Chief 
Investigator (who was not involved in the patient’s initial assessment and 
therefore blinded to the baseline measurement) contacted participants during 
these periods using the participant’s study number and their contact details. 
The Chief Investigator left a voice message with a reminder for the patient to 
call back if they were not contactable. The response rate was facilitated 
through a reminder by post to patients using a self-addressed envelope that 
contained the outcome measures.  
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3.6.18.6 Loss to Follow-up 
This study lasted for 12 months therefore, at 4 months a review of the rate of 
loss to follow-up was undertaken to ensure that this does not affect the 
findings of the study. At 4 months, the rate of loss to follow-up was not much 
higher in one group compared with the other. Patients who were lost to follow-
up, data collected up to that point were included in the analysis based on 
intention to treat (ITT). 
 
3.6.19 Non-Response and Intention to Treat Analysis 
Intention to treat analysis (ITT) is widely accepted as the gold standard for 
evaluating the results of clinical trials particularly if the trial uses a pragmatic 
design. This is consistent with a systematic review by Armigo-Olivo et al 
(2009) that investigated compliance, drop-outs and loss of follow-up data and 
recommended the use of ITT analysis for evaluation of the results of 
pragmatic studies. This is because pragmatic studies (such as the one 
undertaken by this research) examine the effectiveness of a specific 
treatment in a real-life situation (clinical setting). ITT analysis takes into 
account all randomised patients in the groups to which they were randomly 
assigned, regardless of their adherence with the entry criteria, treatment they 
actually received, and subsequent withdrawal from treatment or deviation 
from the study protocol (Fisher et al 1990). Similarly, it means that once a 
participant is randomised to an arm of treatment, they should be analysed in 
the group to which they were allocated to after randomisation notwithstanding 
noncompliance, protocol deviations, and anything that happens after 
randomisation (Kruse et al 2002). ITT analysis therefore helps to prevent two 
major issues such as noncompliance and missing data that are associated 
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with RCT (Gupta 2011). In actual clinical practice where participants are likely 
to be non-compliant and deviate from study protocols, ITT analysis prevents 
over estimation of the efficacy of an intervention by including these in its 
analysis instead of removing them (Wertz 1995, Heritier et al 2003). This will 
further enhance prognostic balance generated from the original random 
treatment allocation giving rise to equitable estimate of treatment effect 
(Wertz 1995, Heritier et al 2003). Other benefits of ITT analysis include 
preservation of the sample size and statistical power, because if non-
respondents and drop outs are excluded from the final analysis, the sample 
size and consequently the statistical power might be significantly reduced 
(Wertz 1995, Heritier et al 2003). Fergusson et al (2002) argues that because 
ITT analysis is cautious in its approach and it enhances greater generalisation 
that it reduces a type 1 error, which is regarded as the probability of 
concluding that a difference between the treatment groups exists when, in 
fact, no difference exists i.e. false positives (Hicks 2009). In this situation, the 
null hypothesis would be falsely accepted. 
 
Although ITT is widely accepted by clinicians and healthcare researchers for 
analysing the results of clinical trials, it has some limitations. For example, 
opponents of ITT analysis (Sommer & Zeger 1991, Rubin 1998) have argued 
that it can be too cautious and thus prone to a type II error (which is the 
probability of concluding that no difference between the treatment groups 
exists when, in fact, a difference exists i.e. false negatives). ITT limitations 
also include difficulty in analysing the data if the number of losses to follow-up 
or non-compliance is significant. However, some practical solutions have 
been suggested for overcoming these challenges. According to Pocock 
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(1983) informing study participants about the study objectives, treatment 
protocol and follow-up schedules will improve their cooperation and thereby 
reduce non-compliance and minimise loss to follow-up. Maintaining a tight 
follow-up regime by contacting patients at the agreed date and time will 
reinforce compliance and avoid drop outs. In this study, to enhance 
compliance and improve follow-up rate, participants were contacted at an 
agreed date and a more convenient time by telephone. And those that could 
not be reached by this method had the follow-up measures sent to them by 
post with a self addressed envelope included for them to complete and then 
return to the researcher. The use of these approaches significantly minimised 
loss to follow-up, and only one participant dropped out of the study after 
randomisation at both 8 and 12 weeks follow-up despite being contacted by 
phone and being sent a self addressed envelope to their address. 
 
In practice a patient is generally allowed a maximum of 3 sessions of 
cortisone injection in a year (Haslock et al 1995, Saunders & Longworth 
2012). Therefore, in this study where a patient has had a failed injection, such 
a patient was allowed a repeat dose, but the treatment data was not included 
in the analysis. However, data collected up to this point was recorded as part 
of the study analysis using ITT analysis. Participants who withdrew from the 
study after being randomised were included in the analysis based on ITT.  
 
3.6.20 Plan of Analysis 
All analyses will be undertaken on an intention to treat basis. The results of 
both outcome measures will give a difference in scores from the baseline to 8 
and 12 weeks. Both the SPADI and PROMs measures are considered 
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continuous scales. Therefore, the data is likely to assume normality; that is 
the mean, median and mode will converge. It is likely they will have a 
unimodal, bell shape, which means skewness and kurtosis will approach 
zero, and 95% of the data will be accounted for within 2 standard deviations. 
Data was therefore analysed using an independent t-test (Field 2009). 
Normality was checked using the Sharipo-Wilk test since the sample size was 
110. Independent t-test gives a p value indicating whether there is a 
statistically significant difference between the two groups for outcome 
measures at the pre-specified timescales (Field 2009). Statistical significance 
was set at 5% to detect a minimal clinically important difference of 13 points 
between the groups receiving lateral or posterior approach to subacromial 
injection. Confidence intervals were set at 95% to give an indication of the 
direction of clinical significance. Descriptive statistics such as mean age, 
gender and manual occupation were used to describe patient’s baseline 
characteristics 
 
3.7 Phase 2 
3.8 Design: Qualitative Semi-structured Approach 
Traditionally qualitative research methods derive their approach from social 
science and they are usually conducted in a natural setting using data from 
interviews, fieldnotes, audiotapes or videos (Ritchie & Lewis 2003). The 
emphasis on qualitative research is on capturing detail and in-depth meaning 
that people provide about a ‘lived’ experience (the real-life situation) regarding 
a phenomenon. The ontological position of this study was based on the 
premise that SAIS patients who have received subacromial injection were 
perceived as being competent and capable of reflecting on their situation and 
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providing meaningful interpretations of their experiences. The study’s 
epistemological stance was on the premise that qualitative investigations 
assume that patients are active constructors of knowledge about an event or 
experience, therefore they have their own individual interpretation of it 
(Ritchie & Lewis 2003).  A qualitative research approach seeks to explore the 
meaning (ontological position) that patients construct (epistemological) about 
an individual reality of a phenomenon (cortisone injection) through their lived 
experience (Marshall & Rossman 1999, Denzin & Lincoln 2005, Creswell 
2007).  
 
A number of qualitative methods could have been used to explore the 
experiences of participants with SAIS receiving subacromial injections, such 
as focus groups, one-to-one in-depth interviews and semi-structured 
interviews. Each method has its own strengths and weaknesses. While in-
depth interviews and focus groups are suited to investigating perceptions and 
experiences of patients receiving an intervention, they require more time and 
resources compared to a semi-structured interview (Irvine et al 2012). Semi-
structured interviews allow individuals to speak freely (Mason 2002), 
unrestrained by the views of others, unlike a focus group where issues such 
as conflict, power struggles and status difference may become a militating 
factor (Hollander 2004, Rubin & Rubin 2005).  Unlike, the other methods, 
semi-structured interviews are based on a semi-structured interview guide, 
which is an organised presentation of questions or topics that relates to the 
subject matter of the interview (Dicicco-Bloom & Crabtree 2006). The choice 
to use a semi-structured interview was therefore based on consideration of 
the research objectives, the strengths of the semi-structured interview method 
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and the strengths and weakness of the previously mentioned techniques. 
Semi-structured interviews are widely accepted as the most common 
interview method in qualitative research (Horton et al 2004, DiCicco-Bloom & 
Crabtree 2006). A semi-structured interview approach is best suited to 
answer a research question that seeks to understand a lived experience and 
the sense patients make of it (Reid et al 2005). In this study, a semi-
structured interview method was used because it is suited to obtaining data 
by telephone and it fits with normal clinical practice and pragmatic RCT. This 
approach led to obtaining data that enhanced the understanding of 
experiences of participants about their symptom relief and patient care after a 
subacromial injection (Mason 2002, Coombes et al 2009).  
 
In normal practice, patients who have had shoulder injections are contacted 
by telephone at follow-up times to evaluate its outcomes. The qualitative 
telephone interviews took place after participants had participated in the 
quantitative study and they were linked to normal practice follow-up times. 
Here the focus is to gain an in-depth and interpreted understanding of 
individuals’ experiences concerning shoulder injection in a normal clinical 
setting. 
 
3.8.1 Sampling Method and Participant Selection 
In qualitative research, there is flexibility in the rules regarding the size of 
sample needed and sample size is generally small compared to quantitative 
research (Morse 2000, Mason 2002). However, a number of factors can affect 
the number of interviews needed to achieve saturation, which is the point 
where very little new evidence is obtained from each individual field unit or 
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when nothing new is being added (Morse 2000, Mason 2002). These include 
the purpose of the study, the research question, the nature and scope of the 
researcher, number of interviews per participant, sampling procedures, and 
practical constraints of time and cost (Morse 2000, Mason 2002). Purposive, 
convenience sampling as suggested by Patton (2002) was used to identify 
participants from those that have participated in phase 1 of the quantitative 
study and have agreed to being contacted for interview. This sampling 
strategy is flexible and hence a positive feature of qualitative study that allows 
research to develop as the data is collected and analysed simultaneously 
(Patton 2002, Tongco 2007). Twenty potential participants, ten each from the 
experimental and standard treatment group were recruited by the Chief 
Investigator. Participants with different gender, ages and socio-economic 
backgrounds including negative responders to subacromial injections were 
selected to offer a broad understanding of the topic being studied (Patton 
2002, Tongco 2007, Ritchie & Lewis 2003) and allowed maximum variation in 
the data that was collected (Mason 2002).  
 
3.8.2 Recruitment Process 
The recruitment process took place over a year between August 2014 and 
August 2015. The participants were identified from those who participated in 
the RCT study and who gave consent to be contacted to participate in the 
qualitative study. They were selected from the list of those who had complete 
pain relief and those who had residual symptoms after the cortisone injection. 
The Chief Investigator identified 10 participants from each group of the 
subacromial injection routes. They were contacted by telephone by the Chief 
Investigator to first check they were still willing to participate in an interview. If 
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they were, they were re-consented verbally and a date and time for the semi-
structured interview concerning their experiences of the subacromial 
injections was arranged. 
 
3.8.3 Data Collection Methods 
In normal practice, patients who have had injection therapy are sometimes 
contacted by telephone to evaluate its outcomes. A semi-structured interview 
was used as a method of gathering data. This took the form of open-ended 
questions. The interview date, time and convenience were mutually agreed by 
the researcher and the respondents prior to the interview. The researcher 
conducted interviews after participants took part in the quantitative research. 
All interviews were conducted by telephone conversation and were centred 
on symptom relief, aggravation and patient care following an experience of 
subacromial injection (Appendix 7 for the interview guide questions). 
Interviewees were allowed the opportunity to give detailed accounts of their 
experiences with individual interviews lasting approximately 20 - 30 minutes. 
Interviews were Dictaphone-recorded with the consent of the interviewee and 
field notes were taken by the Chief Investigator following the interviews to 
contextualise the data (Ritchie & Spencer 1994, Mason 2000, Ritchie & Lewis 
2013). All data were transcribed verbatim. 
 
3.8.4 Development of Interview Guide and the Process 
To facilitate the interview process, an interview guide was developed and the 
questions were centred about the research questions to ensure that important 
and relevant areas of the aims of the study were covered during the interview. 
The interview guide was used to remind the interviewer about important bits 
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of information to relay to the interviewee such as the purpose of the interview, 
what will happen to the information obtained, and any confidentiality 
concerns. The guide was used to assist with data generation and to allow for 
conversational style of discussion between the researcher and the 
interviewee.   
 
The topic of discussion (that is the experiences of patients that have received 
the subacromial injections) was introduced by the Chief Investigator to allow 
for clarification and further explanation. Interviews were guided using open-
ended questions to allow participants to talk interactively and freely with the 
interviewer (Mason 2002, Patton 2002, DiCicco-Bloom & Crabtree 2006).  
 
3.8.5 Plan of Analysis 
Data analysis took the form of the Framework Method reported by Ritchie and 
Lewis (2003). Data collected from qualitative methods is generally large and 
consists of unstructured accounts of people’s experiences or the meaning 
they give to a particular phenomenon. In order for the researcher to provide 
some consistency and structure to qualitative data (interview transcripts/field 
notes) and yet retain the original accounts and observations of the data, the 
Framework approach was used (Ritchie & Lewis 2003). The choice of the 
framework approach was because it allows the researchers’ interpretations of 
participants’ experiences to be explicit and therefore easily accessible for 
clinicians, health care policy makers and funding providers (Ritchie & Lewis 
2003). Furthermore, the framework method enables systematic and 
comprehensive coverage of the data set, and it allows flexibility of new ideas 
and refinements to occur at almost any stage of the qualitative analysis 
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(Ritchie & Lewis 2003). Although the approach involves a systematic and 
well-defined process of sifting, indexing and coding material according to 
main issues and themes, it has five stages that are interlinked (Ritchie & 
Spencer 1994, Ritchie & Lewis 2003). The key stages involved in framework 
are:  
 
3.8.5.1 Familiarisation 
This is an important foundational step in qualitative data analysis, upon which 
the other stages of the analysis build on (Ritchie & Lewis 2003). This process 
involves being up to date with the data and it entails listening to interview 
audio recordings, reading transcripts of interviews and studying field notes to 
gain an oversight of the richness, depth and diversity of the data (Ritchie & 
Spencer 1994, Ritchie & Lewis 2003). In my study, data (transcribed 
interviews) were initially analysed using a computer software package 
MAXQDA. The software enabled the researcher to manage, shape and make 
sense of unstructured information quickly and easily (Saillard 2011). During 
the familiarisation phase of this study, I not only listened to the audio 
recordings and read the interview transcripts, but also listed key issues, 
concepts and recurrent themes (such as pain relief, treatment efficacy and 
exercise prescription) that emerged as being important to the research 
participants. The captured data reflected the phenomena under investigation 
and the aims and objectives of the thesis as stated in Chapter 2. 
 
3.8.5.2 Identifying a Conceptual Framework or Indexing 
In this stage, the researcher come back to the reviewed material (notes taken 
during the familiarisation stage) and tries to identify the key issues and 
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emerging themes that enable the data to be further examined and then 
referenced (Ritchie & Spencer 1994). The key issues and the emerging 
themes expressed by the participants then form the basis of a thematic 
framework that is used to sift and sort the data (Ritchie & Spencer 1994). 
Although the researcher may have a set of priori issues, Ritchie & Lewis 
(2003) suggest that it is important at this stage of the analysis for key issues 
and emerging themes from the data to be described in language and 
meanings that reflect the participants’ expressions. The researcher allows 
themes to develop from the data collected (bottom-up approach) rather than 
trying to fit data under already formulated core themes (top-bottom approach) 
(Miles & Huberman 1994). In this study, this phase involved identifying 
relevant portions of the data that relate to a particular theme and then 
numbering them systematically. This applies to all the transcripts of interview 
(textual) data and Ritcher & Spencer (1994) suggest that the numbering 
systems for the indexing references are annotated in the margin beside the 
text. In this study, MAXQDA was used to facilitate the indexing of the textual 
data. 
 
3.8.5.3 Labelling or Tagging the Data by Themes and Subthemes 
This stage involves the construction of the initial conceptual framework or 
indexed data by applying the indexed data to the appropriate sentences or 
paragraphs in the interview transcripts (raw data). The process shows which 
theme or concept is being mentioned or referred to within a particular section 
of the interview transcript. In this study, the researcher ensured that pieces of 
data that were lifted from their context were still clearly linked to the 
respondent they came from (Ritchie & Spencer 1994, Ritchie & Lewis 2003).  
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3.8.5.4 Creating Thematic Charts 
This stage of the analytical data abstraction involves identifying common 
concepts or patterns across the participants’ interview transcripts and 
grouping them into categories and charts using the thematic charts (Ritchie & 
Lewis 2003). This involves the building up of specific pieces of the indexed 
data as a whole. Data are lifted from their original textual content and placed 
in charts that consist of headings and subheadings that are drawn from the 
thematic framework (see Table 21) or from a priori research question (Ritchie 
& Spencer 1994:186).  
 
3.8.5.5 Descriptive and Classification Analysis - Identifying Elements 
and Dimensions, Refining Categories, Classifying Data 
 
This stage of the analysis involved unpacking, refining and categorising the 
contents and nature of the key themes (Ritchie & Lewis 2003). It also involved 
identification of a particular theme, refining of categories and assigning 
groups of categories to ‘classes’ usually at a higher level of abstraction 
(Ritchie & Lewis 2003). 
 
3.8.5.6 Dimensions and Explanatory Accounts 
After investigating the descriptive list, identification of specific conceptual 
labels or a number of associated features took place. This stage leads to the 
creation of new or key dimensions and themes under certain typologies. At 
this stage the researcher is familiar with the objectives of qualitative analysis 
which are “defining ideas, creating and refining categories, finding 
associations, creating typologies, providing explanations and developing 
strategies” (Ritchie & Spencer 1994:186). Following the coding of data, 
definition of concepts, finding associations/patterns and providing 
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explanations to core themes were achieved based on the research questions 
stated in Chapter 2 (Ritchie & Spencer 1994).  
 
3.9 Ethical Considerations 
Ethical approval to conduct the study was obtained from the National 
Research Ethics Committee (Ref No: 14/LO/0406 - Appendix 11). Since the 
study involved NHS patients in a non-NHS setting, ethical approval was also 
sought from the non-NHS Research Consortium (14/LO/0849 - Appendix 12). 
 
My academic supervisor, a statistician, a steering group for the research 
project (Senior physiotherapists, ESPs and Administrative staff) and a Patient 
Participation Group (from a local GP practice) were involved in the 
development of the research proposal. The National Lead (a more senior 
clinician) of the Community Musculoskeletal Service also peer reviewed the 
research proposal. 
 
The three principles, described by Ford and Reutter (1990), namely 
autonomy, benefits of the research and potential risks of participation were 
adopted for this study. Also the current NHS Research Ethics Committee 
Guidelines (Integrated Research Application System [IRAS 2013]) were used. 
 
3.9.1 Inclusion / Exclusion Criteria 
The inclusion criteria for the study involved adults 18 years and above, who 
fulfilled the eligibility criteria for subacromial impingement syndrome, who 
gave consent and are eligible for shoulder injection. The exclusion criteria will 
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be contrary - vice versa. The criteria did not discriminate against any 
particular groups of individuals. 
 
3.9.2 Recruitment 
When the first musculoskeletal appointment was posted to the patient, a 
separate envelope containing a letter of invitation to take part in the study was 
also sent. The invitation pack contained a letter of invitation with a Patient 
Information Sheet and two consent forms (for the quantitative part and 
qualitative interview) (Appendix 3 and 4). The invitation pack was posted at 
least 48 hours before they were due to attend their first musculoskeletal 
appointment to allow participants to decide whether or not to take part in the 
study. Participants who were interested in taking part in the study but had 
further questions were encouraged to contact the researcher through a study 
mobile number or postal address. These contact details were provided in the 
patient information sheet. On arriving for their first musculoskeletal 
appointment, participants who provided written informed consent and fulfilled 
the eligibility criteria for the study after being screened by the assessing ESP 
were recruited into the study. 
 
3.9.3 Consent 
Participants were given the opportunity to determine if they want to participate 
in the study or not. The letter of invitation with a PIS and the consent forms 
(for the quantitative part and qualitative interview) were provided before the 
research to allow participants adequate time to reflect on their content, prior 
to giving consent. The PIS stated clearly the purpose and nature of the 
research along with any potential risks and benefits and that participation is 
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voluntary. In the PIS, it is clearly stated that participants were free to withdraw 
from the study at any time. When participants attended their first 
musculoskeletal appointment and if they agreed to participate in the study, 
consent was obtained by ESPs 1 & 2. They were informed through the PIS 
that they would be contacted by telephone by the Chief Investigator for the 
qualitative interview. This was to first check that they were still willing i.e. re-
consent them verbally and to arrange a date and time for the semi-structured 
interview.  
 
Participants had the capacity to give informed consent based on the Mental 
Capacity Act (2005). It was made clear at the consent interview that failure to 
provide consent or withdrawal of consent without giving a reason will not 
affect the treatment that they will receive. Participants were informed that 
should they withdraw from the trial prior to its completion; the data collected 
up to that point would be used in the analysis. The patient’s GP was informed 
via a letter of their patient’s participation in the study, after obtaining consent 
from the participant to do this (Appendix 13). 
 
Participants were asked to read the PIS before attending their first 
musculoskeletal appointment when they had the opportunity to ask questions 
if they wished to participate and they were then asked to sign the consent 
forms. Participants who were interested in taking part in the study but had 
further questions were encouraged to contact the Chief Investigator.  A 
variety of contact methods were provided on the patient information sheet 
including a study mobile number or postal address. The injecting ESP 
checked that the consent forms had been accurately completed by the 
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participants and were valid before accepting them to the study.  This 
information was later scanned into the patient’s medical records. 
 
3.9.4 Risks, Burdens and Benefits 
There are no additional risks involved besides those that could routinely 
possibly be related to the treatment, such as minor bleeding, pain and 
changes in skin colour. The ethics committees were informed that all side 
effects would be managed by normal clinical procedure by the service 
manager, the service clinical lead and the local clinical governance group.  
 
Participants were informed prior to the study, through the information sheet, 
that serious side effects are not commonly reported with subacromial 
injections, however, when they do occur, their effects are normally mild and 
temporary (Kumar & Newman 1999, Penning et al 2012). For example, only 2 
- 10 in every 100 patients having cortisone injection will experience post 
injection flare of pain; and only 1:17000 - 77000 patients will report joint 
sepsis (Kumar & Newman 1999).  Other rare side effects include skin 
depigmentation, erythema, bruising and tendon rupture. 
 
Participants were informed that their GP would be informed of their 
participation in the study and after obtaining consent from them to do so, the 
patient’s GP was informed via a letter of their patient’s participation in the 
study. If a participant is feeling distressed or uncomfortable during the trial, 
they were advised to consult their GP and were excluded from the study, but 
any data collected up to that point was included in the analysis.  
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Participants were informed that there are not any direct personal benefits to 
them taking part in this study. However, the information derived from the 
study would help clinicians to know which of the two shoulder injection 
methods (from either the side or the back) is better in treating patients with 
shoulder pain in the future. Participants were informed that they will be 
offered shoulder injection from either the side or back of their shoulder. 
 
3.9.5 Participants Rights, Safety and Well-being 
Participants were informed prior to the study, through the information sheet, 
that serious side effects are not commonly reported with subacromial 
injections, however, when they do occur, their effects are normally mild and 
temporary (Kumar & Newman 1999, Penning et al 2012). In this study, no 
major adverse event occurred, besides those that could routinely possibly be 
related to the treatment, such as minor bleeding, pain and changes in skin 
colour. 
 
3.9.6 Confidentiality 
Participants’ records were stored and handled in accordance with the Data 
Protection Act (1998) and all the information collected about participants as 
part of this study was handled in confidence. Only those involved in their care 
knew if they participated in the study. Anonymised aggregated findings from 
both aspects of the research were made available to my academic supervisor 
– but they did not contain any personal details that would identify participants, 
for example, name and home address. All participant details, as well as their 
comments, were kept secured and confidential in a locked cabinet (with 
controlled access) and on a password protected computer to which only the 
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researcher had access. Any information provided to the Chief Investigator 
was anonymised using pseudonyms and unique identifying numbers so that it 
was not possible to identify the patient. Dictaphone recordings of interviews 
were destroyed once they had been transcribed and transcripts were stored 
in a locked cabinet (with controlled access) and on a password protected 
computer. 
 
3.9.7 Conflict of Interest 
This area was considered and there was no conflict of interest. A summary of 
the research findings would be made available to any participants who 
requested one. 
 
3.10 Input of Service Users to the Research 
The involvement of patients and members of the public in research has been 
shown to lead to better research, clearer outcomes, and faster uptake of new 
evidence (National Institute for Health Research (2013). During the planning 
stage of this study, services users, administrative staff and ESPs were 
involved as part of the project steering group to look at ways to improve the 
study. Service users were identified through the local public participation 
group linked to the GP practice located at the service where the study took 
place. Engagement with service users was through their coordinator located 
at the GP practice. They were provided with copies of the patient information 
sheet, consent forms and a sample of the qualitative interview questions and 
were asked to make suggestions on ways to improve these documents, 
including their format and details. Following this, some changes were made to 
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the wording of these documents including re-phrasing of the interview 
questions. 
 
3.11 Chapter Summary 
This chapter has described the methodology used for this research including 
the research objectives and hypothesis, design of both the quantitative and 
qualitative aspects, methods of data collection and analysis. In chapter 4, the 
results of both the quantitative and qualitative study are presented. 
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CHAPTER 4 RESULTS 
 
4.1 Introduction 
This chapter will present the results of the quantitative analysis and the semi-
structured interviews. The quantitative aspect will present the sample size, 
normality testing, statistical tests, effect size, the flow of participants through 
the study, and results from the completed primary outcome measures namely 
the PROMs and SPADI. Depending on whether these outcomes were 
normally distributed or not, they were analysed using either a parametric test 
such as a t-test or a non parametric test such as a Mann Whitney test. The 
results include the between group baseline analysis, time change of between 
group differences and the graphs of their means, change over time of within 
and between group differences. Finally an explorative multiple regression test 
was used to evaluate the contribution of the participant's baseline data to the 
outcome measures.  
 
In section 1, the results of the quantitative analysis will be reported and 
section 2 will concentrate on the results of the qualitative semi-structured 
interviews. The qualitative phase will discuss the results of the semi-
structured interviews which were conducted with participants who participated 
in phase 1 of the quantitative study and agreed to be interviewed. This 
section will include the demographics of the participants and the interview 
themes. 
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4.2 Section 1: Quantitative Analysis 
4.2.1 Sample Size Calculation 
Sample size was estimated based on a previous shoulder pain study 
(Ekeberg et al 2009) that estimated the standard deviation (SD) of change in 
SPADI to be 20 points, the power level was set at 90% and statistical 
significance at 5% to detect a minimum clinically important difference (MCID) 
of 13 points. Using these figures a sample size of 100 was estimated. To 
account for a 10% rate of loss at follow-up 110 participants was needed for 
the study. However, only 80 participants were actually recruited into this study 
because of some difficulties such as shortage of staff with the service and 
English language barriers to ethnic minorities.  By recruiting 80 participants 
with the statistical significance set at 5% to detect a MCID at 13 points, with 
SD of 20 points, a power of 87% was achieved by this study. This shows that 
a sample of 80 participants, with only 1 lost to follow-up was adequately 
powered (87%) to show a statistically significant difference because a power 
of 80% - 90% is usually considered adequate (Murray 1991) and previous 
shoulder studies (Mclnerney et al 2003, Ekeberg et al 2009) have used a 
similar figure. 
 
4.2.2 Tests of Normality 
The variables PROMs and SPADI scores were continuous data, however not 
all of them were normally distributed. Normality was checked using measures 
of central tendency and dispersion (such as the mean, median, mode, and 
standard deviation [SD]), histograms, PP plots, and estimates of kurtosis and 
skewness. Normality was also checked using the Sharipo-Wilk test because 
the sample size was 80. Both measures of central tendency and dispersion of 
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the PROMs and SPADI scores were checked if they closely converged and 
their estimates of kurtosis and skewness approached zero and they had a low 
standard deviation. The PP plots of both measures were checked if they 
showed similar variance above and below the diagonal line suggesting that 
these data could be normally distributed or approaching normality. Also the 
histograms of these measures were examined if they did 'fit' into a bell shape 
curve. The results of the Shapiro Wilk test were examined and if the 
measures were not statistically significantly different from a normal 
distribution at 0.05, this could indicate that the variables were normally 
distributed. On balance of probability after using all the above assumptions of 
parametric tests, I concluded that the all the baseline variables were 
"reasonably normally” distributed as parametric statistics are reasonably 
robust to minor deviations from normality. The baseline mean duration of 
symptom variable was not normally distributed therefore it was tested using a 
Mann Whitney test. The PROMs and SPADI scores both at 8 and 12 weeks 
were not normally distributed and were analysed using Mann-Whitney tests. 
The change over time of the outcomes from week 0 to 8, week 0 to 12 and 
week 8 to 12 were normally distributed, therefore they were analysed using 
independent t-tests. See Appendices 14 – 17 for details of how normality was 
decided. Chi square (χ²) was used for dichotomous and nominal variables 
such as groups of age, gender, symptom duration, manual occupation, 
dominant side affected, previous cortisone treatment and current treatment.  
 
4.2.3 Statistical Tests 
Data were analysed according to the principle of intention to treat using last 
observation carried forward and the hypothesis test was two tailed with a level 
150 
   
 
of significance set at 5%. The reasonably normally distributed variables were 
all analysed using independent t-tests. The independent t-test gives a p value 
indicating whether there is a statistically significant difference between the 
two groups (lateral and posterior approaches) for outcome measures at the 
pre specified timescales (0, 8 and 12 weeks). A paired t-test for paired 
samples was used to check the within group difference for each of the groups 
(lateral and posterior) for change in scores. Conversely those variables that 
were not normally distributed such as symptom of duration at baseline, the 
PROMs and SPADI scores both at 8 and 12 weeks were analysed with Mann-
Whitney test for 2 independent samples (Field 2009). The Mann-Whitney test 
gives a p value indicating whether there is a statistically significant difference 
between the two groups (lateral and posterior approaches) for outcome 
measures at the pre specified timescales (0, 8 and 12 weeks) (Field 2009). 
 
4.2.4 Effect Size 
Effect size (symbol = r) tells us the strength of the mean difference between 
two groups (Coe 2002, Ken & Kristopher 2012) for example the mean 
difference of PROMs day time pain of the lateral and posterior groups. Effect 
size is important in estimating and reporting the effectiveness of an 
intervention against the control, hence it is a measure of clinical significance 
(Ken & Kristopher 2012. A statistic called Eta-squared (η2) is one means of 
calculating effect size (Hicks 2009).  Cohen (1992) defines eta squared value 
of 0.01 as indicating a small clinical effect, a value of 0.06 as a moderate 
clinical effect and a value of 0.14 as a large effect. This means that the 
strength is larger as it approaches the value 1. In this study, the eta squared 
for independent t test of the change over time of the within and between 
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groups difference of the lateral and posterior groups from week 0 to 8, week 0 
to 12 and week 8 to 12 are reported. Within groups, eta squared for paired t 
test compares the means of the same group on two occasions - between time 
1 and time 2 (Coe 2002). 
 
4.2.5 Study Participants – Flow through the Study 
Participants were recruited into this study between September 2014 and 
August 2015. Eighty participants who had a diagnosis of SAIS and fulfilled the 
study's eligibility criteria were recruited into this study, 41 (51.2%) to the 
lateral group and 39 (48.8%) to the posterior group (see Table 11). However, 
101 participants with shoulder pain were approached for the study, but 21 
were excluded. Among those excluded from the study, 10 did not have a 
diagnosis of SAIS, 2 did not fulfill the injection eligibility criteria and 9 refused 
to participate in the study. Therefore a total of 80 participants were recruited 
into the study. 
 
Table 11: Number of Patients Recruited into the Study 
Participants Lateral Group Posterior Group Totals 
Male 20 19 39 
Female 21 20 41 
Totals 41 39 80 
 
One participant was lost to follow up at 8 and 12 weeks because they could 
not be reached by phone and postal communication. Two participants were 
lost to follow up at 12 weeks because they could not be reached by phone 
and postal communication. However, the data were analysed based on 
intention to treat analysis using last observation carried forward. Two 
participants were referred to secondary care after 8 weeks’ follow-up 
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assessment because of failed injection and worsening of their symptoms. 
Three participants were further investigated with MRI scan and then referred 
to secondary care after 8 weeks’ follow-up assessment because the cortisone 
injection and other conservative treatments such as physiotherapy were 
unsuccessful. Figure 8 in the next shows the flow of participants through the 
study. 
 
Baseline demographics included age, gender, duration of symptoms, manual 
occupation, dominant side affected, previous cortisone treatment, current 
treatment. The main outcome measures were the PROMs and SPADI. Both 
measures were administered at baseline and at 8 and 12 weeks’ follow-ups. 
Participants recorded their responses on each item on the basis of current 
symptoms. Day time pain and night time pain were measured using the 
PROMs.  Table 12 shows the baseline characteristics of the study sample. 
From Table 12 (in page 154), the lateral and posterior groups at baseline 
were similar with respect to age, gender, duration of symptoms, manual 
occupation, dominant side affected, previous cortisone treatment and current 
drug treatment. Both groups were also similar for initial SPADI and PROMs at 
baseline. There was no statistically significant difference between the means 
of both groups at baseline which meant they were similar at baseline and the 
process of randomisation was robust. 
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Figure 8: Flow Diagram Showing Flow of the Patient through the Trial 
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Table 12: Baseline Characteristics according to Groups 
Values are numbers (percentages) unless stated otherwise 
Characteristic Lateral Group 
( n= 41) 
Posterior Group 
(n = 39) 
P value 
Mean (SD) Age (years) 54.6 (12.6) 56.2 (11.7) 0.578 
18 - 40a 6 (14.6) 5 (12.8) 0.743 
41 - 65a 24 (58.5) 26 (66.7)  
65+a 11 (26.8) 8 (20.5)  
Gender (a) 
Male 
Female 
 
20 (48.8) 
21 (51.2) 
 
19 (48.7) 
20 (51.3) 
 
0.996 
Mean (SD) Symptom duration (weeks) (b) 40.9 (61.6) 36.4 (40.2) 0.429  
0 - 12(a) 13 (31.8) 10 (25.7) 0.366 
13 - 26(a) 15 (36.5) 11 (28.2)  
26+(a) 13 (31.7) 18 (46.2)  
Manual occupation (a) 
Yes 
No 
 
16 (31.0) 
25 (69.0) 
 
18 (46.2) 
21 (53.8) 
 
0.519 
Dominant side affected(a) 
Yes 
No 
 
25 (69.0) 
16 (31.0) 
 
23 (59.0) 
16 (41.0) 
 
0.855 
Previous cortisone treatment(a) 
Yes 
No 
 
10 (24.4) 
31 (75.6) 
 
15 (38.5) 
24 (61.5) 
 
0.175 
Current treatment(a) 
Analgesia 
NSAIDs 
None 
 
25 (61.0) 
10 (24.4) 
  6 (14.6) 
 
27 (69.2) 
  8 (20.5) 
  4 (10.3) 
 
0.263 
Mean (SD) Initial PROMs Score 
Day time pain (SD) 
Night time pain (SD) 
Function affected (SD) 
 
  7.1 (2.1) 
  6.8 (2.4) 
  2.8 (1.1) 
 
  6.2 (2.0) 
  6.3 (2.5) 
  2.7 (1.1) 
 
0.059 
0.345 
0.732 
Mean (SD) Initial SPADI Score 81.6 (25.1) 80.3 (27.6) 0.829 
 
Keys: a = p values of Chi square χ2tests; b = p value of a Mann-Whitney test; where there is 
no symbol the number represents a p value of an independent t - test. 
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4.2.6 Between Group Differences at baseline, week 8 and week 12 
4.2.6.1 PROMs SCORES 
Day Time Pain  
Table 13 shows the results of an independent t-test that compared the mean 
change scores of day time pain between the lateral (n=41) and posterior 
groups (n=39).  
 
Table 13: Results of PROMs and SPADI Scores of Between Group 
Differences at Baseline, Week 8 and Week 12 
 
Lateral 
Group 
Posterior 
Group 
  
 Mean score Mean score Mean difference 
(95% CI) 
Mann-Whitney 
tests (p - 
value) 
PROMs: 
Day time pain 
    
Week 0 7.1 6.2  0.9 (-0.0 to 1.8) 0.059a 
Week 8 3.4 3.9 -0.5 (-1.8 to 0.8) 0.386 
Week 12 3.5 3.0  0.5 (-0.9 to 1.8) 0.590 
Night time pain 
    
Week 0 6.8 6.3  0.5 (-0.6 to 1.6) 0.319 
Week 8 3.8 4.3 -0.5 (-1.9 to 1.0) 0.470 
Week 12 4.1 3.8  0.3 (-1.3 to 2.0) 0.787 
Shoulder 
function 
    
Week 0 2.8 2.7  0.1 (-0.4 to 0.5) 0.643 
Week 8 1.6 1.7 -0.2 (-0.8 to 0.4) 0.497 
Week 12 1.8 1.3  0.6 (-0.1 to 1.2) 0.089 
SPADI 
    
Week 0 81.6 80.6  1.3(-10.5 to 13.0) 0.878 
Week 8 47.7 49.1 -1.4(-17.4 to 14.6) 0.862 
Week 12 50.1 41.1  8.9 (-9.0 to 26.9) 0.324 
 
Key: a = p value of independent t-test 
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There was no statistically significant difference between the groups at 
baseline (p = 0.059). Using a Mann-Whitney test there was no statistically 
significant difference between the groups at week 8 (p = 0.386) and week 12 
follow up (p = 0.590). However, both groups demonstrated improvement from 
baseline of 3.4 (at week 8) and 3.5 (at week 12) for the lateral group and 3.9 
(at week 8) and 3.0 (at week 12) for the posterior group. At 12 weeks the 
posterior group showed better improvement compared with the lateral group, 
however this was not statistically significant. See Figure 9 for a graphical 
display of the results. 
 
Figure 9: Line plot of PROMs day time pain mean scores of lateral and 
posterior group at different times 
 
 
Night Time Pain  
Table 13 shows the results of an independent-sample Mann-Whitney U test 
that compared the mean scores of night pain time between the lateral (n=41) 
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and posterior groups (n=39) at baseline, 8 and 12 weeks. There was no 
significant difference between the groups at baseline (p = 0.319), week 8 (p = 
0.470) and week 12 (p = 0.787). However, both groups demonstrated 
improvement from baseline of 3.8 (at week 8) and 4.1 (at week 12) for the 
lateral group and 4.3 (at week 8) and 3.8 (at week 12) for the posterior group. 
See Figure 10 for a graphical display of the results. 
 
Figure 10: Line plot of PROMs night time pain mean scores of lateral and 
posterior group at different times 
 
 
Shoulder function  
Table 13 shows the results of an independent-sample Mann-Whitney U test 
that compared the change scores of shoulder function between the lateral 
(n=41) and posterior groups (n=39) at baseline, 8 and 12 weeks.  There was 
no significant difference between the groups at baseline (p = 0.643), week 8 
(p = 0.497) and week 12 (p = 0.089), although both groups demonstrated 
improvement from baseline of 1.6 (at week 8) and 1.8 (at week 12) for the 
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lateral group and 1.7 (at week 8) and 1.3 (at week 12) for the posterior group. 
The posterior group improved better at 12 weeks compared to the lateral 
group, but it was not statistically significant. See Figure 11 for a graphical 
display of the results. 
 
Figure 11: Line plot of PROMs shoulder function mean scores of lateral 
and posterior group at different times 
 
 
4.2.6.2 SPADI SCORES 
Table 13 shows the results of an independent-sample Mann-Whitney U test 
that compared the SPADI change scores between the lateral (n=41) and 
posterior groups (n=39) at baseline, 8 and 12 weeks.  There was no 
significant difference between the groups at baseline (p = 0.878), week 8 (p = 
0.862) and week 12 (p = 0.324), although both groups demonstrated 
improvement from baseline of 47.7 (at week 8) and 50.2 (at week 12) for the 
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lateral group and 49.1 (at week 8) and 41.1 (at week 12) for the posterior 
group. See Figure 12 for a graphical display of the results. 
 
Figure 12: Line plot of SPADI mean scores of lateral and posterior group 
at different times 
 
 
4.2.7 Within Group Difference of Change over Time from week 0 to 8, 
week 0 to 12 and week 8 to 12 
 
4.2.7.1 PROMs SCORES 
Day Time Pain  
Table 14 presents the results of a paired t-test that compared the change 
over time of day time pain scores within the lateral (n=41) and posterior 
groups (n=39) between 0 to 8 weeks, 0 to 12 weeks and 8 to 12 weeks. 
Within the lateral group, there was a statistically significant difference in day 
time pain between week 0 to 8 (mean difference = 3.7, SD = 2.6, p = 0.000, 
eta squared = 0.675) and week 0 to 12 (mean difference = 3.6, SD = 3.2, p = 
0.000, eta squared = 0.567). The effect sizes of the differences in the means 
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between week 0 to 8 (mean difference = 3.7, 95% CI: 2.9 to 4.5) and week 0 
to 12 (mean difference = 3.6, 95% CI: 2.6 to 4.7) were large (eta squared = 
0.675 and 0.567) respectively.   
 
Within the posterior group, there was a statistically significant difference in 
day time pain between week 0 to 8 (mean difference = 2.3, SD = 2.6, p = 
0.000, eta squared = 0.441) and week 0 to 12 (mean difference = 3.0, SD = 
2.9, p = 0.000, eta squared = 0.535). The effect sizes of the differences in the 
means between week 0 to 8 (mean difference = 2.3, 95% CI: 1.5 to 3.2) and 
week 0 to 12 (mean difference = 3.0, 95% CI: 2.0 to 4.0) were large (eta 
squared = 0.441 and 0.535) respectively.  
 
There was no statistically significant difference within the lateral (mean 
difference = - 0.2, SD = 2.3, p = 0.626, eta squared = 0.006 and posterior 
groups (mean difference = 0.6, SD = 2.5, p = 0.135, eta squared = 0.441) 
between week 8 to 12. 
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Table 14: Results of PROMs and SPADI Within Group Change over Time between 0 - 8 weeks, 0 - 12 weeks and 8 - 12 
weeks using Paired t-test 
 
 
 Lateral Group (n = 41)  Posterior Group (n =39) 
Measure Mean 
change 
(SD) 
(95% CI) Eta 
squared 
p - value Mean 
change 
(SD) 
(95% CI) Eta squared p - value 
PROMs: 
Day time pain 
        
0 - 8 weeks 3.7(2.6) (2.9 to 4.5) 0.675 0.000 2.3 (2.6) (1.5 to 3.2) 0.441 0.000a 
0 - 12 weeks 3.6 (3.2) (2.6 to 4.7) 0.567 0.000 3.0 (2.9) (2.0 to 4.0) 0.535 0.000a 
8 - 12 weeks -0.1 (2.3) (-0.9 to 0.6) 0.006 0.626 0.9 (2.5) (-0.2 to 1.5) 0.063 0.135 
Night time pain 
        
0 - 8 weeks 3.1 (3.5) (2.0 to 4.2) 0.443 0.000 2.1 (3.1) (1.0 to 3.1) 0.306 0.000a 
0 - 12 weeks 2.7 (4.0) (1.5 to 4.0) 0.329 0.000 2.7 (3.7) (1.4 to 4.0) 0.350 0.000a 
8 - 12 weeks -0.4 (2.4) (-1.2 to 0.3) 0.031 0.267 0.2 (2.0) (-0.5 to 0.9) 0.009 0.561 
Shoulder function 
        
0 - 8 weeks  1.3 (1.3)  (0.9 to 1.7) 0.512 0.000 1.0 (1.3) (0.6 to 1.4) 0.367 0.000a 
0 - 12 weeks  1.0 (1.5)  (0.5 to 1.5) 0.321 0.000 1.4 (1.4) (0.9 to 1.9) 0.484 0.000a 
8 - 12 weeks -0.2 (0.1) (-0.6 to 0.1) 0.063 0.130 0.4 (0.8) (0.1 to 0.7) 0.160 0.016a 
SPADI 
        
0 - 8 weeks 34.0 (31.3) (24.0 to 44.0) 0.580 0.000 31.3 (30.8) (21.2 to 41.0) 0.506 0.000a 
0 - 12 weeks 30.6 (34.7) (19.3 to 41.2) 0.448 0.000 41.3 (35.4) (28.7 to 53.9) 0.583 0.000a 
8 - 12 weeks -3.8 (22.7) (-11.2 to 3.5) 0.025 0.299 6.3 (22.3) (-1.6 to 14.2) 0.074 0.115 
Key: a = p < 0.05
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Night Time Pain  
Table 14 presents the results of a paired t-test that compared the change 
over time of night time pain scores within the lateral (n=41) and posterior 
groups (n=39) between 0 to 8 weeks, 0 to 12 weeks and 8 to 12 weeks.  
 
Within the lateral group, there was a statistically significant difference in night 
time pain between week 0 to 8 (mean difference = 3.1, SD = 3.5, p = 0.000, 
eta squared = 0.443) and week 0 to 12 (mean difference = 2.7, SD = 4.0, p = 
0.000, eta squared = 0.329). The effect sizes of the differences in the means 
between week 0 to 8 (mean difference = 3.1, 95% CI: 2.0 to 4.2) and week 0 
to 12 (mean difference = 2.7, 95% CI: 1.5 to 4.0) were large (eta squared = 
0.443 and 0.329) respectively.  
 
Within the posterior group, there was a statistically significant difference in 
night time pain between week 0 to 8 (mean difference = 2.1, SD = 3.1, p = 
0.000, eta squared = 0.306) and week 0 to 12 (mean difference = 2.7, SD = 
3.7, p = 0.000, eta squared = 0.350). The effect sizes of the differences in the 
means between week 0 to 8 (mean difference = 2.1, 95% CI: 1.0 to 3.1) and 
week 0 to 12 (mean difference = 2.7, 95% CI: 1.4 to 4.0) were large (eta 
squared = 0.306 and 0.350) respectively.  
 
There was no statistically significant difference within the lateral (mean 
difference = - 0.4, SD = 2.4, p = 0.267, eta squared = 0.031 and posterior 
groups (mean difference = 0.2, SD = 2.0, p = 0.561, eta squared = 0.009) 
from week 8 to 12. 
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Shoulder function  
Table 14 presents the results of a paired t-test that compared the change 
over time of shoulder function scores within the lateral (n=41) and posterior 
groups (n=39) between 0 to 8 weeks, 0 to 12 weeks and 8 to 12 weeks.  
 
Within the lateral group, there was a statistically significant difference in 
shoulder function between week 0 to 8 (mean difference = 1.3, SD = 1.3, p = 
0.000, eta squared = 0.512) and week 0 to 12 (mean difference = 1.0, SD = 
1.5, p = 0.000, eta squared = 0.321). The effect sizes of the differences in the 
means between week 0 to 8 (mean difference = 1.3, 95% CI: 0.9 to 1.7) and 
week 0 to 12 (mean difference = 1.0, 95% CI: 0.5 to 1.5) were large (eta 
squared = 0.512 and 0.321) respectively. Between week 8 to 12, there was 
no statistically significant difference (mean difference = - 0.2, SD = 0.1, p = 
0.130, eta squared = 0.063. 
 
Within the posterior group, there was a statistically significant difference in 
shoulder function between week 0 to 8 (mean difference = 1.0, SD = 1.3, p = 
0.000, eta squared = 0.367) and week 0 to 12 (mean difference = 1.4, SD = 
1.4, p = 0.000, eta squared = 0.484). The effect sizes of the differences in the 
means between week 0 to 8 (mean difference = 1.0, 95% CI: 0.6 to 1.4) and 
week 0 to 12 (mean difference = 1.4, 95% CI: 0.9 to 1.9) were large (eta 
squared = 0.367 and 0.484) respectively. Between week 8 and 12, there was 
also a statistically significant difference in shoulder function (mean difference 
= 0.4, SD = 0.8, p = 0.016, eta squared = 0.160). The effect of the differences 
in the means (mean difference = 0.4, 95% CI: 0.1 to 0.7) was moderate (eta 
squared = 0.160). 
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4.2.7.2 SPADI SCORES 
Table 14 presents the results of a paired t-test that compared the change 
over time of SPADI scores within the lateral (n=41) and posterior groups 
(n=39) between 0 to 8 weeks, 0 to 12 weeks and 8 to 12 weeks.  
 
Within the lateral group, there was a statistically significant difference in the 
SPADI scores between week 0 to 8 (mean difference = 34.0, SD = 31.1, p = 
0.000, eta squared = 0.580) and week 0 to 12 (mean difference = 30.6, SD = 
34.7, p = 0.000, eta squared = 0.448). The effect sizes of the differences in 
the means between week 0 to 8 (mean difference = 34.0, 95% CI: 24.0 to 
44.0) and week 0 to 12 (mean difference = 30.6, 95% CI: 19.3 to 41.2) were 
large (eta squared = 0.580 and 0.448) respectively.  
 
Within the posterior group, there was a statistically significant difference in the 
SPADI score between week 0 to 8 (mean difference = 31.3, SD = 30.8, p = 
0.000, eta squared = 0.506) and week 0 to 12 (mean difference = 41.3, SD = 
35.4, p = 0.000, eta squared = 0.583). The effect sizes of the differences in 
the means between week 0 to 8 (mean difference = 31.3, 95% CI: 21.2 to 
41.0) and week 0 to 12 (mean difference = 41.3, 95% CI: 28.7 to 53.9) were 
large (eta squared = 0.506 and 0.583) respectively.  
 
There was no statistically significant difference within the lateral (mean 
difference = - 3.8, SD = 22.7, p = 0.299, eta squared = 0.025 and posterior 
groups (mean difference = 6.3, SD = 22.3, p = 0.115, eta squared = 0.074) 
between week 8 to 12. 
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4.2.8 Between Group Differences in Change over Time from week 0 to 
8, week 0 to 12 and week 8 to 12 using an Independent t-tests on 
Change Scores 
 
4.2.8.1 PROMs SCORES 
Day Time Pain  
Table 15 shows the results of an independent t-test that compared the mean 
change scores of day time pain between the lateral (n=41) and posterior 
groups (n=39) between week 0 to 8, week 0 to 12 and week 8 to 12. Since 
Levene's test was not significant (p > 0.05) the first row of the independent t-
test output was used. At baseline and 8 week follow up there was a 
statistically significant difference in day time pain score in favour of the lateral 
group, with the lateral group showing an improvement of (mean = 3.7) 
compared with the improvement in the posterior group of (mean = 2.3). The 
mean difference between the groups for the improvement in day time pain 
score was 1.4 points (95% CI 0.3 to 2.6, p = 0.018) with a medium effect size 
of 0.071. There was no statistically significant difference between the two 
groups from week 0 to 12 (p = 0.415) and week 8 to 12 (p = 0.141) (see Table 
15). 
 
Night Time Pain  
There was no statistically significant difference between the two groups 
between week 0 to 8 (p = 0.174), week 0 to 12 (p = 0.914) and week 8 to 12 
(p = 0.228) (Table 15). 
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Table 15: Results of PROMs and SPADI Between Group Differences in Change over Time between 0 - 8 weeks, 0 - 12 
weeks and 8 - 12 weeks using an Independent t-test on Change Scores 
 
Lateral Group Posterior Group 
   
Measure Mean change Mean change Mean Difference 
 
(95% CI) 
Eta squared  p - value 
PROMs: 
Day time pain 
     
0 - 8 weeks 3.7 2.3  1.4(0.3 to 2.6) 0.071 0.018a 
0 - 12 weeks 3.6 3.0  0.6(-0.8 to 2.0) 0.009 0.415 
8 - 12 weeks 0.2 0.6 -0.6(-1.9 to 0.3) 0.027 0.141 
Night time pain 
     
0 - 8 weeks  3.1  2.0  1.0(-0.5 to 2.5) 0.021 0.174 
0 - 12 weeks  2.7  2.7  0.1(-1.7 to 1.9) 0.000 0.941 
8 - 12 weeks -0.4  0.2 -0.6(-1.7 to 0.4) 0.020 0.228 
Shoulder function 
     
0 - 8 weeks  1.3  1.0  0.3(-0.3 to 0.9) 0.011 0.346 
0 - 12 weeks  1.0  1.4 -0.4(-1.1 to 0.3) 0.018 0.289 
8 - 12 weeks -0.2  0.4 -0.6(-1.1 to -0.2) 0.105 0.005 
SPADI 
     
0 - 8 weeks 34.0 31.3 2.7(-11.2 to 16.6) 0.002 0.696 
0 - 12 weeks 30.6 41.3 -10.7(-27.2 to 5.9) 0.023 0.202 
8 - 12 weeks -3.8  6.3 -10.1(-20.7 to 0.5) 0.049 0.061 
Key: a = p < 0.05
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Shoulder function between week 0 to 8, week 0 to 12 and week 8 to 12 
There was no statistically significant difference between the two groups in the 
shoulder function scores between week 0 to 8 (p = 0.346), week 0 to 12 (p = 
0.289), however from week 8 to 12 there a statistically significant difference in 
shoulder function in favour of the lateral group -6 (95% CI, -1.1 to -0.2, p = 
0.005). 
 
4.2.8.2 SPADI SCORES 
SPADI scores between week 0 to 8, week 0 to 12 and week 8 to 12 
There was no statistically significant difference between the two groups in the 
SPADI scores between week 0 to 8 (p = 0.696), week 0 to 12 (p = 0.202) and 
week 8 to 12 (p = 0.061) (Table 15). 
 
4.2.9 Exploratory Multiple Regression Analysis to Investigate the 
Contribution of the Independent Baseline Variables on the PROMs 
and SPADI Outcomes 
 
A one layer multiple regression was used to evaluate the contribution of 
participant's baseline characteristics such as age, gender, symptom duration, 
manual occupation, dominant side affected, previous cortisone injection and 
current treatment on the PROMs and SPADI scores between baseline to 8, 
week 0 to 12 and week 8 to 12. The model was inspected to ensure that the 
assumptions of normality, multicollinearity and homoscedasticity were not 
violated. The results of the multiple regression showed that the individual p 
values (> 0.05) were greater than 0.05, which means that each individual 
variable was not a significant predictor of the outcome measures. This implies 
that the participant's baseline variables were not a statistically significant 
contributor in predicting the outcomes. For example, see Tables 16 to 19. 
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Table 16: Coefficients for PROMs Day Time Pain Scores from Baseline 
Coefficients for PROMs Day Time Pain Scores  
 0 - 8 weeks 0 - 12 weeks 8 - 12 weeks 
 B  Beta P B Beta P B Beta P 
Constant 4.471   0.036  4.243  0.099 -0.461  0.816 
Patient's age in years  -0.013  -0.059  0.640  0.012 0.036 0.739  0.032  0.152 0.249 
Patient's gender  -0.216  -0.041  0.740 -0.622 0.765 0.419 -0.619 -0.130 0.304 
Duration of symptoms in weeks 0.005  -0.093  0.463 -0.005 0.008 0.509  0.001  0.025 0.850 
Manual occupation: No = 0; Yes = 1   0.039   0.007  0.955 -0.317  0.805 0.695 -0.300 -0.063 0.635 
Dominant side affected: No = 0; Yes = 1   0.380   0.070  0.580  0.307 0.815 0.707 0.018 0.004 0.978 
Previous cortisone injection: No = 0; Yes = 1   0.085   0.015  0.908 -0.329 0.860 0.704 -0.671 -0.132 0.321 
Current treatment analgesia = 1; NSAIDS = 2  -0.274  -0.111  0.365 -0.241 0.367 0.514  0.021  0.009 0.943 
R Square    0.032   0.036    0.047  
 
Keys: B - (Unstandardised Coefficients); Beta (Standardised Coefficients) 
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Table 17: Coefficients for PROMs Night Time Pain Scores from Baseline 
Coefficients for PROMs Night Time Pain Scores  
 0 - 8 weeks 0 - 12 weeks 8 - 12 weeks 
 B  Beta P B Beta P B Beta P 
Constant   1.827   0.476 0.098  0.975 -1.964  0.285 
Patient's age in years   0.019   0.069  0.581  0.005  0.162 0.209  0.049  0.242 0.060 
Patient's gender   0.368   0.056  0.643  0.181  0.024 0.847 -0.655 -0.146 0.238 
Duration of symptoms in weeks   0.000   0.005  0.967 -0.001 -0.008 0.950  0.003  0.065 0.617 
Manual occupation: No = 0; Yes = 1   0.847   0.127  0.311  1.326  0.174 0.183  0.566  0.126 0.331 
Dominant side affected: No = 0; Yes = 1  -0.274  -0.041  0.743 -0.651 -0.085 0.516 -0.432 -0.095 0.463 
Previous cortisone injection: No = 0; Yes = 1   0.618   0.087  0.489  0.883 -0.108 0.405 -0.266 -0.055 0.668 
Current treatment analgesia = 1; NSAIDS = 2  -0.764  -0.248  0.041 -0.647 -0.180 0.155 -0.005 -0.003 0.984 
R Square    0.074   0.081    0.098  
 
Keys: B - (Unstandardised Coefficients); Beta (Standardised Coefficients) 
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Table 18: Coefficients for PROMs Shoulder Function Scores from Baseline 
Coefficients for PROMs Shoulder Function Scores  
 0 - 8 weeks 0 - 12 weeks 8 - 12 weeks 
 B  Beta P B Beta P B Beta P 
Constant   2.306   0.017 0.887  0.470 -1.393  0.081 
Patient's age in years -0.001  -0.006  0.960  0.018  0.134 0.302  0.018  0.211 0.103 
Patient's gender -0.313  -0.122  0.287 -0.246 -0.065 0.501  0.080  0.043 0.732 
Duration of symptoms in weeks -0.003  -0.119  0.315  0.001  0.046 0.728  0.005  0.263 0.047 
Manual occupation: No = 0; Yes = 1  -0.026   0.049  0.682  0.391  0.134 0.321  0.356  0.188 0.162 
Dominant side affected: No = 0; Yes = 1   0.062   0.024  0.841  0.063  0.021 0.873 -0.028 -0.014 0.913 
Previous cortisone injection: No = 0; Yes = 1   0.272   0.099  0.411  0.257  0.083 0.525 -0.155 -0.077 0.550 
Current treatment analgesia = 1; NSAIDS = 2  -0.428  -0.359  0.002 -0.416 -0.310 0.514  0.015  0.017 0.895 
R Square    0.156   0.117    0.139  
 
Keys: B - (Unstandardised Coefficients); Beta (Standardised Coefficients) 
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Table 19: Coefficients for SPADI Scores from Baseline 
Coefficients for SPADI Scores  
 0 - 8 weeks 0 - 12 weeks 8 - 12 weeks 
 B  Beta  P B Beta P B Beta P 
Constant 46.197   0.050 25.962  0.380 -22.436  0.209 
Patient's age in years  0.040  0.015  0.899  0.300  0.096 0.467  0.337  0.165 0.178 
Patient's gender  -3.019  -0.049  0.675 -5.119 -0.073 0.568 -4.103 -0.090 0.448 
Duration of symptoms in weeks -0.063  -0.106  0.383  0.003  0.005 0.972  0.094 -0.222 0.077 
Manual occupation: No = 0; Yes = 1 -1.644  -0.027  0.828 5.524  0.079 0.588 9.016  0.197 0.115 
Dominant side affected: No = 0; Yes = 1 -2.021 -0.032  0.790 2.757  0.039 0.771  4.950  0.107 0.387 
Previous cortisone injection: No = 0; Yes = 1 15.416   0.234  0.060 8.583  0.113 0.398 -11.520 -0.233 0.062 
Current treatment analgesia = 1; NSAIDS = 2  -6.964  -0.244  0.040 -4.219 -0.127 0.328  1.730  0.080 0.505 
R Square    0.025   0.046    0.183  
 
Keys: B - (Unstandardised Coefficients); Beta (Standardised Coefficients) 
 
 
 
 
 
 
 
172 
   
 
 
4.2.10 Summary of Quantitative Results 
At baseline, the lateral and posterior groups were similar with respect to the 
baseline demographics and outcome measures. 
 
The results of an independent t-test showed that there was no statistically 
significant difference between the group's day time pain mean change scores 
at baseline (p = 0.059). Similarly, a Mann-Whitney test found no statistically 
significant difference between the groups at week 8 (p = 0.386) and week 12 
follow up (p = 0.590).  
 
The results of an independent Mann-Whitney test showed that there was no 
significant difference between the group's night time pain mean change 
scores at baseline (p = 0.319), week 8 (p = 0.470) and week 12 (p = 0.787). 
Similarly, there was no significant difference between the groups for shoulder 
function mean change scores at baseline (p = 0.643), week 8 (p = 0.497) and 
week 12 (p = 0.089). Also, no significant difference was demonstrated 
between the groups for the SPADI mean change scores at baseline (p = 
0.878), week 8 (p = 0.862) and week 12 (p = 0.324). 
 
Within both groups, a paired t test found that there was a statistically and 
clinically significant difference in day time pain between week 0 to 8 and week 
8 to 12. Within the lateral group, the improvement was 3.7 points (p = 0.000, 
eta squared = 0.675) between week 0 to 8 and 3.6 points (p = 0.000, eta 
squared = 0.567) between week 0 to 12.  Within the posterior group, it was 
2.3 points (p = 0.000, eta squared = 0.441) between week 0 to 8 and 3.0 
points (p = 0.000, eta squared = 0.535) between week 0 to 12. However, 
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within both groups (lateral group p = 0.626; posterior group p = 0.135) no 
statistically significant difference was demonstrated between week 8 to 12. 
 
Within both groups, a paired t test found that there was a statistically and 
clinically significant difference in night time pain between week 0 to 8 and 
week 8 to 12. Within the lateral group, the improvement was 3.1 points (p = 
0.000, eta squared = 0.443) between week 0 to 8 and 2.7 points (p = 0.000, 
eta squared = 0.329) between week 0 to 12. Within the posterior group, it was 
2.1 points (p = 0.000, eta squared = 0.306) between week 0 to 8 and 2.7 
points (p = 0.000, eta squared = 0.350) between week 0 to 12. However, 
within both groups (lateral group p = 0.267; posterior group p = 0.561) no 
statistically significant difference was found between week 8 to 12. 
 
Within both groups, a paired t test found that there was a statistically and 
clinically significant difference in shoulder function between week 0 to 8 and 
week 8 to 12. Within the lateral group, the improvement was 1.3 points (p = 
0.000, eta squared = 0.512) between week 0 to 8 and 1.0 points (p = 0.000; 
eta squared = 0.321) between week 0 to 12. Within the posterior group, it was 
1.0 points (p = 0.000, eta squared = 0.367) between week 0 to 8 and 1.4 
points (p = 0.000, eta squared = 0.484) between week 0 to 12. However, 
within both groups (lateral group p = 0.267; posterior group p = 0.561) no 
statistically significant difference was found between week 8 to 12. Within the 
lateral group, between week 8 to 12, there was no statistically significant 
difference reported (mean difference = - 0.2, p = 0.130, eta squared = 0.063). 
Whereas, within the posterior there was (mean difference = 0.4; p = 0.016, 
eta squared = 0.160). 
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Within both groups, a paired t test found that there was a statistically and 
clinically significant difference in the SPADI scores between week 0 to 8 and 
week 8 to 12. Within the lateral group, the improvement was 34.0 points (p = 
0.000, eta squared = 0.580) between week 0 to 8 and 34.7 points (p = 0.000, 
eta squared = 0.448) between week 0 to 12. Within the posterior group, it was 
31.3 points (p = 0.000, eta squared = 0.506) between week 0 to 8 and 35.4 
points (p = 0.000, eta squared = 0.583) between week 0 to 12. However, 
within both groups (lateral group p = 0.299; posterior group p = 0.115) no 
statistically significant difference was found between week 8 to 12. 
 
The results of an independent t-test between the lateral and posterior groups 
demonstrated a statistically and a moderate clinically significant difference in 
day time pain (mean change score) in favour of the lateral group (mean = 3.7) 
compared with the posterior group of (mean = 2.3) between week 0 to 8 (1.4 
points [95% CI 0.3 to 2.6, p = 0.018]). However, there was no statistically 
significant difference between the two groups from week 0 to 12 (p = 0.415) 
and week 8 to 12 (p = 0.141). 
 
Using an independent t-test, there was no statistically significant difference in 
night time pain between the groups between week 0 to 8 (p = 0.174), week 0 
to 12 (p = 0.914) and week 8 to 12 (p = 0.228). Also, no statistically significant 
difference was found in shoulder function scores between the two groups 
between week 0 to 8 (p = 0.346), week 0 to 12 (p = 0.289). However, 
between week 8 to 12 there was a statistically significant difference in favour 
of the lateral group -0.6 (95% CI, -1.1 to -0.2, p = 0.005). There was no 
statistically significant difference between the groups in the SPADI scores 
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between week 0 to 8 (p = 0.696), week 0 to 12 (p = 0.202) and week 8 to 12 
(p = 0.061). 
 
The results of a one layer multiple regression that was used to evaluate the 
contribution of participants' baseline characteristics on the PROMs and 
SPADI scores between baseline to 8, week 0 to 12 and week 8 to 12 found 
that the participant's baseline variables were not a statistically significant 
contributor in predicting the outcomes. 
 
4.3 Section 2: Qualitative Analysis 
4.3.1 Introduction 
This section will present the results of the semi-structured interviews which 
were conducted with participants who have participated in phase1 of the 
quantitative study and agreed be interviewed. From the interviews conducted, 
five major themes associated with experiencing subacromial injection by the 
participants with SAIS were identified from the analysis. They included 
expectation of treatment, treatment outcome, procedure, patient education 
and access to treatment. 
 
4.3.2 Sample Demographic 
Data collection occurred between March 2015 and June 2015. Eighty 
participants completed phase 1 of the quantitative study. A purposive sample 
of 20 was chosen from the above sample, to participate in a semi-structured 
interview. They included 9 males and 11 females aged between 18 to 65 
years and above (n = 20). Twelve had a lateral approach and 8 had a 
posterior approach of subacromial injection. Ten were those with complete 
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pain relief and ten were those that improved, but still had residual pain to the 
injection outcomes or no improvement (See Table 20). 
 
Table 20: Description of Interview Participants 
Characteristic Number 
  Injection Location 
Lateral 
Posterior 
 
11 
9 
Gender 
Male 
Female 
 
10 
10 
Age (years) 
18 - 40 
41 - 65 
Above 65 
 
3 
14 
3 
Responders 
Complete pain resolution 
Improved, but with residual pain/No 
improvement 
 
10 
10 
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                           Table 21: Characteristics of the Participants 
Participant ID Participant Gender Age in years Group Duration of symptoms (weeks) Responders 
002L Male 43 Lateral 12 Improved, but with residual pain 
007L Female 64 Lateral 36 No improvement 
0014P Male 47 Posterior 52 Complete pain resolution 
0025P Female 31 Posterior 12 Complete pain resolution 
0027L Female 58 Lateral 52 Complete pain resolution 
0028L Female 71 Lateral 208 Improved, but with residual pain 
0029L Male 70 Lateral 12 Improved, but with residual pain 
0031P Female 54 Posterior 26 Complete pain resolution 
0032L Male 55 Lateral 26 No improvement 
0034P Female 55 Posterior 20 Complete pain resolution 
0035P Female 49 Posterior 208 Improved, but with residual pain 
0038P Male 54 Posterior 16 No improvement 
0039L Female 67 Lateral 26 Complete pain resolution 
0045L Male 55 Lateral 20 Improved, but with residual pain 
0047L Female 64 Lateral 16 Complete pain resolution 
0049P Male 38 Posterior 20 Complete pain resolution 
0052P Male 43 Posterior 54 Improved, but with residual pain 
0055L Female 51 Posterior 13 No improvement 
0056P Male 51 Posterior 5 Complete pain resolution 
0058L Male 36 Lateral 78 Complete pain resolution 
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4.3.3 Data Analysis 
The 20 interviews were tape recorded and transcribed verbatim. Using 
MAXQDA as the data management tool the 20-textual data or transcripts 
were organised and categorised using general comments from the interview. 
This study adopted the hierarchical framework analysis (bottom-up approach) 
by Ritchie & Lewis (2003) to guide the data analysis. This is to ensure that the 
data analysis was strategic, systematic and robust. Ritchie & Lewis (2003) 
described some strategic steps based on the framework analytical model, 
these were adopted by this study and are shown in Figure 13. 
Figure 13: An illustration of the iterative and hierarchical process of 
qualitative data analysis adopted for this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data Management (20 transcripts) 
Transcribed interview 
Read transcripts and annotate common concepts 
Identify initial descriptive accounts  
Identify and create templates for preliminary categories  
Indexing or coding data 
Into general themes and subthemes 
Cross-labelling or tagging 
Indexing of all 20 transcripts to create them and subthemes from raw data 
Higher level descriptive accounts 
Summarising and creating thematic charts from refined categories, indexing and 
crossing labelling 
Explanatory accounts 
Detecting pattern of association in the thematic charts based on the main themes or 
phenomena 
Report findings and seek application to wider clinical situations 
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4.3.4 Hierarchical Framework Analysis Approach (Ritchie & Lewis 
2003) 
 
The concept of the framework not only enabled me to gain an overview and 
make sense of the data, but to also manage, synthesise and interpret the 
data in a structured and systematic manner using descriptive and illustrative 
accounts. Figure 14 shows a diagrammatic representation of the hierarchical 
framework analysis model proposed by Ritchie & Lewis (2003), used to guide 
the analysis in this study. 
Figure 14: A diagrammatic representation of the hierarchical framework 
analysis model used to guide the data analysis  
The hierarchical framework analysis model 
 
Seeking applications to 
wider theory/policy 
strategies 
EXPLANTORY 
ACCOUNTS 
 
Iterative process 
throughout analysis 
Developing explanation 
(answering 'how' and 'why' 
questions) 
Assigning data to refined 
concepts to portray 
meaning 
Detecting patterns 
(associative analysis and 
identification of clustering) 
 
 
Establishing typologies 
 
Refining and distilling more 
abstract concepts 
Identifying elements and 
dimensions, refining 
categories and classifying 
data DESCRIPTIVE 
ACCOUNTS 
 
 
Summarising or 
synthesising data 
Assigning data to 
themes/concepts to portray 
meaning 
Sorting data by theme or 
concept (in cross-sectional 
analysis) 
 
 
Labelling or tagging data 
by concept or theme 
 
DATA 
MANAGEMENT 
 
 
Assigning meaning 
 
Identifying initial themes or 
concepts 
Generating categories, 
themes and concepts 
 
 
RAW DATA 
 
 
 
(Adapted from Ritchie and Lewis 2003: 212) 
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The framework model also allows for a systematic formulation of preliminary 
identification of emerging ideas, concepts and patterns with the focus on the 
content of the interview transcripts (Ritchie & Lewis 2003). Data accuracy was 
enhanced by returning the transcribed text to participants for re-validation.  
 
4.3.5 Familiarisation Stage (Identifying Initial Themes and Concepts) 
From Figures 13 and 14, this process of the data management was enhanced 
by the data management tool – MAXQDA and led to data extraction of some 
descriptive accounts and common concepts that participants used in the data 
set. According to Ritchie & Lewis (2003) this is the first and essential point to 
qualitative data analysis stage. During the familiarisation stage of this study, 
the researcher listened to the audio recording of the interviews, read through 
the interview transcripts and observation notes and then made notes 
(memos) of important issues and recurrent themes (such as improvements) 
that were mentioned by the research participants. The researcher ensured 
that initial codes that were identified reflected similarities or differences in 
participants’ views about specific issues related to both the aims and 
objectives of the research as well as the research question. From the 
interviews, the descriptive phrases were then categorised using broader 
terms to describe the emerging patterns. The categories of phrases were then 
reviewed so that those with similar themes were grouped together. Examples 
of initial descriptive items used by the participants to express their 
experiences of receiving subacromial injections are shown in Appendix 8. 
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4.3.6 Identifying Conceptual Framework or Indexing  
This stage involved indexing of the phrases and identifying links between 
categories, grouping them thematically and then sorting them according to 
different levels of main and subthemes. This process was informed by the 
methods shown in Figures 13 and 14. The key issues and emerging themes 
that were expressed by the participants formed the basis of the thematic 
framework, which was then utilised to filter and classify the data (Ritchie & 
Spencer 1994, Ritchie & Lewis 2003). The researcher ensured that the key 
themes and emerging themes from the data mirrored the participant's 
language and concepts, as well as the research objectives (Braun & Clarke 
2006). In this study, the overall index contained 68 subthemes or categories 
that were grouped under just 10 main substantive themes or headings.  The 
key themes and subthemes were then systematically numbered with the help 
of MAXQDA to produce an indexing reference (see Figure 15). 
 
Figure 15: Indexing - major themes and subthemes identified during the 
interview  
1. Expectation of treatment 
1.1 Pain relief 
1.2 Better shoulder movement 
1.3 A complete cure or pain relief 
1.4 Expectation not met 
1.5 Self-healing – natural resolution 
1.6 Not sure what treatment they were going to receive 
1.7 Other issues – physiotherapy or cortisone injection 
 
2. Information and advice from the clinicians 
2.1 Explanation of every aspect of the treatment and care 
2.2 Not knowing what was going in the shoulder  
2.3 Explaining what was going on the shoulder and what to do about it 
2.4 Been listened to and involved in the treatment 
2.5 Exercise information 
2.6 General treatment information 
2.7 Explanation of treatment procedure 
2.8 Other issues 
 
3. Participants perception of the injecting ESP and the injection procedure 
3.1 Politeness and how knowledgeable the clinician was 
3.2 Caring and helpful attitude of the clinician 
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3.3 Treated as an individual 
3.4 Injection technique 
3.5 Professionalism of the injecting clinician 
3.6 Other issues 
 
4. Description of pain and associated factors 
4.1 Duration of pain – 2 weeks, 18-24 months 
4.2 Onset of pain – gradual 
4.3 Nature of pain – constant 
4.4 Pattern of pain – 24 months 
4.5 Complete resolution of pain or residual or on-going symptoms 
4.6 Location of the pain  
4.7 Inflammation of the shoulder 
4.8 Stiffness of the shoulder 
4.9 Pain on movement of the shoulder at work and during sports 
4.10 Sleep disturbance due to night time pain 
4.11 Other issues - frustration 
 
5. Understanding of where pain is coming from 
5.1 Not sure where the problem is coming from 
5.2 Not knowing what was going in the shoulder  
5.3 Query diagnosis -? impingement or tendonitis or full tear 
5.4 Researching where the pain is coming from 
5.5 Self-diagnosis – frozen shoulder 
5.6 Other issues – related to elbow 
 
6. Access to treatment 
6.1 Easy parking 
6.2 Near distance and within walking distance 
6.3 Referral system 
6.4 Quick appointment and seen sooner 
6.5 Location and environment 
6.6 The ease and convenience 
6.7 Phone call received about appointment 
6.8 Other issues – seeking partner’s opinion on what to do 
 
7. Outcome perceived after receiving treatment 
7.1 Improvement – gradual or immediate 
7.2 Better because of the cortisone effect 
7.3 Effect on movement – better or same 
7.4 Better within few weeks or months 
7.5 Not been treated as just another candidate 
7.6 The injection helped after 2 weeks 
7.7 The way the injection was performed 
7.8 Satisfaction/Efficient treatment/Service recommendation 
7.9 Referred to another specialism 
7.10 Other issues – it did not hurt, I did not feel pain 
 
8. Going to the doctor – seeking help from the GP 
8.1 GP took about 3-4 weeks to do the referral 
8.2 Got appointment 2 weeks after GP referred 
8.3 GP’s expectation – patient to have cortisone, or surgery or a scan 
8.4 GP’s diagnosis – agreement / disagreement 
 
9. Physiotherapy/cortisone referral suggested 
9.1 GP initiated physiotherapy 
9.2 Family and friend suggested physiotherapy 
9.3 Other issues – injection suggested by some friends including GP 
 
10. Service delivery  
10.1 Prompt and friendly service 
10.2 Good customer service 
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10.3 Not kept waiting for an appointment or before been treated 
 
 
4.3.7 Labelling or Tagging the Data by Themes and Subthemes 
After constructing the initial conceptual framework or indexed data, this stage 
involved applying the indexed data in Figure 15 to the appropriate sentences 
or paragraphs in the interview transcripts (raw data). The process shows 
which theme or concept is being mentioned or referred to within a particular 
section of the interview transcript. Figure 16 is an example of labelling or 
tagging of the indexed themes and subthemes. In this example, the text is a 
small excerpt of the participant’s transcript (0014P) that was cross-labelled 
and indexed. 
 
Figure 16: An Example of Labelling or Tagging of the Indexed Themes 
and Subthemes of part of an Interview Transcript of a Participant 
The text that follows is small excerpt of an interview with participant 0014P 
Interviewer: Has there been any improvement since having the 
injection? 
 
Participant – 0014P 
“There was improvement, it was a turning point, until then I was at 
the peak of the pain, the pain not going any further. 
 
The pain started gradually, and pain in the shoulder sort of 
gradually improved. I had constant pain initially and did not know 
where I was heading for and when I had the injection it brought 
down the pain level to 7/10 but it did not go up any further since 
then but is sort of came down gradually. At the same time, I had 
the psychology that this was going to heal itself with time. Until 
then I was not getting anywhere and the pain was going up week 
by week. Myself been a Nurse I was researching about the 
condition quite a lot and I knew that the pattern of pain was about 
24 months. However, no matter what you know about it, not been 
able to sleep at night because of constant pain can be annoying. It 
was quite a relief that the pain has decreased. I will recommend 
this to anyone, while it is does not give instant cure it brings down 
the pain gradually. The time factor of 18-24 months important, you 
never know whether it will take the whole time”. 
Index 
 
 
 
7.1 
 
 
4.2 
4.3/2.2 
 
7.1 
1.5 
 
5.4 
 
4.4 
4.10/4.11 
 
7.8 
4.2 
4.4 
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In the above example, participant 0014P reported that since receiving the 
cortisone injection there has been an improvement (index 7.1). He talked 
about how the onset of his shoulder pain has been gradual (index 4.2), and 
that the pain was constant at the beginning (index 4.3), but he did not know 
the cause of it (index 2.2). He went on to say that while the injection reduced 
his pain in a gradual fashion (index 7.1), he thought it would get better with 
the passage of time (index 1.5). He referred to his Nursing career which 
enabled him to investigate about his shoulder problem (index 5.4) and how 
long it might last for (index 4.4). He felt that the knowledge of the problem in 
itself is not sufficient, because the pain was not only disturbing his sleep at 
night time (index 4.10), but also frustrating (index 4.11). He admitted he will 
recommend the treatment to other people because of the benefits he derived 
from it (index 7.8).  
 
4.3.8 Creating Thematic Charts 
This stage of the analytical data abstraction involves identifying common 
concepts or patterns across the participants’ interview transcripts and 
grouping them into categories and charts using the thematic charts (Ritchie & 
Lewis 2003). MAXQDA was used to generate the thematic matrices or charts 
for some key themes and subthemes, which were displayed in a single 
spreadsheet or code matrix browser in Appendix 9. Six themes and 44 
subthemes are contained in the matrix. The first column of the thematic chart 
consists of each participant’s identification code number and the rows consist 
of the main themes and subthemes that correspond to each participant’s code 
number.  Each of the main themes has subthemes with column numbers that 
ranged from 1 to 14 columns depending on the number of subthemes 
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associated with it.  An example of the layout of the thematic chart taken from 
Appendix 9 is shown in Table 22. This example represents two participants, 
0047L and 0031P. Excerpts from the analysis of their interview transcripts are 
shown under each subtheme in rows 2.1 to 2.5. They include the exact 
accounts that the participants gave about their injection experience. 
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Table 22: Example of a Thematic Chart Showing the Views of two Participants during Interview 
 THEMATIC CHART 2:  
PATIENT INFORMATION  
AND ADVICE 
 2.1 2.2 2.3 2.4 2.5 
Participant ID, 
Gender, Age, 
Treatment 
Group 
Explanation 
about 
treatment and 
care 
Not knowing about 
the shoulder 
problem 
Explanation of shoulder 
problem 
Patient involvement 
in their treatment 
Exercise information 
0047L, Female 
64, lateral group 
I think it is just 
been explained 
to, just the 
general 
explanation 
and feeling at 
ease 
Actually, I was 
scared initially, I 
knew nothing about 
the problem before I 
went. It was less 
alarming after you 
got the experience 
of explaining what it 
all about. 
 
Why they thought I was 
having the problem and 
feeling I know all about the 
problem because actually I 
knew nothing about the 
problem before I went and 
generally feeling comfortable 
with the treatment because it 
seemed the right way to go. 
The whole 
experience you know 
was very easy and I 
wasn’t at all 
concerned after it 
was all explained me. 
 
Been talked through 
certain movements I do 
and why it is not 
working 
0031P, Female 
54, posterior 
group 
Everything was 
great, the 
injection, the 
way he 
performed it, 
the knowledge 
I got, the 
exercises  
Know what is going 
on in the shoulder 
and what I need to 
do. 
You know with you and the 
other Doctor that did the 
injection actually listened and 
you explained. You know you 
felt like you were a patient 
and you are being listened to.  
When I come there 
everything you said 
made me feel like you 
are being listened to. 
In the hospital, they 
do not seem to do 
that. 
I think where I had the 
injection and I followed 
the exercises he gave 
me. I think the 
combination of it all 
improved the shoulder 
itself 
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4.3.9 Descriptive and Classification Analysis - Identifying Elements and 
Dimensions, Refining Categories, Classifying Data 
 
This stage of the analysis involved unpacking, refining and categorising the 
contents and nature of the key themes (Ritchie & Lewis 2003). It also involved 
identification of a particular theme, refining of categories and assigning 
groups of categories to ‘classes’ usually at a higher level of abstraction 
(Ritchie & Lewis 2003). Appendix 10 is an excerpt from participant’s 0052P 
transcript and is an example of using the Framework approach for descriptive 
and classification analysis.  
 
Table 23 is an example of the descriptive and classification process 
performed for the subthemes. Column A is the participant unique identification 
number, column B contains the original quotes from the transcripts, while 
column C is a close description of the participant’s original quotes, but now 
contains mainly the relevant elements of the initial quotes. Column D is a 
higher level of categorisation where elements detected have been interpreted 
in a more conceptual manner to provide a new meaning. For example, in 
column C “unsure about the pain” from (participant 0014P) and “Lack of 
knowledge about the problem” from (participant 0047L) were both categorised 
in column D as uncertainty about the cause of pain. 
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      Table 23: Example of using Framework for Descriptive and Classification Analysis 
Participant ID, 
Gender, Age, 
Treatment Group 
Column B 
Data charted in column 2.2:  Not 
knowing about the shoulder problem 
Column C 
Elements/Dimensions identified 
Column D 
Categories/classes 
0014P, Male, 47, 
Posterior group 
The pain started gradually, and pain in the 
shoulder sort of gradually improved. I had 
constant pain initially and not sure of the 
pain and when I had the injection it brought 
down the pain level to 7/10 but it did not go 
up any further since then but is sort of 
came down gradually. At the same time, I 
had the psychology that this was going to 
heal itself with time. Until then I was not 
getting anywhere and the pain was going 
up week by week. Myself been a Nurse I 
was researching about the condition quite 
a lot and I knew that the pattern of pain 
was about 24 months. However, no matter 
what you know about it, not been able to 
sleep at night because of constant pain 
can be annoying. I was quite relief that the 
pain has decreased. I will recommend this 
to anyone, while it is does not give instant 
cure it bring down the pain gradually. The 
time factor of 18-20 months important, you 
never know whether it will take the whole 
time”. 
Pain started and improved slowly 
Pain was continuous at first 
Unsure of the pain 
 
Injection slowly improved the pain 
 
 
Felt he will get better with passage 
of time 
Took advantage of his profession to 
investigate the problem 
 
Pain lasting up to 24 months 
 
Night pain affecting his sleep 
Expression of pain irritation 
Happy pain improved 
Pain slowly improved 
Could not guarantee complete pain 
resolution with the injection 
Relevance of time to pain  
Gradual onset of pain 
Constant nature of pain 
Uncertainty about the cause of 
pain 
Gradual improvement of pain 
 
 
Natural resolution of pain 
 
Felt motivated to investigate the 
cause of pain 
 
Prognosis of the problem 
 
Affected sleep 
Sense of frustration with pain 
Positive outcome  
Gradual improvement of pain 
Uncertainty about complete pain 
resolution 
Importance of prognosis 
0047L, Female 64, 
Lateral group 
Actually, I was scared initially, I knew 
nothing about the problem before I went. It 
was less alarming after you got the 
experience of explaining what it all about. 
Fear of what was going on 
Lack of knowledge about the 
problem 
Less frightening following 
information about the problem 
Anxiety about the problem 
Uncertainty about the cause of 
pain 
Sense of reassurance following 
education 
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Finally, after application of the above process of analysis in Table 23 to all the 
main thematic charts and reviewing the descriptive items in column D above, 
a descriptive list of discovered items that represent new categories were 
compiled. They represent the participants’ concepts regarding their 
experiences of receiving subacromial injections from injecting ESP’s working 
in normal community practice. Examples of descriptive items include: 
• Anxiety about the problem 
• Uncertainty about the cause of pain 
• Sense of reassurance following education 
• Gradual onset of pain 
• Constant nature of pain 
• Gradual improvement of pain 
• Natural resolution of pain 
• Felt motivated to investigate the cause of pain 
• Prognosis of the problem 
• Affected movement and sleep 
• Sense of frustration with pain 
• Positive outcome  
• Uncertainty about complete pain resolution 
• Importance of prognosis 
• Expectation of pain relief 
• Self- efficacy 
• Injection efficacy 
• Satisfaction with treatment and care received 
• Clinician’s skill, knowledge and experience 
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• Receiving clear information about the problem, treatment and care 
• Good system with treatment appointment 
• Good treatment location with parking arrangements 
• Lack of trust in GP injection 
• Professionalism of the injecting clinicians 
 
4.3.10 Dimensions and Explanatory Accounts 
After investigating the descriptive list, identification of specific conceptual 
labels or a number of associated features took place. This resulted in the 
creation of eight new or key dimensions and themes which consist of:  
1. Shoulder pain issues: This relates to participants’ conceptualisation 
of shoulder pain and factors associated with it - anxiety and uncertainty 
about the shoulder problem, onset of pain been gradual and constant 
in nature, frustration about the persistent nature of pain and pain 
interfering with movement and sleep.  
2. Diagnosis and Prognosis of the problem: These aspects relate to 
participants’ views about what they think and what they were told by 
the injecting clinicians was the cause of their problem, whether they 
will improve or not and when the problem will be resolved. 
3. Interaction with the injecting clinicians: This dimension represents 
the participants’ experiences of their involvement and encounters with 
the injecting clinicians. This includes their views and opinions of the 
assessment and treatment they received as well as the clinician’s 
knowledge, skills and experience.  
4. Information received: This dimension involves the communication 
participants received about their problem, treatment procedure, before 
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and after care. It also relates to information about preventing 
aggravation of symptoms, exercise, daily activities and work. 
5. Participant’s expectation: This dimension represents participant’s 
anticipation of immediate pain relief following cortisone injection. Some 
expected it to be gradual. Few thought they were coming to receive 
physiotherapy not knowing cortisone injection was a possibility. 
6. Treatment Location: This relates to participants’ accounts or 
experiences of receiving treatment within the community. They include 
access and facilities. 
7. Referral system: This dimension represents participants’ journey 
experience from when they were referred by their GP for treatment up 
till the point when they were being treated. They include expectation of 
receiving early appointment, treated on time, good and friendly service. 
It also includes delay getting in appointment. 
8. Outcome of Treatment: This represented participants’ opinion and 
conclusion about outcome of the treatment they received – many being 
positive, with few disappointments.  
The eight dimensions conceptualise the overall account of the participants’ 
experiences of receiving subacromial injection. These main categories were 
then re-sorted and revised generating five main final themes. They include: 
expectation of treatment, treatment outcome, procedure, patient education 
and access to treatment. Finally, explanation of the core themes was 
achieved using the theoretical framework of the research to tell the story that 
participants with SAIS gave about their experiences of receiving subacromial 
injection performed by ESPs working in a community setting. This is 
discussed in the next section. 
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4.3.11 MAIN THEMES 
4.3.11.1 Expectation of Treatment 
Participants that were interviewed said that the onset of shoulder pain could 
be gradual or sudden and was either constant or intermittent. The participants 
mentioned that the reason why they had cortisone injection was mainly 
because they were in pain but also because they had limited shoulder 
movement.  This is consistent with a shoulder study that found that reduction 
in shoulder pain and an increase in shoulder function were the most important 
reasons why patients with symptoms of shoulder pathology sought help from 
their doctor (Ainsworth et al 2009). The International Association for the Study 
of Pain defines pain as being "an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage" (Bonica, 1979: 
278). Shoulder pain is one of the most common musculoskeletal reasons why 
patients visit their GP for help in the community (Roquelaure et al 2006). Pain 
relief was a key expectation of the participants because they confirmed that 
after they had received the subacromial cortisone injection they expected 
their shoulder pain to subside or resolve completely. This is to enable them to 
use their shoulder better and without much pain so they could perform their 
normal everyday activities more easily such as lifting a kettle, changing gear 
and opening a door. Most of the participants interviewed said their 
expectation of complete pain relief was achieved after receiving the injection 
into their shoulder while for very few people it was only partial (that is they still 
had some residual pain). For example two patients commented: 
"I think actually, I believe my shoulder was quite inflamed and 
I had it for quite a long time and it probably restricted my 
movement quite a lot and the injection just improved all of 
that". (0047L, 64 year old female) 
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"I thought it was going to clear it, but my arm still aches and 
there is still a bit of pain when I use it in different directions if 
you know what I mean, it jerks then it really hurts". (0029L 70 
year old male) 
 
This study has highlighted the importance for clinicians and researchers to 
understand that the key expectation of patients with SAIS who have received 
subacromial cortisone injection is that they expect to see their shoulder 
symptoms improved or completely resolved so that they function more 
effectively. This is particularly relevant in cases where physiotherapy and 
other conservative treatments such as cold or hot therapy have failed to 
improve symptoms of SAIS. This is consistent with previous 
recommendations that subacromial injection should be the treatment choice 
for SAIS patients who have failed physiotherapy or where pain is limiting them 
from performing shoulder exercise (Hanchard et al 2004, Lewis 2011). 
 
Few of the participants who had ongoing symptoms asked if they have some 
physiotherapy and were been offered, while others were given the option of 
physiotherapy and they accepted. Very few who did not improve following the 
injected were further investigated with MRI or ultrasound scan and referred 
onward for surgical considerations. 
 
4.3.11.2 Treatment Outcome 
A key theme from the interviews was the outcome of the cortisone injection. 
In this study some of the participants who said their pain got better after the 
injection said that it was certainly due to the efficacy of the cortisone injection. 
One of the participants who had the injection via lateral route said: 
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"Yes definitely. It’s been about 98% okay because of the 
cortisone injection" (0058L 36 year old male). 
 
Most of the participants said that the cortisone injection provided complete 
and immediate pain relief, while some mentioned it was a gradual process. 
Those who said it was a gradual process also mentioned that their shoulder 
movement improved in a gradual fashion as well. In this study it was 
discovered that those who had immediate and complete pain relief did not 
request physiotherapy and also declined the option of physiotherapy because 
they would rather self-manage at home with exercises. This highlights the 
importance of the therapeutic effect of subacromial injection in improving pain 
and function in patients with SAIS thereby reducing clinical dependency and 
improving self efficacy. However, some of the participants who said their 
improvement was gradual wanted some physiotherapy and were therefore 
offered it. For participants who improved (either through a lateral or posterior 
route of subacromial injection), the effectiveness of the cortisone injection in 
reducing pain meant their shoulder movement improved also. For example 
two participants who received the injection via lateral route commented: 
 
"Because after you've had the injection you are back to 
completely normal again, you are free from pain and you are 
free from everything" (0039L 67 year old female). 
 
"Yes, definitely, it gave me more movement the pain is still 
there, still throbbing, but now not as severe and it has at least 
given me 30-40% more movement in the last 5 or 6 weeks. 
(0045L 55 year old male) 
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4.3.11.3 Procedure 
Phrases like "it was brilliant!", "very professional", "1st class!", "very good 
indeed" and "10 out 10" were used to describe how participants felt about the 
injection technique. These comments involved both groups of the study and 
included those who had complete pain relief and those who had residual pain. 
In this study all the injections were performed by two injecting clinicians who 
were trained and had adequate experience and skills. All injections followed 
the recommended PGD guidelines and were performed after obtaining both 
verbal and written informed consent from the participants. The primary 
objectives for any shoulder injection procedure are for the needle to be 
inserted correctly at the selected site in the shoulder with minimal pain and 
discomfort without introducing infection or causing any adverse effect. These 
objectives were important not only for the clinicians who performed the 
injections but also for the participants who received them. Most participants 
confirmed that the injecting clinicians were knowledgeable of the injection 
procedure and delivered it in a way that was intended to ensure no pain or 
discomfort. For example, two participants said: 
 
"It seems fine where I had it and no trouble at all. I thought 
the guy was very professional he knew what he was doing. 
When I had it before the GP did not really know what he was 
doing. He stuck the needle in my shoulder and started 
wiggling it round. But this Doctor numb it first and use the 
same needle to inject the steroid that was really good" (0052P 
43 year old male). 
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"I did enjoy it and I did not feel it, I did not feel any pain or 
discomfort when I had the injection" (0039L 67 year old 
female). 
 
Very few participants said the outcome of the cortisone injection was not very 
successful, despite that, they still maintained that the way that the injections 
were performed was very professional. For example, one participant said: 
 
"Your man who did the injection was polite and he knows 
what he was doing and everything else except this, I do not 
think the injection made any difference" (002L 43 year old 
male).  
 
Participants were asked about their preference of the injection site, whether 
they would have preferred it either from the side or the back of their shoulder. 
Most of them (from both injection groups) said they did not have a specific 
preference for the injection site; rather what they wanted was for the injection 
to improve their pain and shoulder function. A few of the participants that did 
not have a very good successful outcome after the injection said they were 
not exactly sure if the outcome would have been any different if they had 
received it from a different site. However, when they were given the option of 
a repeat injection and they had the option of a second injection site and took 
it. For example, if a posterior route was initially unsuccessful then the repeat 
injection was performed via a lateral approach. 
  
4.3.11.4 Patient Education 
In this study shoulder pain and how the injection works were explained to 
participants before the treatment. They were also informed about the potential 
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risks and benefits of the treatment and were they provided with before and 
aftercare advice about the injection.  Although this study is only investigating 
the effectiveness of subacromial injection through a lateral or posterior 
approach, cortisone injection was not given as a stand-alone treatment. 
Rather participants were given exercise information both in verbal and written 
form to enhance their shoulder function as this is the recommended clinical 
practice. However, the exercises were not standardised. Most participants 
said that before the injections, they had anxiety about the reason for their 
shoulder pain because they lacked understanding of what was causing it. 
However, after their appointment with the injecting ESP, the participants said 
they were provided with good information and received full explanations and 
advice on their care and treatment. They said that this gave them a better 
understanding of their condition, the effects of the cortisone injection and 
what to do after the treatment. This further put their mind at ease and gave 
them the confidence to better use their shoulder without fear of causing more 
harm. They also expressed their appreciation of the way and manner things 
were explained to them, which ultimately enhanced their overall improvement. 
For example, one participant said that she will definitely recommend the 
service to others because she found her shoulder pain was less alarming 
after she was given appropriate information regarding her condition and 
treatment. This highlights the significance of patient education, including 
aftercare advice and exercise information both in verbal and written forms, to 
shoulder pain patients receiving subacromial injection. This was echoed by 
one of the participants:  
"Yes there has been improvement. Hmm because everything 
was explained thoroughly to me and everyone was very 
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helpful, so wasn't left wondering what was going to happen. 
Everything was explained to me and straight away I knew 
exactly what was going to happen and the staff were 
absolutely fantastic and the overall result has been very good 
so I would not say anything negative" (0027L 58 year old 
female). 
 
Participants attributed their improvement in shoulder function not only to 
cortisone injection but also to the exercises that they were given by the 
injecting clinician. Providing exercise information meant that participants 
understood what to do, how to do them, when to do them and how many 
times to do them. Two participants said: 
"The way the exercises was explained and I have been doing 
it regularly. I have been doing it every day for past 3 weeks" 
(0034P 55 year old female). 
 
"Everything was great, the injection, the way he performed it, 
the knowledge I got, the exercises, the understanding of what 
was going on. I sort of push myself. Knowing what is going on 
in the shoulder and what I need to do, and like I say I was 
treated really well by everyone. I will sing the praise to 
everybody and I will go all day. I am trying to push my 
husband to have his done. I am glad it really improved it, I 
really am" (0031P 54 year old female). 
 
4.3.11.5 Access to Treatment  
Quick and easy access to a community musculoskeletal service is essential 
for the management of patients with shoulder pain in order to enhance 
treatment outcomes. Most of the participants said they were pleased at being 
treated in a community service because it was more local, easier and quicker 
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to access and parking was easier compared to the acute hospital. Although a 
few participants felt their appointment should have been sooner, most 
participants expressed their satisfaction for having a quicker appointment. 
They were also complimentary about the clinicians who treated them because 
they were not kept waiting for long periods of time before they were treated. 
These comments included those that improved completely and those that had 
ongoing shoulder symptoms. Some participants spoke about their previous 
experience of going to the acute hospital for treatment. They said they had to 
travel a longer distance to get to the acute hospital and that they were kept 
waiting for long periods before being treated by the injecting ESP. For 
example when two participants were asked if they would have preferred their 
treatment in the community or the acute hospital and they had this to say: 
 
"In the community I think the hospital it so far, so long and 
you have to wait in the waiting room for hours and hours. 
Yours was really well, really fast, it was fast and really worked 
well. I thought I was coming for check-up and suddenly I had 
the treatment, I was very impressed with it". (0055L 51 year 
old female). 
 
Oh no, in the community it was good. I got the appointment 
fairly quick and was seen so fairly quickly. I did not have to 
wait for too long. The location is fine because of the car park 
(0034P 55 year old female). 
 
Some participants also mentioned that they received a very good customer 
service and the phone calls for their appointments were polite and prompt. 
For example, one participant said: 
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"The experience regarding appointment time, phone call all 
very good. Very professional, 10 out 10 really for you because 
you've given out all the instructions of what to do (0056P 51 
year old male)". 
 
However, there were a few participants who said they had difficulty contacting 
the service by telephone and could not speak to someone directly and that 
parking had been an issue. 
 
All the comments above highlight the importance of locating a 
musculoskeletal service, such as the one where this study took place, within a 
central location in the community with easy access, parking availability and 
good customer service. There were very few participants who did not mind 
where they received their treatment; rather what was more important to them 
was improvement of their shoulder symptoms. 
 
4.4 Summary of Qualitative Results 
From the semi-structured interviews the five major themes which emerged 
are expectation of treatment, treatment outcome, procedure, patient 
education and access to treatment. Participants felt that their shoulder 
symptoms improved not only because of the effect of the cortisone injection, 
but also because of other factors such as education about their treatment, 
exercise information, the experience and skills of the injecting clinicians, 
access to treatment as well as good customer service. Participants of both 
groups of the study including those who had complete pain relief and those 
who still had some residual pain expressed these views. Even though very 
few participants felt the outcome of the cortisone injection was not entirely 
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successful, they still said that the clinicians who performed the injections were 
professional and they had received a good service. They did not attribute the 
lack of success to anything in particular. 
 
4.5 Chapter Summary 
In conclusion, this chapter has presented the results of the quantitative study 
and qualitative semi-structured interviews. The next chapter will build on 
previous chapters and provide a more in-depth discussion on relevant 
aspects including some personal perspectives on key issues such as strength 
and weakness of the study, implication of this research in clinical practice and 
recommendation for further research. 
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CHAPTER 5 DISCUSSION 
 
5.1 Introduction 
The study findings demonstrated that in normal musculoskeletal practice, 
subacromial injections performed using anatomical land-marks provided 
significant clinical improvements in day time pain, night time pain, shoulder 
function and disability in participants with SAIS. They also indicated that 
clinical outcomes, such as the pain relief of participants receiving subacromial 
injection were influenced by their experiences of these injections. These 
experiences included their expectation of treatment, treatment outcomes, the 
information they received before and after the injections, the way the 
injections were performed and access to treatment. 
 
This chapter discusses the issues in normal musculoskeletal practice 
regarding needle placement in subacromial injection with patients with SAIS, 
and discusses the research questions: Is lateral approach to subacromial 
injection more effective at improving shoulder pain and function in patients 
with SAIS compared to a posterior approach? What are the experiences of 
patients with SAIS receiving lateral versus posterior approach to subacromial 
injections? 
 
5.2 Clinical Improvements 
A pain free shoulder is vital for shoulder function which is necessary for 
performing everyday tasks such as washing, dressing and lifting. Therefore, 
even small improvements in pain reduction can facilitate activities of daily 
living. The most important expectation of a patient with shoulder pain is pain 
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reduction and the ability to live a comfortable life (Fashanu 2014). The current 
study has demonstrated that cortisone injection, when provided by 
experienced and trained ESPs, gave early pain relief and improved shoulder 
function. Although the precise mechanism of action is not well understood, its 
therapeutic value has been reported to include reducing pain and 
inflammation, reflex muscle spasm, and influencing tissue metabolism 
(Neustadt 1991). Paavola et al (2002) in a study of the role of cortisone 
injections in tendon pathologies reported that corticosteroids can suppress 
inflammation by changing the release of noxious chemicals that are produced 
by degenerate tendons. They reported that the other effects of cortisone 
injections are inhibition of collagen production and granulation tissue and 
prevention of fibrosis.  
 
Although the benefits of the injection in this study were short term it did 
enable participants to carry on with their normal everyday tasks, such as 
washing, and dressing and they therefore, did not require further treatment 
thus improving self efficacy and reducing clinical dependency (Ainsworth et al 
2009). Because these participants did not require further consultations, more 
appointment spaces were available to other patients who needed them, 
thereby reducing the waiting times for them to see a clinician. This view was 
reflected by participants in the qualitative aspect of this current study. For 
example participants who improved after the injection therapy did not request 
further treatment or physiotherapy. In fact, those that were given the option of 
physiotherapy or self management said they would rather self manage with 
home exercises because they had improved and did not see the need for 
physiotherapy. In a recent qualitative semi-structured interview study, 
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Fashanu (2014) reported that some of the participants observed that having a 
cortisone injection was what actually improved their pain and it was only then 
that they were able to do the exercises they had been given. This highlights 
the importance of the therapeutic effect of subacromial injection in SAIS in 
improving pain and function and thus reducing clinical dependency and 
hospital admissions. It is widely reported that corticosteroids are important 
anti-inflammatory and pain relieving medications, which act at both local and 
systemic levels (Akgun et al 2004, Ekeberg et al 2009).  
 
There were a few participants who said that their improvement was gradual or 
that they had residual pain. They took up the offer of physiotherapy treatment 
and were able to comply with the treatment following better pain control. Very 
few participants had either a repeat injection and or were referred for 
diagnostic imaging (ultrasound or MRI scan) and then referred onward to 
secondary care for surgical opinion or intervention. This was because their 
symptoms had not improved with the cortisone injection and/or with 
physiotherapy. The evidence suggests that surgery is usually considered as 
the last option when conservative treatments such as physiotherapy and 
cortisone injection have been unsuccessful (Lewis 2010, Hanchard et al 
2013). 
 
Most of the participants in this study had experienced shoulder problems for a 
considerable period of time with an average of over 6 month’s duration of 
symptoms. Despite the long duration of symptoms, participants experienced 
an overall improvement in pain and function regardless of which group they 
were randomised into. This is consistent with the one layer multiple 
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regression that was used to evaluate the contribution of participant's baseline 
characteristics such as symptom duration and the PROMs and SPADI scores 
between baseline to 8 weeks, week 0 to 12 and week 8 to 12. The results of 
the multiple regression showed that duration of symptoms was not a 
significant predictor of the outcome measures. This is consistent with 
Ainsworth et al (2009) who reported that despite the long durations of 
symptoms, their cohort of 60 people with rotator cuff tears still showed 
significant improvement in the clinical outcomes of shoulder pain and function 
irrespective of the group they were randomised to. However, it contrasts with 
the findings of Ekeberg et al (2009) who, after a study of ultrasound guided 
corticosteroid injection versus systematic steroid injection in rotator cuff 
patients, suggest that the duration of rotator cuff pathology might influence 
the outcome of cortisone injection treatment. The authors believe that 
longstanding chronic symptoms have a negative impact on treatment 
outcomes. In this study, the fact that both groups improved may be a 
reflection of the combined effects of efficacy of cortisone injection and the 
experience of the ESPs who managed the whole procedure and gave these 
injections. This view was supported by the comments of the participants in the 
semi-structured interview. They felt that they improved not only because of 
the effect of the cortisone injection but also because the ESPs who performed 
the injections were very confident in what they were doing and behaved in a 
very professional manner.  
 
5.2.1 Within Group Difference 
There was a statistically and clinically significant difference (p = < 0.05) within 
the groups at improving day time pain, night time pain, shoulder function and 
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SPADI scores both from 0 to 8 weeks and 0 to 12 weeks follow up. The 
findings suggest that both routes of cortisone injection produced similar 
clinically important reductions in shoulder pain and improvement in shoulder 
function and disability. Similarly, participants in the semi-structured interviews 
which were conducted 12 weeks after the treatment confirmed that after they 
received the subacromial injection it improved their shoulder pain, function 
and disability. This highlights the importance of the therapeutic efficacy of 
cortisone injection in controlling pain and improving shoulder joint and muscle 
function. This could lead therefore, to reduced clinical dependency on repeat 
cortisone injection and consequently free up more appointment slots for other 
patients that need them most and ultimately reduce the waiting times. This 
could equate to cost savings for both the patients who could be becoming 
over dependent on pain medication and/or the healthcare service.  
 
The findings of this study are also consistent with several clinical guidelines 
that have recommended the use of subacromial injection in the treatment of 
SAIS particularly in cases were pain is the most limiting factor (Hanchard et al 
2004, Diercks et al 2014, NICE 2015). It is also consistent with systematic 
reviews that found significant benefits with cortisone injections in the 
treatment of patients with shoulder pain (Johansson et al 2002, Buchbinder et 
al 2003 and Arrol & Goodyear-Smith 2005, Gaujoux-Viala et al 2009). The 
result of this study also compares favourably with Akgun et al (2004) who, in 
a randomised controlled study, investigated whether cortisone injection would 
provide additional benefit when combined with previous medication and 
exercise regime. They found that subacromial cortisone injection produced 
added benefit by relieving pain which affected sleep as well as day time 
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activities. Gaujoux-Viala et al (2009) in a meta-analysis of RCTs involving 618 
shoulders found that although the effects of steroid injections were 
comparable to NSAIDs, they were more favourable in improving shoulder 
pain and shoulder function compared to other treatments. The authors 
concluded that cortisone injection was well tolerated, with rare and minor side 
effects such as transient post injection pain and skin modification.  Similarly, 
Mohamadi et al (2016) in a recent systematic review and meta-analysis of 11 
RCTs found that cortisone injections provided moderate pain relief for 
patients with rotator cuff disorders up to two months after the injection, but the 
effect was not sustained after three months. However, two systematic reviews 
(Van der Heijden GJ et al 1996, Koester et al 2007) have reported that the 
evidence establishing the efficacy of subacromial cortisone injection in 
shoulder pathologies is unequivocal.  The reviews consisted of few studies 
that lacked adequate methodological quality and most of them had small 
sample sizes and were not adequately powered.  
 
5.2.2 Between Group Findings 
There was a moderate clinically and statistically significant improvement in 
day time pain score between 0 to 8 weeks follow up in favour of the 
participants treated by lateral route subacromial injection compared to the 
posterior group. Because previous shoulder studies (Sardelli & Burks 2008, 
Marder et al 2012) have both demonstrated that a lateral route subacromial 
injection was more accurate compared to a posterior route, it was expected 
that the lateral group would show a statistically significant better improvement 
compared with the posterior group in all the outcomes. However, this current 
study was unable to demonstrate a statistically significant difference between 
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the groups in night time pain, shoulder function and SPADI scores from week 
0 to 12 and week 8 to 12.  
 
No previous research has reported improvement in day time pain in favour of 
the lateral route of subacromial injection compared with the posterior between 
weeks 0 to 8 using anatomical landmarks. In clinical practice, the standard 
follow up period for evaluating the success of a shoulder injection outcome is 
usually between 6 to 8 weeks. Since the lateral route subacromial injection 
was more effective in reducing day time pain between 0 to 8 weeks, it should 
therefore be recommended as the standard procedure for subacromial 
injection. This is particularly so for SAIS patients who only suffer day time 
pain, with no night symptoms. From my personal clinical experience a patient 
with an improved day time shoulder pain at 8 weeks follow-up, will be 
considered for a further injection if they have significant night time pain or 
other on-going symptoms.  Therefore, if the patient's night time pain is not 
significant and the cortisone injection has resulted in improvement of their day 
time activities, instead of having a repeat injection the patient could be 
discharged with advice on self management and a home exercise 
programme. 
 
The patient could be advised to pace their activities and avoid activities that 
could strain the shoulder and cause aggravation of the night time pain. But if 
a lateral cortisone injection has improved a patient's day time pain and they 
still have ongoing night time pain they should be provided with the option of 
being referred to their GP for prescription of pain medication and/or sleeping 
tablets to use at night. They should also be given the option of having 
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physiotherapy. These options when applied are much cheaper compared to 
surgical interventions hence reducing hospital admissions. They are easy to 
access and could potentially reduce the number of repeat cortisone injections 
and save costs for the GPs and commissioners of community 
musculoskeletal practice. 
 
Three previous studies (Yamakado 2002, Sardelli & Burks 2008 and Marder 
et al 2012) have supported the use of lateral approach of subacromial 
injections with patients with SAIS compared to the posterior route. However, 
they did so by investigating the accuracy in placing these injections into the 
bursa using either arthroscopy or radiographic reference. Therefore, these 
studies represent an arthroscopic rather than a clinical model and they do not 
represent what happens in normal ESP musculoskeletal practice. In contrast, 
this current study evaluated the effectiveness of needle placement using 
anatomical landmarks (blind) which is common clinical practice. Dogu et al 
(2012) reported that blind subacromial injections performed by experienced 
clinicians in patients with SAIS not only produced improvements in shoulder 
pain and function but were applicable to routine clinical practice. 
 
5.2.3 Cortisone Injection and Advice 
Besides the positive effect of the cortisone injection in reducing pain and 
improving function in the participants with SAIS, most of the participants that 
were interviewed acknowledged the importance of patient education and 
exercise advice as contributors to their improvements. The post injection 
information advised rest from strenuous activities such as heavy lifting for a 
period of 1 – 2 weeks while keeping active within pain limits and a gradual 
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return to normal everyday tasks. Participants said they were provided with 
information and received full explanations and advice about their care and 
treatment which they thought ultimately contributed to their overall 
improvement. Participants attributed their improvement in shoulder function 
not only to the cortisone injection but also to the exercises that they were 
given by the injecting clinician.  
 
Cranshaw et al (2010) in a large pragmatic randomised study involving 235 
participants with moderate to severe shoulder pain investigated the effect of 
cortisone injection plus exercise versus exercise only. They reported that by 
12 weeks the majority of patients treated with cortisone injection and shoulder 
exercise had greater pain relief and improved muscle function compared with 
the exercise group. There were some participants who were referred from 
physiotherapy for cortisone injection because pain was preventing them from 
exercising. Following a successful outcome of the cortisone injection most of 
them then continued with their physiotherapy and exercise regime. Fashanu 
(2014) found that exercise prescription to patients with severe shoulder pain 
was counterproductive to the initial outcome of pain relief. Some of the 
participants in the study observed that having a cortisone injection was what 
actually improved their pain and only then they were able to do the exercises 
they were given. 
 
Although the patient education and exercise information were found to be of 
additional benefit, the exercise prescriptions were not standardised amongst 
the participants. However, it has been suggested that exercises prescribed by 
clinicians should be from a patient-focused perspective (Epstein 2010). The 
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injection information and consent form were standardised. The lack of 
standard exercise information could present a weakness in this study and a 
gap in the evidence. Therefore, further research on a review of the exercises 
prescribed from a patient-focused perspective (Epstein 2010) or a standard 
format is suggested.  
 
5.2.4 Follow-up Periods 
The timeframes (week 0 to 8 and week 0 to12) used in this study for follow-up 
were not only longer than some previous studies but also consistent with 
current musculoskeletal practice and both the posterior and lateral groups 
improved during these periods. In contrast, previous studies have used 
shorter study timeframes. For example, Adebajo et al (1990) and Petri et al 
(1987) in two separate trials found that subacromial cortisone injection in 
patients with rotator cuff disease reduced pain and improved shoulder 
function compared with placebo, but the follow up period in both studies was 
only 4 weeks.  
 
Compared with this study, Blair et al (1996) used a longer follow-up period to 
evaluate the effectiveness of subacromial injection. The authors reported that 
a combination of cortisone injection and Lidocaine (Kenalog) produced better 
pain relief and an increased range of shoulder movements when compared 
with Lidocaine only. However, the post injection outcomes for the cortisone 
group and placebo group were assessed at different times, with the cortisone 
group being followed up at 33 weeks and the placebo group at 28 weeks. The 
difference in the follow-up periods between the groups makes the findings of 
this study difficult to apply to normal clinical practice and the pooling of the 
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results difficult for meta-analysis. This is in agreement with a Cochrane review 
(Buchbinder et al 2003) that investigated the benefits of subacromial 
injections for shoulder pain, but had difficulties in pooling the result of the Blair 
et al (1996) study for a meta-analysis (Buchbinder et al 2003). In this study, 
the consistencies of the follow-up periods are not only applicable to routine 
clinical practice but they also have the benefit of contributing to systematic 
review and meta-analysis. 
 
5.3 Safety and Adverse Effects 
There were no safety concerns or adverse effects reported in this study and 
this could be attributed to the injection technique, experience and skills of the 
injecting clinicians (Mclnerney et al 2003). This was reconfirmed by the views 
expressed by participants in the semi-structured interview. They said that the 
injecting clinicians were knowledgeable about the injection procedure and that 
the injections were delivered in a very safe and professional manner. They 
did not express any concern or report any adverse effects from the injections. 
This highlights the importance of subacromial injections being performed by 
trained and experienced ESPs who were also following the PGDs. 
Subacromial cortisone injections are relatively very safe (Saunders & 
Longworth 2012) however, some authors have suggested that they may have 
some adverse local effects such as skin discoloration and tendon rupture 
(Akgun et al 2004). This is in contrast with this study and also McInerney et al 
(2003) study that reported no adverse effects of subacromial cortisone 
injection in their cohort of 98 patients with post-traumatic shoulder 
impingement. Other studies (Dickson 1995, Kumar & Newman 1999, Penning 
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et al 2012) however, have reported minor adverse effects such as post 
injection flare of pain. 
 
5.4 Ultrasound Guided Injections versus Anatomical Landmarks 
(Blind) 
 
This study has demonstrated that the use of anatomical landmarks (blind) for 
placing subacromial injections by ESPs has the effect of improving clinical 
outcomes of reducing shoulder pain and improving shoulder function and 
disability. This study has also shown that standard shoulder injections (blind) 
not only produce good clinical outcomes but they are also safe, involve less 
time and a lower cost compared to previous studies that have used either 
ultrasound guided or MRI scan guided injections, both of which come at a 
much higher cost (Sage et al 2013). This compares favourably with several 
other authors who have demonstrated that there are no statistically and 
clinically significant differences between USG and blind shoulder injections in 
the management of SAIS (Lee et al 2009, Panditaratne et al 2010, Dogu et al 
2012, Zufferey et al 2012).  However, previous shoulder studies (Naredo et al 
2004, Chen et al 2006) found that patients who received USG injections 
showed a significant improvement in shoulder pain and function compared 
with the non-USG (blind) group. Notwithstanding, more recent studies are in 
agreement with the findings of my study. For example, in a recent UK study 
Roddy et al (2016) conducted a RCT using a 2x2 factorial design to compare 
physiotherapy-led exercise programme versus standard exercise leaflet and 
USG injection versus blind subacromial injection for SAIS patients. The study 
involved 256 patients. SPADI was the primary outcome and was measured at 
6 weeks, 6 and 12 months. The authors concluded that USG subacromial 
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injection did not produce better clinical outcomes compared to blind or 
unguided subacromial injection. Furthermore, a Dutch study by Brandi et al 
(2016), that involved a cohort of 56 patients with SAIS found no significant 
differences in the clinical outcomes between the USG subacromial injections 
and blind subacromial injections.  
 
This study successfully used anatomical landmarks for the placing of the 
injections and this could be attributed to the training, knowledge, skills and 
clinical experience of the two ESPs who performed these injections. This 
assertion was supported by the feedback received from participants in the 
semi-structured interview. Most of the participants said that they thought that 
the effectiveness of their treatment and care was because the clinicians who 
performed the injections were knowledgeable about the injection procedure 
and confident about the outcomes. Similarly, a study by Stanhope et al (2012) 
found that injections performed by the ESPs working in orthopaedic 
outpatients improved the patients' health outcomes because they were 
properly trained and had adequate experience. It has also been shown that 
standard shoulder injections (blind) performed by experienced clinicians were 
reliably accurate and very effective in improving shoulder pain and function in 
SAIS patients during the short-term follow-up. They are also applicable to 
daily clinical practice (Dogu et al 2012). Chambers et al (2005) in a 
retrospective study that compared the accuracy and efficiency of subacromial 
injection through an anterior approach by a consultant, registrar and a 
specialist physiotherapist, found that the injections of the specialist 
physiotherapist (ESP) were comparable to those of the consultant and 
generally better than the registrar's.  
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In summary, the findings of the above studies suggest that currently the use 
of USG subacromial injections does not provide greater clinical benefit when 
compared with standard shoulder injections (blind) that are much cheaper 
and readily available within the community MSK service. The current study 
has clearly demonstrated that having a single blind cortisone injection either 
through a lateral or a posterior route for SAIS patients provided significant 
pain relief, both at day and night time and also improved shoulder function 
and disability. This is comparable with current evidence that subacromial 
injection is effective in shoulder pain and function. In practice, most CCG 
service specifications for community MSK services recommend the provision 
of cortisone injection using shoulder landmarks (blind) which is the usual 
practice. This study's finding not only supports this proposal but it also 
equates to cost savings for services as there is no need to invest heavily in 
expensive diagnostic ultrasound machines, which come with additional 
training costs for the clinicians who will use them. However, there are 
instances where the use of ultrasound guided injections is useful. For 
example, in Barbotage procedure for patients with calcific tendinosis (Diercks 
et al 2014) as well as painful small joints such as carpometacarpal joint of the 
thumb where blind injections might prove difficult to achieve. 
 
5.5 Methodological Issues 
The inclusion of participants in trials on strict clinical criteria alone has been 
suggested to limit the number of participants that could potentially be 
recruited into a trial (Ekeberg et al 2009). In this study, the inclusion criteria 
for diagnosis of SAIS were therefore based not only on the use of clinical 
presentation and tests, but also on clinical examination. This is based on the 
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work of Lewis et al (2005) who found that the use of clinical presentation and 
tests increased the accuracy of a clinical diagnosis of SAIS. The current study 
combined the presence of a positive impingement sign, such as Neer’s or 
Hawkins Kennedy, painful arc sign and shoulder pain localised to the 
acromion, as some of its criteria for diagnosing SAIS (Kuhn 2009). This is not 
only consistent with Lewis et al's study, but also with several authors who 
found that using composite tests increased the post-test probability of the 
diagnosis of SAIS (Murrell & Walton 2001, Park et al 2005, Michener et al 
2009). For example, Park et al (2005) achieved a post test probability of 95% 
(proportion of patients with that particular test result who have the target 
disorder) of impingement with similar inclusion criteria to that which were 
adopted for this study. The comparability of this study to previous shoulder 
trials therefore, makes it readily applicable to normal clinical practice and 
future shoulder research. The less restrictive strict inclusion criteria adopted 
for this study could mean that a less homogeneous group of patients were 
recruited into the study.  However, this is acceptable because pragmatic trials 
often utilize less restrictive criteria (Godwin et al 2003, Alford 2007) to 
improve the external validity (generalisability). 
 
Compared to previous studies (Henkus et al 2006, Kang et al 2008, Sardelli & 
Burks et al 2008, and Marder et al 2012) where needle placements were 
performed by one clinician, in this current study all the injections were 
performed by 2 qualified and experienced ESPs. This could therefore 
enhance intra-rater reliability and reduce potential treatment bias that could 
have resulted from a single practitioner giving these injections. However, 
intra-rater reliability was not measured in this current study because it was not 
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part of the study objectives. Although each of the injecting ESPs injected by 
both lateral and posterior routes, they could not pre-determine which injection 
site to inject because they were blinded to the participant's treatment 
allocation. Since the participants were randomised the possibility of treatment 
bias should have been reduced. 
 
In this study, participants were randomised by the selection of an opaque 
envelope prior to treatment. The result of statistical analysis showed that 
there was no statistically significant difference between the means (SPADI 
and PROMs) of both groups at baseline, which means that they were not only 
similar at baseline, but that the process of randomisation was adequate. 
 
In summary, the findings of the quantitative aspect of this study have shown 
that cortisone injection is beneficial to patients with SAIS in the short term; 
however, it did not explicitly prove the hypothesis that a lateral approach is 
clinically more beneficial to a posterior approach for subacromial injection. 
 
5.6 Patients' Experiences 
To my knowledge no study has investigated the experiences of patients with 
SAIS receiving subacromial injection either through a lateral or a posterior 
approach. Currently, this study is the first to explore the experiences of 
patients with SAIS who have received a cortisone injection from either the 
side or the back of the shoulder. This section discusses the real life 
experiences of the participants regarding cortisone injection. 
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5.6.1 The Importance of Patients' Education 
Participants that were interviewed confirmed that they were given adequate 
information and good explanations about their care and treatment by the 
injecting clinicians. According to the participants, patient education involved 
being listened to and being involved with decision making about their 
treatment, understanding the possible outcome of the treatment and being 
given exercise advice. They said they felt involved in the discussions and 
decision-making process regarding their care and treatment. Some of the 
participants said that initially they had had anxiety about their condition and 
the treatment but that they were reassured after being listened to by the 
injecting ESP who thoroughly explained their condition to them in manner 
they could easily understand. This highlights the contribution that patient 
education makes in enhancing the overall experience of treatment for 
shoulder patients and consequently improving their clinical outcomes. This is 
consistent with a recent qualitative shoulder study by Fashanu (2014) who 
explored patients' expectations and experiences of physiotherapy and 
shoulder pain. He concluded that some shoulder pain patients lacked 
awareness of the possible causes of their pain and what was wrong with their 
shoulder (Fashanu 2014). Fashanu (2014) suggested that providing patients 
with information concerning their shoulder pain, its possible causes and 
diagnosis could ultimately prevent further deterioration and so enhance their 
improvement and self-efficacy. The participants were advised regarding a 
home exercise programme, to pace themselves and to avoid strenuous 
activities such as awkward or heavy lifting that could compromise their 
improvements. It has been reported that lifting heavy loads, working in 
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awkward postures and engaging in repetitive movements aggravates 
shoulder pain (Van der Windt et al 2000).  
 
Participants felt that patient education as well as the therapeutic effect of the 
cortisone injection contributed to their overall experience and improvement of 
shoulder pain. The importance of patient education as a key factor in 
improving pain of musculoskeletal origin is consistent with other studies that 
have investigated the experiences and/or perceptions of patients with 
musculoskeletal conditions regarding physiotherapy treatment. Cooper et al 
(2008) in a qualitative study explored the perceptions of patients with chronic 
low back pain and physiotherapy treatment. They found that patients 
considered the discussions about their care and the exercise information they 
were given by the physiotherapist as very important aspects in meeting their 
individual needs and treatment outcomes. Similarly, a report by the 
Department of Health (DoH 2008) found that patients who received individual 
advice and education about their problem not only improved but also went on 
to live a more independent life. Furthermore, Jones et al (2013) in a 
qualitative study that explored the experiences and perceptions of people 
living with primary frozen shoulder found that the participants were more 
interested in understanding and finding a solution to the cause of the shoulder 
pain than in resolving it. Harrison & Williams (2000) reported that a lack of 
adequate information and involvement of physiotherapy patients in their 
treatment were some of the reasons why patients were not satisfied with their 
care. This highlights the importance of involving patients with musculoskeletal 
problems in all aspects of their care and treatment in order to enhance their 
overall experience and improve treatment outcomes. In this current study, 
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participants confirmed that their shoulder pain improved not only because the 
cortisone injection worked but also because the injecting ESPs involved them 
in the decision making processes of their care and management and any 
questions they had about their care were thoroughly explained to them.  
 
There are also other aspects of the patient information, which the participants 
thought contributed to their overall experience. In general, they said that the 
information they received about their appointment together with access to the 
service, including the parking arrangements, also enhanced their experience. 
Some of the participants said that they felt that having quicker appointment 
times and not being kept waiting for too long by the injecting clinician as well 
as receiving very good customer care contributed to their overall 
improvement. However, a few participants felt that the information about their 
appointment was not clear enough and that they could have been seen 
sooner. Several authors (Holdworths et al 2008, Webster et al 2008) including 
the Department of Health (2008) have reported that if patients with chronic 
musculoskeletal conditions are given faster and quicker access to treatment 
they are more likely to manage their condition better and be more 
independent  thus avoiding unplanned hospital admissions and improving 
self-efficacy.  
 
In summary, the qualitative study revealed that the benefits of having 
cortisone injection either through a lateral or posterior approach are enhanced 
by other factors such as education about the treatment, exercise information, 
the experience and skills of the injecting clinicians, access to treatment as 
well as good customer service. 
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5.7 Chapter Summary 
This chapter has discussed both the quantitative and qualitative study's 
findings and the issues in normal musculoskeletal practice regarding shoulder 
injections in SAIS patients. It also identified that the blind subacromial 
injections performed by trained and experienced ESPs were not only safe (no 
adverse reaction reported) and produced good clinical outcomes but were 
comparable to USS or MRI scan guided injections. It also discussed the 
contributions that patient education made in enhancing the overall experience 
and treatment outcomes for patients with SAIS. 
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CHAPTER 6 CONCLUSION 
 
This study set out to determine the effectiveness of a lateral compared to a 
posterior approach to a subacromial injection used for the treatment of SAIS 
and to evaluate the experiences of the patients receiving the injections. It has 
complied with the nine dimensions for assessing the level of pragmatism in a 
trial, as proposed in the pragmatic-explanatory continuum indicator summary 
2 (PRECIS-2) (Loudon et al 2015).  
 
This study has demonstrated that there is strong evidence supporting the 
effectiveness of both lateral and posterior routes of subacromial cortisone 
injection in improving shoulder pain, function and disability in patients with 
SAIS at 8 weeks and 12 weeks. This supports the null hypothesis, which 
states that ‘there is no significant difference in the effectiveness of lateral 
approach compared with posterior approach to subacromial injection at 
improving shoulder pain and function in patients with SAIS’. It has also 
demonstrated that the lateral route of subacromial injection is more effective 
when compared to the posterior route in improving day time pain in the short 
term. However, it did not demonstrate that the lateral group compared to the 
posterior approach was better at improving night time pain, shoulder function 
and the SPADI score. Therefore, it is difficult to state that this study has 
completely proved that the alternate hypothesis which states ‘lateral approach 
to subacromial injection is more effective at improving shoulder pain and 
function in patients with SAIS compared to a posterior approach’ is correct. 
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The study has confirmed that cortisone injections performed by trained and 
experienced ESPs using anatomical landmarks are not only safe (no adverse 
reaction reported) and are comparable to USG injections, but they are also 
effective, cheaper and easier to administer. These findings were also 
supported by the comments of the participants in the semi-structured 
interviews.  
 
This study has shown that either posterior or lateral routes of subacromial 
injections should be considered in patients with SAIS where pain is present 
that is limiting daily life activities, and where physiotherapy has not helped. It 
has also shown that either route of subacromial injection is not only effective 
but is also necessary in cases where exercise or physiotherapy is aggravating 
the patient's symptoms. However, where shoulder pain is reduced or 
completely resolved after receiving a subacromial injection, but where there is 
still poor muscle control, clinicians should consider recommending 
physiotherapy to strengthen and improve muscle function. This will ultimately 
prevent the patient from having a recurrence of their symptoms which may 
lead to loss of working hours and life style changes. It will also reduce 
dependence on pain medication which comes with potential side effects such 
as abdominal irritation and constipation. By applying the recommendations 
that the researcher will make later in this chapter to clinical practice, clinical 
effectiveness will improve, the patients' treatment journey will be enhanced, 
and healthcare providers will potentially be saved the extra cost of patients 
having too many treatments. 
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This study found that participants did not have a preference for either 
posterior or lateral routes of subacromial injection. Since a maximum of three 
treatment sessions for injections are normally recommended within 
timescales of varying length, if one approach of injection does not improve the 
patient's symptom, a repeat injection could be considered using a different 
route. This highlights the importance for musculoskeletal services to ensure 
that clinicians, such as ESPs, who work in them are trained and experienced 
in performing injections using both routes and that they should keep their 
skills up to date by attending relevant revision courses. 
 
From the themes discussed in the semi-structured interviews, this study has 
demonstrated that participants with SAIS felt that their shoulder pain and 
function improved not only because of the effect of the cortisone injection, but 
also because of other factors. These include the education they received 
about their treatment, exercise information, the experience and skills of the 
ESPs who performed the injections and because they were very professional. 
The study has clearly shown that involving patients in the decision making 
processes of their care and treatment and trying to answer any questions they 
had about their ongoing care contributed to their understanding of shoulder 
pain and therefore enhanced their recovery. The study also revealed that 
having a quicker and easier access to treatment not only addressed their 
individual needs but also contributed to their overall experience and therefore 
to their improvement. It is therefore clear from this study that there are 
multifactorial influences in the understanding of the therapeutic role of 
subacromial injection in SAIS and the overall experience of patients receiving 
the injections. These include the biological effect of cortisone injection, patient 
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education about SAIS and subacromial injection, exercise information, the 
experience and skills of those performing the injections. Others include the 
way and manner in which the injections were performed, the professionalism 
of the injecting clinicians, access to treatment as well as good customer 
service.  
 
To my knowledge, this is the first study that has used a mixed methods 
research design that combines both a pragmatic RCT to investigate to 
investigate the effectiveness of lateral versus posterior approach to 
subacromial injection together with semi structured qualitative interviews to 
explore the experiences of the patients receiving the injections. This study 
has demonstrated that a pragmatic RCT combined with semi-structured 
interviews provides a better understanding of the clinical outcomes of 
cortisone injections in SAIS patients and the meaning they provide about their 
experiences of receiving the injections. This finding is consistent with previous 
authors (Shaw et al 2010, Rowell & Polipnick 2008) who have supported the 
use of mixed methods research design in evaluating treatment interventions 
and the experience of those patients receiving such treatments. Future 
research should therefore consider the use of a mixed methods approach that 
combines both a quantitative and a qualitative approach when investigating 
shoulder pathologies.  
 
6.1 Limitations of the Study 
In this study, the injections were performed by two injecting ESPs who were 
trained and had adequate experience and skills. However, before the study 
there was no agreement on the number of injections that each of the ESPs 
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would perform. It was difficult therefore to determine whether one of the ESPs 
performed more injections in comparison to the other or whether they used 
one approach more than the other. The lack of an equal amount of injections 
provided by each of the clinicians could limit inter-rater reliability of the 
interventions. However, since the participants were adequately randomised 
and the injecting clinicians were trained and knowledgeable about the 
injection techniques, the outcomes of the interventions should still be reliable. 
 
The injecting clinicians provided verbal after care advice and written exercise 
information, but the exercises were not standardised for all the participants 
because they were intended to meet the specific needs of each patient.  This 
is the usual practice. The lack of standardised exercise information could 
constitute a weakness in the study. However, my study was mainly 
investigating the effectiveness of two routes of subacromial injections and not 
the effect of patient education or specific exercise prescription on SAIS 
patients. The written consent information that was provided to the participants 
before the injections and the after-care information they received were 
however, similar. 
 
The limitations due to the inclusion criteria adopted for this study, whereby 
some patients that could have been recruited into the study may have been 
missed, are hard to eliminate. Another weakness in this study could be the 
fact that the inclusion criteria were based mainly on clinical grounds; this 
could mean that specific pathology located in the subacromial space might 
have been missed (Henkus et al 2006). As with many pragmatic trials 
(Ainsworth et al 2009), one of the weaknesses of this study was the lack of 
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blinding of the injecting ESPs to the injection approaches, which may have 
introduced a bias. However, the ESPs were blinded to participant treatment 
allocation in order to minimise experimenter bias and the assessor was 
blinded to the baseline measures to reduce assessment bias. According to 
Gøtzsche (2006), assessment error is defined as error in the assessment of 
clinical outcomes.  
 
The method of data collection in the qualitative study could be another 
weakness in this study. The semi-structured interview period was short and 
there were few variations in the amount of time spent on the interviews, with 
some participants having more time than others. This could have reduced my 
ability to probe for more in-depth responses which are necessary for obtaining 
richer data (Patton 1990). However, I did make an effort to try to ensure that 
enough information was gathered from the participants during the interviews. I 
also used respondent re-validation by sending the transcript back to the 
participants to ensure that its contents matched what had been said. I used a 
semi-structured interview design to guide the process of the interview. This 
meant that interview questions were more focused around key issues of the 
patients' experiences of cortisone injection, thus ensuring that data relevant to 
the key issues was collected from all participants.  
 
6.2 Reflection on my Current Practice 
This study has reinforced my clinical experience that providing subacromial 
injections using the standard anatomical landmarks method (blind) does not 
only produce good clinical outcomes, but is also safe because no adverse 
reaction or significant side effect was reported. This study has also shown 
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that the successful use of anatomical landmark injections could be attributed 
to the years of training, knowledge, skills and clinical experience of the 
injecting ESPs. Therefore, as the Clinical Lead of my service, I will continue to 
encourage and support the training of potential ESPs in injection therapy to 
enhance the overall needs of the service and improve clinical outcomes. 
 
This research has highlighted to me the significant benefit of including patient 
experiences as part of a quantitative research study. As an Extended Scope 
Physiotherapist, my training and clinical experience has its root in a medical 
or biomedical model of assessing and treating patients with musculoskeletal 
pathologies such has SAIS. Over the years, I have adopted some 
biopsychosocial approaches by taking into consideration patients' 
expectations and experiences of the treatment they receive as part of my 
management strategy. Now the role of the psychosocial aspects 
(experiences) of a patient's recovery is even more evident to me since 
undertaking this research. This study has shown that the experiences of 
patients' regarding subacromial injection were significant contributors to the 
outcomes of their treatment. For example, providing patients with adequate 
information about their treatment further puts their mind at ease and gives 
them the confidence to use their shoulder better without fear of causing more 
harm. This fact has led me to be more patient focused in my subjective 
questioning and treatment using a more psychosocial approach. This is 
consistent with a recent systematic review that recommended the use of a 
psychosocial approach in the management of subacromial pain syndrome 
(Shanahan & Sladek 2011).  
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Participants in my study were of the opinion that not being kept waiting for too 
long by the injecting clinician as well as receiving very good customer care 
also contributed to their overall improvement. Although in my practice, I make 
it a point of duty to treat my patients on time, however, on a personal level, I 
am now even more determined to try not to keep them waiting for too long 
before being seen.  
 
6.3 Implications of the Study and Recommendations for Practice 
6.3.1 To Provide Subacromial Cortisone Injection for SAIS Patients 
This study has demonstrated that subacromial injection improves shoulder 
pain, function and range of movement in the short-term in adult patients with 
SAIS; therefore, I would recommend that it should be considered as an early 
intervention for patients with shoulder pain. The study also agrees with 
previous authors that subacromial injection should be considered where 
physiotherapy has failed to improve symptoms of SAIS or the shoulder is 
acutely painful. It should also be used as an adjunct to physiotherapy, to 
enhance and reduce the number of physiotherapy sessions substantially 
(Hanchard et al 2004, NICE 2015).  
 
6.3.2 To Refer Shoulder Injection Patients for Physiotherapy 
In agreement with previous studies, this study has shown that participants' 
shoulder function improved not only with a cortisone injection but also from 
the exercises that they were given by the injecting ESP. I would recommend 
that clinicians such as GPs, rheumatologists and orthopaedic consultants 
should consider referring patients with shoulder pain to physiotherapy for 
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exercise advice after they have received shoulder injections particularly 
where the patients have residual poor muscle control/strength.  
 
6.3.3 To Provide Lateral Route of Cortisone Injection 
This study has showed that the lateral route of subacromial injection 
produced better day time pain relief when compared to the posterior 
approach. I would therefore recommend that the lateral route of injection 
should be considered in the first instance for patients who only suffer day time 
pain and who have no night symptoms as this may be more beneficial for 
them. 
 
6.3.4 To Train more ESPs to Provide Cortisone Injection 
This study has also confirmed that subacromial injections in combination with 
patient education and exercise information are effective in patients with SAIS 
and should therefore be used in their treatment. This study did not report any 
adverse effects with the subacromial injections given, therefore, clinicians 
such as ESPs and GPs should be encouraged to provide it as the treatment 
of choice, particularly in shoulder patients were pain is the main limiting 
factor. This would suggest that if ESPs working in community or outpatient 
musculoskeletal practice were trained to perform these injections this could 
potentially reduce the number of unplanned hospital visits by patients with 
shoulder pain thus reducing costs for the CCG and NHS. Therefore, more 
ESPs working in community or outpatient musculoskeletal practice should be 
trained to perform these injections. 
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6.3.5 To Involve Shoulder Injection Patients in Their Treatment 
This study has highlighted the importance of providing good information and 
knowledge to patients with shoulder pain receiving subacromial injection. 
Participants felt that being involved with discussion and decision making 
about their care and treatment enhanced their understanding, expectations 
and ultimately the success of their treatment outcome. This suggests that 
clinicians such as GPs and Rheumatologists who also provide shoulder 
injections should be aware of the contributions that good patient information 
and knowledge can add to both the patients experience and treatment 
outcomes. Therefore, ESPs as well as other clinicians such as GPs and 
Rheumatologist should ensure that they involve patients in care and 
treatment plan and also provide them with adequate information to improve 
their treatment outcomes and experience. 
 
6.3.6 To Encourage Clinicians and Services to be Professional 
This study has shown the benefit how the professionalism of the injecting 
clinicians, access to treatment as well as good customer service contributed 
to the overall experience of the patients. This implies that MSK 
physiotherapists should be aware of how their professionalism and 
therapeutic relationship with the patients they treat contributes to the overall 
patient experience and clinical outcomes. It also follows that the 
Administrative staff who provide patients with treatment appointments over 
the telephone should consider how their rapport with them could influence the 
patients' treatment experiences and outcomes. This learning should be 
reinforced and applied to other areas of musculoskeletal practice such as 
back pain patients.  
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6.3.7 To Set Up Musculoskeletal Service within the Community 
This study has highlighted the importance of setting up a musculoskeletal 
practice within a central location in the community with easy access and good 
customer service. It is important therefore for commissioners, GP groups and 
service providers to work closely together to address these issues before 
commissioning a community musculoskeletal practice. It is equally vital to 
seek the opinions of service users during the commissioning phase of such a 
project. Those who manage such services should to endeavor to make 
available treatment appointments so that patients are seen sooner, thereby 
avoid long waiting list. Clinicians working in such a service should ensure they 
do not keep patients waiting for long before being treated because this could 
impact on their overall experience and treatment outcomes. 
 
6.4 Recommendations for Future Research 
This was a pragmatic single centre RCT with participants from several GP 
practices from across the area, therefore future research could consider the 
use of a multicentre RCT to further enhance the geographical spread of the 
study and therefore the generalisation of the findings. In this study, the 
exercise information was not standardised but was provided to the patients 
based on their individual needs. Future studies could therefore compare the 
use of exercises prescribed from a patient-focused perspective or from a 
standardised format in order to establish the contribution of different 
approaches to exercise to subacromial injection outcomes.  
 
The results of the study have shown that both lateral and posterior routes of 
subacromial injection are effective in treating patients with SAIS in the short 
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term, further work is therefore necessary to establish long term effectiveness 
of these treatments. However, this may be difficult to assess due to 8 and 12 
weeks’ loss to follow-up. The follow-up periods in this study were consistent 
with some previous studies, therefore, if future research investigating 
subacromial injections were to adopt similar follow-up periods this would 
enhance the possibility of systematic review and meta-analysis in this area. 
 
This study has shown that a mixed methods research design that combines 
RCT and semi-structured interviews to investigate subacromial injections in 
patients with SAIS provides a better understanding of the factors that 
contribute to the patients’ overall experiences and clinical outcomes. In view 
of these benefits, future studies could therefore consider the use of both a 
quantitative and qualitative research method in the investigation of 
musculoskeletal conditions such as shoulder conditions.  
 
Finally, this study has clearly shown the benefits of using a mixed methods 
research design to investigate the effectiveness of lateral versus posterior 
approach to subacromial injection and also the experiences of the patients 
receiving the injections in normal musculoskeletal practice. Although there 
were no real significant differences in the treatments, this study has clearly 
demonstrated that subacromial injections performed using anatomical land-
marks by ESPs provided significant clinical improvements in day time pain, 
night time pain, shoulder function and disability in participants with SAIS. It 
has also shown that these benefits were not due to the effects of the 
cortisone injection only but also because of other factors such as patient 
education and their involvement in the treatment, exercise information, the 
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professionalism, experience and skills of the injecting clinicians, access to 
treatment as well as good customer service. 
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APPENDICES 
Appendix 1: Standard Operating Procedure for the Research 
Standard Operating Procedure (SOP) for the Research titled: Needle 
Placements in Patients with Subacromial Impingement Syndrome: A 
Comparison of Two Approaches 
Service and Premises to Which SOP applies: 
• The (name of service) Community Musculoskeletal (MSK) Service 
(place of service) 
Version Control 
Date: v1 21st July 2014 
Date: v2 14th August 2014 
Objectives/Purpose: 
The purpose of this document is to enable the service, particularly all those 
involved in the research, to be aware of what their involvement and roles are. 
Scope: 
This procedure document applies to the Extended Scope Practitioners 
participating in the study working in the service and the Service centre and 
Administrative staff at Hastings who might be involved. 
Responsibilities: 
• The Chief Investigator - the Clinical Lead is to ensure that all aspects 
of patients' participation in the research including data collection and 
recording are met. 
• It is the responsibility of the Extended Scope Physiotherapists involved 
in the research to be aware of their roles. 
• It is the responsibility of the Administrative staff involved in the 
research to be aware of their roles. 
Related Guidelines and Standard Operational Procedures (SOP) to be 
read in conjunction with this SOP: 
 
• CSP Code of Members' Professional Values and Behaviour (2012);  
Introduction: 
 
The (name of service) MSK Service aims to provide the highest form of 
quality care and in doing so set clear guidelines regarding aspects of the 
service, such as staff participation in research. 
 
Definitions  
 
1.0 
 
0.1.  ESP –Extended Scope Physiotherapist 
0.2.           CSP –Chartered Society of Physiotherapy 
0.3.           SPADI –Shoulder Disability Index 
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0.4.           PROMS –Patient Reported Outcome Measures 
 
2.0 Health & Safety 
 
2.1 There are no Health & Safety implications associated with the 
implementation of this procedure regarding normal procedures 
to minimise risk of needle stick injury 
2.2. All the ESPs involved in the study must ensure they have 
adequate training, experience and skills required. While the 
Administrative staff involve will receive guidance necessary for 
their involvement 
 
3.0 Procedure 
 
3.1 Participant Identification  
3.1.1 Patients referred by their GP with shoulder pain and 
associated pathologies and then triaged to participating 
ESPs for possible injection 
3.1.2 Patients referred by GP with shoulder pain, with specific 
request for cortisone injection and then triaged to 
participating ESPs for possible injection 
3.1.3 Patients referred by Physiotherapists with shoulder pain 
to ESPs for review 
3.1.4 Patients referred by Physiotherapists with shoulder pain 
to ESPs for possible cortisone injection 
 
3.2 Participant Recruitment 
3.2.1 When the first musculoskeletal appointment is posted to 
the patient, a separate envelope containing the letter of 
invitation to take part in the study will be sent also. This 
will include patients with first shoulders appointments and 
all new shoulder injection appointments 
3.2.2 The invitation pack will contain a letter of invitation with a 
Patient Information Sheet (Patient Information Sheet) and 
two consent forms (for the quantitative part and 
qualitative interview) (consent forms) 
3.2.3 Participants are to bring the consent forms  with them to 
their first appointment with the ESP 
3.2.4 Those who forget to bring consent forms will be provided 
with copies upon arrival for their appointment 
 
3.3 Clinicians Involvement 
3.3.1 Injecting ESPs will be directly involved in this study.  
3.3.2 The injecting ESPs will be involved in consenting, 
assessing and injecting patients 
3.3.3 Both injecting ESPs to complete the study’s screening log 
that include date, hospital no, eligible, not eligible and 
why not, name of screener and signature 
3.3.4 Both injecting ESPs will be involved in recording the 
baseline Shoulder Pain Disability Index (SPADI) and 
PROMS measures including the study no 
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3.3.5 Both injecting ESPs are to provide the Reception on duty 
with the baseline SPADI and PROMS sheet after every 
clinic 
3.3.6 Chief Investigator will be involved in the follow-up 
assessments at 8 and 12 weeks 
3.3.7 Chief Investigator to provide Reception Staff on duty with 
records of follow-up assessments at 8 and 12 weeks 
3.3.8 Chief Investigator to undertake data cleaning after 
completion of follow-ups 
3.3.9 Chief Investigator will be involved with telephone 
interview of the patients after the quantitative study 
 
3.4 Service Centre Involvement 
3.4.1 When the first musculoskeletal appointment is posted, to 
provide all shoulder patients that have been triaged to 
ESP clinic with the Participant Information Sheet (PIS), 
letter of invitation and consent forms 
3.4.2 To book appointment with injecting ESP’s only when they 
are working at (place of service) 
 
3.5 Administrative/Reception Staff  
3.5.1 When patients with shoulder pain are referred from 
physiotherapists to ESP, to provide them with the study’s 
letter of invitation, PIS and consent forms along with their 
appointment letters 
3.5.2 After an eligible patient has given consent to participant in 
the study, Reception staff should open the serially 
numbered sealed envelope and inform injecting ESPs of 
the allocation by randomisation (injection route) and the 
patient’s study no 
3.5.3 Reception staff should record on the envelope the 
patient’s study number and allocation route 
3.5.4 Reception staff should record the patient’s study number, 
hospital number, gender, age, initials, allocation date, 
allocation route, name of investigator in the study 
allocation sheet and then sign it 
3.5.5 Reception staff to provide the Chief Investigator with the 
patient’s name, contact telephone number including 
mobile number and the patient’s study number 
3.5.6 Reception staff to enter the following details from: 
3.5.6.1 The study allocation sheet – Hospital 
number,  
3.5.6.2 Baseline data – Date, Study number, Age, 
Gender, Duration of symptoms, Manual 
occupation (yes or no), Dominant side affected 
(yes or no), Previous cortisone injection (yes or 
no), Current treatment Analgesia/NSAIDS, Initial 
SPADI score, and Initial PROMS score (Current 
pain level, how much of night pain is causing 
sleep disturbance and how of much of function 
is affected),  
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3.5.6.3 SPADI outcome at 8 weeks, PROMs 
(Current pain level, how much of night pain is 
causing sleep disturbance and how much 
function is affected) at 8 weeks 
3.5.6.4 SPADI outcome at 12 weeks, PROMs 
(Current pain level, how much of night pain is 
causing sleep disturbance and how much 
function is affected) at 12 weeks 
 
3.6 Regional operations manager, service manager, service 
centre manager 
3.6.1 Regional operations manager, service manager, service 
centre manager to please ensure the Service centre staff 
understand and comply the research SOP 
3.6.2 To inform the GP’s via the CCG using the Research letter 
to GP’s  
3.6.3 To provide individual GP’s the research letter to GP’s if 
requested 
3.7 Research Coordination 
3.7.1 Chief Investigator to coordinate all aspects of the 
research SOP, with Regional operations manager, 
service manager, service centre manager and National 
MSK Lead  
 
3.8 Glossary 
3.9 Reception Staff -  
3.10 Injecting ESP’s -  
3.11 Chief Investigator – Clinical Lead - Collins Ogbeivor 
3.12 Service Manager –  
3.13 Service Manager –  
3.14 Regional Operations  
3.15 National MSK Lead –   
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Appendix 2: Letter of Invitation to Participants     
Study Title: Comparison of the Effectiveness of Side versus Back 
Approach of Shoulder Injections in Patients with Shoulder pain  
 
Dear Sir/Madam, 
 
My name is Mr Collins Ogbeivor. I am a professional doctorate student in the 
School of Health and Human Sciences at the University of Essex, Colchester. 
I am conducting a research study as part of the requirements of my degree in 
Physiotherapy and I would like to invite you to participate. This study is 
sponsored by the University of Essex. 
 
I am studying what difference it will make injecting people suffering from 
shoulder pain from the side or back of the shoulder with cortisone injection. 
This study is in two parts; the first part is to find out whether people with 
shoulder pain who are injected from the side of their shoulder would have 
better pain relief and improved shoulder function compared to those who are 
injected from the back of the shoulder. The second part is to find out the 
experiences of patients with shoulder pain who have received a cortisone 
injection from either the side or the back of the shoulder.  
 
If you decide to participate, you will be asked to you receive a shoulder 
injection containing cortisone injection and Lidocaine either from the side or 
back of the shoulder. You will also be asked to participate in an interview 
discussion about your experience of the shoulder injection. The interview will 
take place over the telephone at your home or a place convenient at a 
mutually agreed upon time and place, and should last about 15 - 20 minutes. 
The interview will be audio taped so that I can accurately reflect on what is 
discussed. The tapes will only be reviewed by members of the research team 
who will transcribe and analyze them. They will then be destroyed. 
 
We will be happy to answer any questions you have about the study. You 
may contact me on (telephone number or email), or my work supervisor, 
(name), on (telephone number) or (email) if you have study related questions 
or problems.  
 
Thank you for your consideration. If you would like to participate, please open 
the invitation pack containing a Patient Information Sheet and two consent 
forms and read them. When you are done reading them and you wish to 
participate in the study, please bring these documents along with you during 
your first musculoskeletal appointment with the Extended Scope Practitioner 
(Musculoskeletal Clinical Specialists) at (unit address). 
 
With kind regards,  
 
Collins Ogbeivor (MSc, BMr-Physio, MCSP, SRP) 
Clinical Lead/Extended Scope Practitioner 
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Appendix 3: Participant Information Sheet 
 
A Comparison of the Effectiveness of Side versus Back Approach of Shoulder 
Injections in Patients with Shoulder pain (Subacromial Impingement Syndrome) 
 
You have been invited to take part in this study 
 
My name is Mr Collins Ogbeivor. I am a professional doctorate student in the School of 
Health and Human Sciences at the University of Essex, Colchester. I am conducting a 
research study as part of the requirements of my degree in Physiotherapy and I would like to 
invite you to participate. This study is sponsored by the University of Essex. I would like to 
invite you to help us with this study and participate in this research. I hope to find out what 
difference it will make injecting people suffering from shoulder pain from the side or back of 
the shoulder. 
 
Before you make your mind up, it is necessary for you to understand why the study is being 
done and what it would involve. I hope you will take time to read this information sheet 
carefully before you are asked to give your consent to being part of the research. If there is 
something that you do not understand, please ask me. My contact details are given at the 
end of this leaflet. 
 
Why have been invited? 
 
You have been invited to participate in this research because you have been referred by your 
GP to (address of unit) service because you could benefit from injection therapy for treatment 
of your shoulder pain. 
 
What is the purpose of the study? 
 
• In the UK, the incidence of shoulder pain is very common. 
• Whilst a cortisone injection is effective in relieving symptoms of pain and inflammation in 
people with shoulder pain, we do not know if people are more likely or less likely to 
benefit if they are injected from the side or the back of the shoulder. 
• The purpose of this research is to find out what difference it will make in terms of 
better pain relief and improved shoulder function injecting people suffering from 
shoulder pain from the side or back of the shoulder  
 
The diagram below illustrates the difference between the lateral (side) and posterior 
(back) approach of subacromial injection 
 
Figure 3a      Figure 3b 
Figure 3: (a) External view of left shoulder showing the location of the lateral shoulder 
portal (b) External view of left shoulder showing the location of the posterior shoulder 
portal 
279 
   
 
 
• In addition, the study aims to find out the experiences of patients with shoulder pain who 
have received a cortisone injection from either the side or the back of the shoulder. 
Are there any benefits if I take part in this study? 
 
There will not be any direct personal benefit by taking part in this study. However the 
information we derive from your participation in this study will help us to know how better to 
treat patients with shoulder pain using shoulder injections in the future. 
 
Do I have to take part? 
 
No, it is up to you to decide. If you agree to participate, you will be given a consent form 
which you should read in full and sign if you are willing to participate. If you decide not to 
participate or wish to withdraw from the study later, you may do so at any time and without 
giving a reason. This will not affect the standard of care you receive. 
 
What will happen if I agree to participate? 
 
• You will be asked to complete the consent form contained inside the enclosed envelope. 
You will need to bring this with you to your first musculoskeletal appointment. 
• You will be randomised onto the study to either receive a lateral or posterior 
shoulder injection 
• Your musculoskeletal assessment and treatment will take place as usual.  
• Eight and twelve weeks after your first injection therapy a clinician will contact you 
through telephone to assess your progress. 
• Twelve weeks after your injection therapy you may be contacted to part take in a 
telephone interview about your experiences regarding the treatment you received – if you 
agreed to this in the consent form. 
Are there any possible risks and disadvantages involved in taking part? 
 
There are no additional risks involved besides those that could routinely possibly be related 
to the treatment, such as minor bleeding, pain, skin colour changes, seizure (convulsion) 
and anaphylactic shock. Please be informed that you will be offered an injection therapy 
either through the side or back of your shoulder. 
 
Your appointment may take a little longer than if you were not participating in this study. 
 
Will the information collected from me be kept confidential? 
 
Yes, following ethical and legal practice, all the information collected about you as part of this 
study will be handled in confidence. Only those involved in your care will know if you are 
participating in the study. The findings from both aspects of the research will be made 
available to the course supervisor Dr Sheila Black of the Essex University. However, these 
will not contain any personal details that will identify you, for example your name, home 
address.  
 
All your details, as well as your comments, will be kept secure and confidential. Recordings 
of the interview will be kept anonymously on tape. Any information you provide to the 
researcher will be anonymised using pseudonyms and unique identification numbers, so that 
it will not be possible to identify you. 
 
Will my GP be informed of my participation in the study? 
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I would like you to provide written informed consent that we have your permission to inform 
your GP that you are participating in this study. If you are uncomfortable or your pain is 
getting worse, please contact your GP, who will be happy to help. 
 
What will happen to the results of the research study? 
 
The results of this study will be written up and presented as a research thesis submitted in 
partial fulfillment of the requirements for a degree of Doctor of Physiotherapy that is being 
undertaken by the researcher.  A copy of the thesis will be deposited in the Albert Sloman 
Library at the University of Essex. In addition, the results will be shared with the NHS 
including GP practices.  The thesis and results will not contain any names or details that will 
be identifiable to you personally. 
 
Who is organising and funding the research? 
 
There is no funding for this research. This study is being undertaken as part of a Doctoral 
thesis by Collins Ogbeivor - Extended Scope Practitioner and Clinical Lead under the 
supervision of Dr Sheila Black who is a lecturer at the University of Essex, and the clinical 
supervisor. 
 
Who has reviewed the study? 
 
All research involving human participants is looked at by an independent group of people, 
called a Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study will be reviewed and approved by the National Research Ethics Service London – 
Chelsea Research Ethics Committee. In addition, because the study will involve NHS 
patients in non-NHS setting –Community Musculoskeletal Service, it will be reviewed by the 
NHS Research Consortium and approved by the (address of unit) Research Board. 
 
Who can I speak to if I have more questions or concerns? 
 
If you have any further questions or concerns before, during or after the research, please 
email us through the details provided below. The researcher will also be happy to talk to you 
after the research has concluded, if you have any concerns.  
Chief Investigator name Collins Ogbeivor Contact details Tel: xxxxxx, Email 
aocogb@essex.ac.uk 
 
I would like to participate in this study. What happens now? 
 
1. Read the consent form 
2. Bring the consent form and the participant information sheet with you to your first 
orthopaedic appointment. Please do not leave them at the reception desk 
3. You will be asked to sign the consent form after you have had an opportunity to ask any 
questions that you may have. 
What if I do not want to participate in the study? 
 
You do not have to do anything more. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should speak to the Chief 
Investigator, Collins Ogbeivor (Tel:xxxxxx) who will do his best to answer your questions. If 
you remain unhappy and wish to complain formally, you can do this by contacting the Service 
Manager at the (address of unit) (Tel xxxxxx) 
 
CONTACT INFORMATION 
If you have further questions about the study please contact Collins Ogbeivor 
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Landline/Answer Machine: (Telxxxxx) There is an answering machine on the landline. 
Please leave a message and Collins Ogbeivor will return your call. 
Study Specific Mobile Number: xxxxxx 
Email address: You may also wish to email your questions to me at aocogb@essex.ac.uk 
Postal Address: Collins Ogbeivor, (address of unit) 
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Appendix 4: Consent Forms 
Section 1 – Quantitative Study 
Title of Project: Comparison of the Effectiveness of Side versus Back 
Approach of Shoulder Injections in Patients with Shoulder Pain 
Name of Chief Investigator: Collins Ogbeivor 
 Please Initial 
each box 
separately 
1. I confirm that I have read and understand the participant information 
sheet dated 02/01/2013 (version 1), provided for the above study 
and have had the opportunity to ask questions 
 
2. I understand that I will be offered an injection therapy through either 
the side or back of the shoulder.  
 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without having to give any reason, without my 
medical care or legal rights being affected 
 
4. Should I wish to withdraw from the study I am aware that any 
information already collected can still be used 
 
5. I understand that my GP may be informed of my participation in the 
study and I give my consent               
 
6. I understand that relevant sections of my medical notes and data 
collected during the study, which is anonymised, may be looked at 
by individuals from (address of unit), from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my anonymised records 
 
7. I understand that the findings of the above study will be made 
available to the academic supervisor (Dr Sheila Black of University 
of Essex) and that, the information I give will be anonymised so I 
cannot be identified 
 
8. I agree to take part in the above study  
 
 
 
Name of Patient                                              Date                            Signature 
 
Chief Investigator                                            Date                            Signature 
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Section 2 – Qualitative Semi-structured Interview Study 
 
Title of Project: What are the experiences of patients with shoulder pain 
experiencing side versus back approach to shoulder injections? 
 
Name of Chief Investigator: Collins Ogbeivor 
 
 Please Initial 
each box 
separately 
1. I confirm that I have read and understand the participant 
information sheet 02/01/2013 (version 1), provided for the 
above study and have had the opportunity to ask questions and 
will take part in a semi-structured interview 
 
2. I agree to be contacted to arrange a date and time convenient 
for the interview  
 
3. I confirm that I am happy to have the interview taped 
anonymously 
 
4. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without having to give any reason, and 
without my medical care or legal rights being affected. 
 
5. Should I wish to withdraw from the study I agree that any 
information already collected can still be used 
 
6. If I decide to leave this study I understand that this will not affect 
my future care 
 
7. I understand that the findings of the above study will be made 
available to the academic supervisor (Dr Sheila Black of 
University of Essex) and that, the information I give will be 
anonymised so I cannot be identified 
 
8. I agree to take part in the above study  
 
Name of Patient                                Date                            Signature 
 
Chief Investigator                              Date                           Signature 
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Appendix 5: Patient Reported Outcome Measures 
 
 
SHOULDER INJECTION BASELINE MEASURE   NHS 
 
 
Study No        Date    
  
Age       Gender: Male or Female 
Duration of Symptoms in weeks   Manual Occupation: Yes or No, if 
yes -- 
Dominant side affected Yes or No   Previous Cortisone Rx Yes or No 
Current treatment analgesia/NSAIDS (type)      
BEFORE THE INJECTION: 
Are you able to do your usual work?   YES        NO        N/A 
  
Are you able to do your usual sports/hobbies?  YES        NO        N/A 
  
On a scale of 0 to 10, If 0 = no pain, 10 = very severe pain? (Please circle correct 
number) 
What is your current shoulder pain level? 
0 1 2 3 4 5 6 7 8 9 10 
What is the level of shoulder pain at night time causing sleep disturbance on a scale 0 – 10? 
0 1 2 3 4 5 6 7 8 9 10 
How much is function affected (specify function_____________________________) 
0% 20% 40% 60% 80% 100% 
Plan at 8/52: (mark appropriate category) 
 Consider repeat injection 
 Further investigation 
 Refer to In-house Consultants or Secondary Care 
Comment.....................................................................................................................................
....................................................................................................................................................
....................................... 
Thank you Patient signature.........................................................Date ...../..../..... 
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Appendix 6: Shoulder Pain and Disability Index 
Shoulder Pain and Disability Index (SPADI)  NHS 
 
Study No        Date  
Please place a mark on the line that best represents your experience during the last 
week attributable to your shoulder problem.  
 
Pain scale  
How severe is your pain?  
Circle the number that best describes your pain where: 0 = no pain and 10 = the 
worst pain imaginable. 
 
At its worst? 0  1 2 3 4 5 6 7 8 9 10 
When lying on the involved side?  0  1 2 3 4 5 6 7 8 9 10 
Reaching for something on a high shelf? 0  1 2 3 4 5 6 7 8 9 10 
Touching the back of your neck? 0  1 2 3 4 5 6 7 8 9 10 
Pushing with the involved arm? 0  1 2 3 4 5 6 7 8 9 10 
 
Disability scale 
How much difficulty do you have? 
Circle the number that best describes your experience where: 0 = no difficulty and 10 
= so difficult it requires help. 
Washing your hair? 0  1 2 3 4 5 6 7 8 9 10 
Washing your back? 0  1 2 3 4 5 6 7 8 9 10 
Putting on an undershirt or jumper? 0  1 2 3 4 5 6 7 8 9 10 
Putting on a shirt that buttons down the 
front? 
0  1 2 3 4 5 6 7 8 9 10 
Putting on your pants? 0  1 2 3 4 5 6 7 8 9 10 
Placing an object on a high shelf? 0  1 2 3 4 5 6 7 8 9 10 
Carrying a heavy object of 10 pounds 
(4.5 kilograms)  
0  1 2 3 4 5 6 7 8 9 10 
Removing something from your back 
pocket? 
0  1 2 3 4 5 6 7 8 9 10 
 
Total Score:    /130 
 
 
286 
   
 
 
Appendix 7: Qualitative Semi-Structured Questions 
1. Has there been any improvement since having the injection? 
2. If given the choice would have preferred your injection from the side or 
the back of the shoulder? Why did you answer that way? 
3. Now that you have had you treatment, how did you find the 
experience? 
4. What are your experiences concerning your patient care from when 
your GP referred you to this service? 
5. If provided with the opportunity, would you have preferred to have the 
injection in the acute trust or in the community? Why did you answer 
that way? 
6. Would you recommend this treatment to a friend or relative who had 
the same problem? Why did you answer that way? 
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Appendix 8: Examples of Descriptive Items by the Participants 
Participants expression of the actual needing experience 
 I did not realise it had been done  
 No real pain  
 I did enjoy it and I did not feel it  
 I didn’t feel any pain  
 The experience as fine  
 It is very good, it is not painful at all having the injection  
 It’s been good, the injection did not hurt  
 
Participants expression of the injection treatment 
 From the injection 2 weeks I started to see improvement  
 Everything was great, the injection, the way he performed it  
 Possibly both the injection and exercises made the difference  
 I have 100% improvement, when I had the last injection  
 As far as I am concerned the injection was what improved the pain  
 Because after you’ve had the injection you are back to complete  
 The injection, I don’t really know because it is stiff  
 
The impact of exercise information to treatment 
 I think where I had the injection and I followed the exercises 
 The way the exercises were explained and I have been doing them 
 Everything was great, the injection and the exercise 
 I think it is from the exercises I have been given 
 Yes, it has not been bad, the exercises I have been given 
 The exercises as well to strengthen my muscles 
 
Participants description of factors associated with their shoulder pain 
 My shoulder was quite inflamed and painful 
 Using my arm at work could have cause the pain 
 Not been able to sleep because of the pain 
 The time factor of 18-20 months was important 
 I played regular Badminton 
 I had the psychology that this was going to heal itself with time 
 
Perception of the injection technique and clinician’s attitude 
 Probably technique as well 
 The man who did the injection was polite and knew what he was doing 
 He was more than helpful 
 The way I was treated, I did not feel I was another candidate 
 The guy was professional and he knew what he was doing 
Uncertainty and anxiety about the shoulder problem and the treatment 
 Actually, I was scared Initially  
 I did not know what was going in the shoulder 
 Because I play regular Badminton I was not sure if it was impingement or 
tendonitis or full tear 
 I had constant pain initially and did not know where I was heading for 
 I did not know much about it 
 I don’t know I was coming for an injection 
 I wasn't sure what the problem was whether it was due to spondylolitis that is 
coming from the neck or just injury to my shoulder pain. 
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The impact of patient education 
 Because everything was explained thoroughly to me 
 Knowing what was going in the shoulder and what I need to do 
 I did not know much but I followed the advice 
 The way the exercises were explained to me 
 I think just been explained to and been talked thorough certainly helped 
 Very professional, 10 out of 10 really because you were listened to 
 I thought it was explained, he showed me what to do 
 The way things were explained to me and how the injection works 
Participants expression of satisfaction 
 10 out of 10 definitely 
 Very good, yes no problem, no problem at all 
 He was so caring, oh yes, he was a wonderful man 
 If the other one goes, I will be knocking at your doors 
 I will sing the praise of everybody and I will go on all day 
 Thank you for giving me my shoulder back it is wonderful 
 I couldn’t fault it at all 
 Everything has been every good everyone looked after me 
 My experience was a good one 
 All done fine and perfect 
 Once I had appointment with you, patient care was wonderful 
 It has been brilliant  
Participants preference for been treated in a community setting 
 I can go down there, I can pack and I can walk 
 I will prefer it at the station, it was not hurried 
 Oh no in the community was good 
 Coming to you was better, the time and it was a bit more friendly 
 Anywhere I don’t mine, so, it was suitable here, no waiting 
 In the community or hospital it makes no difference to me 
 In the community, it is fine because it is easy and convenient 
 Because it is nearer 
 The appointment did not take long 
 The experience regarding the time, phone call all very good  
Perceptions about cortisone injection 
 People do have concerns about steroid, but I would say to them have it 
 I will be sending them to you because it works 
 It didn’t help me, probably it could help someone else 
 It took a long time, it took a few months than I thought 
 The injection and time. It took more than 2 months to work 
Result after seeing their GP to be referred for treatment 
 They said I was not meeting the criteria because I could lift my shoulder  
 I had to insist on physiotherapy and have MRI scan 
 The GP letter took about 3-4 weeks, but apart from that everything was fine 
 I went to the GP, and 2 weeks later I got the appointment 
 When I had of the sound of physiotherapy, I could have preferred physio 
 Since having the injection I had to go and have MUA 
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 I had the appointment fairly quickly and was seen so fast 
 No problem because my GP retired 6 months ago 
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Appendix 9: Code System 
A. Charts with boxes 
 
 
Keys: Boxes represent number of codes 
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B. Charts with number codes 
 
 
 
Keys: Numbers represent codes
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Appendix 10: Example of using Framework for Descriptive and 
Classification Analysis 
 
Participant 
ID, Gender, 
Age, 
Treatment 
Group 
Column B 
Data charted in 
column 3.5:  
Professionalism of 
the injecting 
clinician 
Column C 
Elements/Dimensions 
identified 
Column D 
Categories/classes 
0052P, Male, 
43, Posterior 
group 
It seems fine where I 
had it and no trouble 
at all. I thought the 
guy was very 
professional he knew 
what he was doing. 
When I had it before 
the GP did not really 
know what he was 
doing. He stuck the 
needle in my shoulder 
and started wiggling it 
round. But this Doctor 
numb it first and use 
the same needle to 
inject the steroid, it 
was really good. 
No problem with the 
injection site 
 
Knowledge and skill of 
the injecting clinician 
 
Previous bad GP 
experience 
 
The way the GP did the 
injection 
 
The way the ESP 
performed the injection 
 
 
Injection outcome  
 
Positive injection 
experience 
 
Professionalism of 
the injecting ESP 
 
Lack of GP’s 
injection experience 
 
GP’s injection 
technique 
 
ESP’s injection 
technique 
 
 
Successfully 
experience 
 
Appendix 10 above is an excerpt from participant’s 0052P transcript. It is an 
example of using Framework approach for descriptive and classification 
analysis. Column A is the participant unique identification number, Column B 
contains the original quotes from the transcripts, while Column C is a close 
description of the participant’s original quotes, but now contains mainly the 
relevant elements of the initial quotes. Column D is a higher level of 
categorisation where elements detected have been interpreted in a more 
conceptual manner to provide a new meaning. For example, column B is an 
excerpt from the participant’s original transcript that matches item 3.5 in the 
index on Figure 15 in page 182. In column C “knowledge and skill of the 
injecting clinician” and “injection outcome” from were both categorised in 
column D as professionalism of the injecting ESP and successfully injection 
experience respectively. 
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Appendix 11: Approval of National Research Ethics Committee (NREC)  
 
 
 
NRES Committee London - Chelsea 
HRA 
Research Ethics Committee (REC) London Centre 
Ground Floor 
80Skipton House 
London Road 
London 
SE1 6LH 
 
Telephone: 02033117294  
Facsimile: n/a 
14 April 2014 
 
Mr Collins A O Ogbeivor 
Clinical Lead/Extended Scope Practitioner of Musculoskeletal Service 
(address of unit) 
 
Dear Mr Ogbeivor 
 
Study Title: A comparison of the effectiveness of lateral versus 
posterior approach for cortisone injection in patients 
with subacromial impingement syndrome 
REC reference: 14/LO/0406 
IRAS project ID: 137935 
 
Thank you for your letter of 09 April 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation.   
 
The further information has been considered on behalf of the Committee by the 
Chair.  
 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details, unless you expressly withhold permission 
to do so. Publication will be no earlier than three months from the date of this 
favourable opinion letter. Should you wish to provide a substitute contact point, 
require further information, or wish to withhold permission to publish, please contact 
the REC Manager Miss Gemma Oakes, 
 
nrescommittee.london-chelsea@nhs.net.   
 
Confirmation of ethical opinion   
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation as revised, subject to the conditions specified below.   
Ethical review of research sites   
 
 
NHS sites   
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
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start of the study (see "Conditions of the favourable opinion" below).  
 
Non-NHS sites  
 
The Committee has not completed any site-specific assessment (SSA) for the non-
NHS research site(s) taking part in this study. The favourable opinion does not 
therefore apply to any non-NHS site at present. We will write to you again as soon as 
an SSA application(s) has been reviewed. In the meantime no study procedures 
should be initiated at non-NHS sites.   
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study.   
 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned.  
 
Management permission ("R&D approval") should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.  
 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give 
permission for this activity.  
 
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host 
organisations   
 
Registration of Clinical Trials   
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publicly accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees).     
 
There is no requirement to separately notify the REC but you should do so at the 
earliest opportunity e.g. when submitting an amendment. We will audit the 
registration details as part of the annual progress reporting process.   
 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory.   
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions 
to be made. Guidance on where to register is provided within IRAS. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site 
(as applicable). 
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Approved documents   
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document  Version  Date   
Evidence of insurance or indemnity  (name of 
insurance 
company) Heath 
letter   
16 September 
2013  
 
Evidence of insurance or indemnity  Chartered 
Society of 
Physiotherapy 
Insurance 
Certificate - Mr. 
Collins Ogbeivor 
 
 
GP/Consultant Information Sheets  1  12 February 
2014  
 
Interview Schedules/Topic Guides  Qualitative Semi 
Structured 
Interview 
Questions V1  
14 February 
2014  
 
Investigator CV  Mr. Collins 
Ogbeivor  
 
 
Letter from Sponsor  University of 
Essex letter  
19 February 
2014  
 
Letter from Statistician  letter from Sarah 
Barter-Godfrey 
(undated)  
 
 
Letter of invitation to participant  1  12 February 
2014  
 
Other: Flow chart for research design  1  10 January 
2012  
 
Other: Chartered Society of Physiotherapy 
Certificate - Mr. Collins Ogbeivor  
 19 September 
2005  
 
Other: Health Professions Council registration 
certificate - Mr. Collins Ogbeivor   
  
 
Other: Letter from confirming insurance   06 November 
2013  
 
Other: Summary of Product Characteristics - 
Lidocaine Hydrochloride Injection  
  
 
Other: Semi Structured Interview Questions - 
Guide  
1  10 January 
2014  
 
Other: PGD for Lidocaine Hydrochloride    
 
Other: PGD for Triamcinolone    
 
Other: CV - (name of investigator)    
 
Other: CV - (name of investigator)    
 
Other: CV - Sheila Black    
 
Other: CV - (name of investigator)    
 
Other: Non NHS SSI  1  19 February 
2014  
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Participant Consent Form: Section 2 - Qualitative 
Semi Structured interview study  
1  19 February 
2014  
 
Participant Consent Form: Section 1 - Quantitative 
Study 
1  10 January 
2014  
 
Participant Information Sheet  1  19 February 
2014  
 
Protocol  1  10 January 
2014  
 
Questionnaire: SPADI  1  14 January 
2014  
 
Questionnaire: Patient reported outcome 
measures - Injection  
1  14 January 
2014  
 
Questionnaire: xx    
 
Questionnaire: Injection Outcome Measure  1  10 January 
2014  
 
REC application  1  19 February 
2014  
 
Referees or other scientific critique report  letter from Mr. 
(name of 
referee)  
21 February 
2014  
 
Summary/Synopsis  Flow Diagram 
showing 
movement of 
patient through 
the trial V1  
10 February 
2011  
 
 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
 
After ethical review   
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including:   
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study   
The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
 
Feedback   
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the website.   
Further information is available at National Research Ethics Service website > After 
Review 
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14/LO/0406   Please quote this number on all correspondence 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/    
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
Dr Shelley Dolan 
Chair 
 
Email: nrescommittee.london-chelsea@nhs.net   
 
Enclosures:   “After ethical review – guidance  
 for researchers” [SL-AR2]   
 
Copy to:  Sarah Manning-Press, sarahm@essex.ac.uk   
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Appendix 12: Approval of Non-NHS Research Consortium  
 
 
 
 
NRES Committee London - Chelsea 
Research Ethics Committee (REC) Bristol Centre 
Level 3, Block B 
Whitefriars 
Lewins Mead 
Bristol 
BS1 2NT 
 
Telephone: 0117 342 1380 
23 May 2014 
 
Mr Collins A O Ogbeivor 
Clinical Lead/Extended Scope Practitioner of Musculoskeletal Service 
(address of unit) 
 
Dear Mr Ogbeivor 
 
Study Title: A comparison of the effectiveness of lateral versus 
posterior approach for cortisone injection in patients 
with subacromial impingement syndrome 
REC reference: 14/LO/0406 
SSA reference: 
IRAS project ID: 
 
14/LO/0849 
137935 
The REC gave a favourable ethical opinion to this study on the 16 April 2014. 
 
Following site-specific assessment by the committee, I am pleased to confirm that 
the extension of the favourable opinion to the new site(s) and investigator(s) listed 
below: 
 
Research site Principal investigator / Local Collaborator 
(name and address of unit) Mr Collins A O Ogbeivor 
 
The favourable opinion is subject to management permission or approval being 
obtained from the host organisation prior to the start of the study at the site 
concerned. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.  
 
14/LO/0406: Please quote this number on all correspondence   
 
Yours sincerely   
 
Gemma Oakes REC Manager   
Email: nrescommittee.london-chelsea@nhs.net 
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Appendix 13: Letter to GPs 
 
School of Health and  
Human Sciences 
T 01206 872754 
F 01206 873765 
E hhs@essex.ac.uk 
Colchester Campus 
Wivenhoe Park 
Colchester CO4 3SQ 
United Kingdom 
T 01206 873333 
F 01206 873598 
 
www.essex.ac.uk 
 
 
Letter to General Practitioners (GP’s) 
 
Dear Doctor … 
 
My name is Mr Collins Ogbeivor. I am a professional doctorate student in the School 
of Health and Human Sciences at the University of Essex, Colchester. I am 
conducting a research study as part of the requirements of my degree in 
Physiotherapy. This study is sponsored by the University of Essex. 
 
This is to inform you that your patient Mr/Mrs Xxxxxxxxxx is taking part in my 
shoulder injection study. The study is to determine the effectiveness of lateral 
approach versus posterior approach of subacromial injection for the treatment of 
subacromial impingement syndrome (SAIS). It also aims to understand the 
experiences of patients with SAIS experiencing lateral versus posterior approach to 
subacromial injections. 
 
The patient will be provided with enough information regarding the relevance of the 
research and reason they have been asked to join via a patient information sheet 
and will have signed the consent form. They will be allowed to ask questions in any 
area relating to the research as well as their participation. The patient information 
sheet will be provided before the research, to allow potential participants adequate 
time to reflect on their contents, prior to giving consent. They will be informed that 
their participation in the research in voluntary and it will be made clear that consent 
could be withdrawn at any stage, without having to give any reason, without their 
medical care being affected. Participants should have capacity to give informed 
consent based on the Mental Capacity Act (2005).  
 
Serious side effects are not commonly reported with subacromial injections. 
Participants will be informed prior to the study, through the information sheet, that if 
they do occur, their effects are normally mild and temporary. They would be advised 
to contact their GP if they are feeling distressed or deteriorating rapidly during the 
trial. Potential participants’ records will be stored and handled in accordance with the 
Data Protection Act (1998). If you have any queries, please contact me on xx or at 
Collins.Ogbeivor@xxxx.co.uk. 
 
Thank you 
 
Yours Faithfully 
 
 
Collins Ogbeivor (MSc, BMr-physio, SRP, MCSP) 
Clinical Lead/Extended Scope Practitioner
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Appendix 14: Baseline Continuous Variables. Is the data normally distributed - deciding with central tendency and 
Dispersion 
 
Characteristic  Mean Median Mode Skewness Kurtosis S.D Conclusion 
Age (years) 55.38 55.00 54.0 - 0.18 - 2.05 12.12  
Symptom duration (weeks) 37.00 26.00 23.00 3.12 10.66 52.01  
Mean (SD) Initial PROMs Score 
       
Day time pain (SD) 6.79 7.00 8.00 - 0.81 1.03 2.02  
Night time pain (SD) 6.58 7.00 7.00 - 0.40 - 0.71 2.45  
Function affected (SD) 2.79 3.00 3.00 - 0.65 0.16 1.11  
Mean (SD) Initial SPADI Score 80.99 83.00 79.00 - 0.54 - 0.27 26.19  
 
Appendix 15: Baseline Continuous Variables. Is the data normally distributed - deciding with different techniques 
 
Characteristic  Visual  
inspection 
p-p plots Central tendency  
and dispersion 
Shapiro-Wilk 
test 
Conclusion -
normal or not 
Age (years)    0.572 Normal 
Symptom duration (weeks)    0.000 Not normal 
Mean (SD) Initial PROMs Score 
     
Day time pain (SD)    0.000 Normal 
Night time pain (SD)    0.002 Normal 
Function affected (SD)    0.000 Normal 
Mean (SD) Initial SPADI Score    0.130 Normal 
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Appendix 16: Outcomes Variable. Is the data normally distributed –
Deciding with central tendency, dispersion and distribution 
 
Characteristic  Mean Median Mode Standard 
Deviation 
Skewness Kurtosis Conclusion 
PROMs Day 
time pain 
      
 
at 8 weeks    
3.62 
4.0   4.0  2.85   0.40 - 0.69  
at 12 weeks    
3.25 
3.0   0.0  2.94 - 0.52 - 0.74  
from 0 - 8 weeks 3.02 3.0   1.0  2.67 - 0.13 - 0.30  
from 0 - 12 
weeks 
3.34 3.0   0.0  3.04 - 0.17 - 0.57  
from 8 - 12 
weeks 
0.21 0.0   0.0  2.39 - 0.13 - 0.24  
PROMs Night 
time pain 
      
 
at 8 weeks 4.01  4.0   0.0  3.19   0.28 - 1.07  
at 12 weeks    
3.96 
 4.0   0.0  3.52   0.26 - 1.37  
from 0 - 8 weeks    
2.57 
 2.0   0.0  3.33 - 0.45 - 0.55  
from 0 - 12 
weeks 
   
2.71 
 3.0   0.0  3.81 - 0.13 - 0.48  
from 8 - 12 
weeks 
 -0.13  0.0   0.0  2.26   0.43   1.42  
PROMs 
Function 
affected 
      
 
at 8 weeks    
1.65 
 2.0   0.0  1.33   0.21 - 1.10  
at 12 weeks    
1.57 
 2.0   0.0  1.38   0.28 - 1.18  
from 0 - 8 weeks    
1.14 
1.0   1.0  1.29 - 0.38 - 0.47  
from 0 - 12 
weeks 
   
1.17 
 1.0   0.0  1.45 - 0.38 - 0.11  
from 8 - 12 
weeks 
   
0.04 
 0.0   0.0  0.95   0.45   1.12  
SPADI score: 
      
 
at 8 weeks  
48.37 
51.0   0.0 35.58   0.13 - 1.28  
at 12 weeks  
45.99 
43.50   0.0 38.00   0.28 - 1.33  
from 0 - 8 weeks  
32.65 
23.00 23.0 30.88   0.60 - 0.38  
from 0 - 12 
weeks 
 
35.53 
29.00 18.0 35.19   0.19 - 0.63  
from 8 - 12 
weeks 
   
0.82 
  0.0   0.0 22.91 - 0.46   1.11  
302 
   
 
 
Appendix 17: Outcomes Variable. Is the data normally distributed –
Deciding with different techniques 
 
Characteristic  Visual  
inspection 
p-p 
plots 
Central 
tendency  
and dispersion 
Shapiro
-Wilk 
test 
Conclusion 
-normal or 
not 
PROMs Day time 
pain 
     
at 8 weeks    0.000 Not 
at 12 weeks    0.000 Not 
from 0 - 8 weeks    0.162 Normal 
from 0 - 12 weeks    0.145 Normal 
from 8 - 12 weeks    0.040 Normal 
PROMs Night 
time pain 
     
at 8 weeks    0.000 Not 
at 12 weeks    0.000 Not 
from 0 - 8 weeks    0.012 Normal 
from 0 - 12 weeks    0.308 Normal 
from 8 - 12 weeks    0.000 Normal 
PROMs Function 
affected 
     
at 8 weeks    0.000 Not 
at 12 weeks    0.000 Not 
from 0 - 8 weeks    0.002 Normal 
from 0 - 12 weeks    0.000 Normal 
from 8 - 12 weeks    0.000 Normal 
SPADI score: 
     
at 8 weeks    0.001 Not 
at 12 weeks    0.000 Not 
from 0 - 8 weeks    0.055 Normal 
from 0 - 12 weeks    0.297 Normal 
from 8 - 12 weeks    0.020 Normal 
 
 
 
 
 
